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Mikalsen. 
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SUMMARY 
There is an increasing interest in bioactive peptides from marine secondary products, as they offer a great 
potential for incorporation into functional food and for medical purposes.  Bioactive peptides from marine 
sources have been found to display a wide range of physiological functions including antioxidative, 
antihypertensive, antimicrobial, immunomodulatory, anticancer and diabetes 2 effects among others. 
However, majority of the research has been focusing on the peptides derived from hydrolysis with 
commercial industrial enzymes and the usefulness of these hydrolysates. 
 It could be interesting whether digestion of fish secondary tissue with gastrointestinal proteases generates 
peptides, which also have these health promoting properties either in relation to gastrointestinal digestion 
or as an alternative to the use of industrial proteases. Furthermore, as a bioactive defense system against 
the bacterial load in the water, fish is expected to possess bio-components as small peptides. It could 
therefore be relevant whether these naturally occurring peptides exhibit other functional and health 
promoting bioactive properties.  
 
On this background the overall goal of the present PhD research was to discover and characterize novel 
bioactive peptides from marine secondary products. The research was divided into two more specific 
objectives in different parts. Part I was to investigate naturally occurring peptides for bioactivities as radical 
scavenging activity, Angiotensin I-converting enzyme (ACE) and intestinal dipeptidyl peptidase (DPP-IV) 
inhibiting properties and protease inhibiting activity in tissue of secondary products such as gills, belly flap 
muscle and skin from salmon (Salmo salar). This was conducted in extracts from untreated and heat-
treated tissue by using in vitro assays. Furthermore, if any detected, an aim was to characterize the 
corresponding candidate bioactive molecules. Part II was to investigate peptides in hydrolysates from 
salmon (Salmo salar) belly flap muscle and skin generated by gastrointestinal proteases for radical 
scavenging activity, DPP-IV and ACE inhibiting properties. Furthermore it was the aim to study the stability 
and mechanism of the muscle hydrolysates towards ACE and DPP-IV activity. Also, the corresponding 
candidate bioactive molecules, - if any, in selected hydrolysates should be characterized. 
 
For the naturally occurring peptides investigated in part I, radical scavenging activity was detected in <10 
kDa extracts of gills, belly flap muscle and skin with EC50 values of 39, 82 and 100 µg/mL, respectively. No 
ACE and DPP-IV inhibiting activity could be detected. Mass spectrometry analysis of dominating compounds 
in active fractions from size exclusion chromatography showed that families of related compounds were 
found in several fractions from different tissues but most pronounced in gills. One family was defined 
according to content of a specific amino acid sequence (PW). Three families were defined by the m/z value 
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of the smallest compound reported in each family (219, 434 and 403). The three latter families did not 
contain standard unmodified amino acids, indicating peptides with modified amino acids or other kinds of 
molecules. 
For the peptides in the hydrolysates generated by gastrointestinal proteases investigated in part II, analysis 
of <10 kDa hydrolysates showed that gastrointestinal proteases generated peptides with clear radical 
scavenging activity and DPP-IV and ACE inhibiting activity as well.  Hydrolysates from pepsin digestion 
exhibited the lowest EC50 values for radical scavenging activity and ACE inhibition, whereas EC50 increased 
in hydrolysates after subsequent digestion with pancreatic and mucosal proteases. Interestingly, EC50 
values for the DPP-IV inhibition were hardly affected by sequential digestion. Inhibition modes for the 
muscle hydrolysates were both competitive and non-competitive, but prolonged incubation showed that 
the inhibitory properties were unstable, and therefore properly digested as competitive substrates by 
gastrointestinal proteases.  
When fractionated by size exclusion chromatography, radical scavenging activity was found in all obtained 
hydrolysates, though hydrolysates from belly flap muscle showed a much stronger activity compared to 
skin hydrolysates. DPP-IV and ACE inhibiting activity was observed in nearly all fractionated hydrolysates, 
only in the pepsin generated hydrolysates no pronounced (or maybe none) DPP-IV inhibitory effect was 
observed. This is notable, as it was not in agreement with the obtained results from EC50 values for the 
three-fold dilution curves. However, it is interesting, as it might be due to a synergy effect only present in 
the main hydrolysates, which vanishes when the hydrolysates are separated into fractions. 
Finally, mass spectrometry analysis of dominating compounds in active fractions from size exclusion 
chromatography from belly flap muscle and skin hydrolysate generated from pancreatin/mucosa digestion, 
showed that many compounds were present in several fractions. Currently it has not been possible to 
identify candidate bioactive compounds responsible for a certain bioactivity, as a more thorough analysis 
and characterization is required.  
Overall, this PhD research clearly showed a potential for bioactive peptides with health promoting 
properties from fish secondary tissues, especially when generated with gastrointestinal proteases, both in 
relation to gastrointestinal digestion and as an alternative to the use of industrial proteases.  
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SAMMENFATNING 
Der er en stigende interesse i bioaktive peptider fra marine sekundære produkter, idet de er i besiddelse af 
et stort potentiale for at blive inkorporeret til funktionelle fødevarer og til medicinale formål. Bioaktive 
peptider fra det marine område er observeret værende i besiddelse af et bredt spekter af fysiologiske 
funktioner bl.a. antioxidative, blodtrykssænkende, antimikrobielle, anticancer samt effekt mod diabetes 2. 
Størstedelen af forskningen har dog fokuseret på peptider genereret fra hydrolyse med kommercielle 
industrielle enzymer og anvendelsen af disse hydrolysater.  
Det kunne være interessant at finde ud af om nedbrydelse af sekundære produkter fra fisk med 
fordøjelsesproteaser genererer peptider, som også er i besiddelse af disse sundhedsfremmende 
egenskaber, enten set i relation til fordøjelse eller som et alternativ til anvendelsen/brugen af industrielle 
proteaser. Generelt må fisk være udstyret med et særligt bioaktivt forsvar mod den store 
bakteriemængede i vandet, og må derfor forventes at være i besiddelse af bio-molekyler såsom små 
peptider.  Det kunne derfor være relevant at undersøge om disse naturligt forekommende peptider 
indeholder andre funktionelle og sundhedsfremmende bioaktive peptider.  
På denne baggrund har dette PhD projekt haft til formål at finde og karakterisere hidtil ukendte bioaktive 
peptider fra marine sekundære produkter. Projektet var inddelt i to mere specifikke formål. Del I var at 
undersøge naturligt forekommende peptider for bioaktiviteter som radikal scavenging aktivitet, 
Angiotensin I-converting enzym (ACE) og dipeptidyl peptidase (DPP-IV) inbiberende egenskaber og protease 
inhiberende aktivitet i væv fra sekundære produkter som gæller, buglap muskel og skind fra laks (Salmo 
salar). Dette blev udført i ekstrakter fra ubehandlet og varmebehandlet væv ved hjælp af in vitro assays. 
Hvis bioaktivitets molekyler blev påvist, var det desuden et mål at karakterisere de korresponderende 
bioaktivitets kandidater. I del II var formålet at undersøge peptider i hydrolysater fra buglap muskel og 
skind genereret ved hjælp af fordøjelsesproteaser for radikal scavenging aktivitet, ACE og DPP-IV 
inbiberende egenskaber. Yderligere var formålet at studere stabiliteten og mekanismen af muskel 
hydrolysat overfor ACE og DPP-IV aktivitet. Derudover, hvis bioaktivitets molekyler var påvist, var det 
ligeledes et mål at karakterisere de korresponderende bioaktivitets kandidater. 
For de naturligt forekommende peptider undersøgt i del I, blev radikal scavenging aktivitet fundet i <10 kDa 
ekstrakter fra gæller, buglap muskel og skind med respektive EC50 værdier på 39, 82 og 100 µg/mL. Der 
kunne ikke detekteres ACE og DPP-IV inhiberende aktivitet. Analyse af dominerende komponenter i aktive 
fraktioner fra gel kromatografi ved hjælp af massespektrometri viste, at familier fra beslægtede 
komponenter var i mange fraktioner i forskelligt væv, men mest udtalt i gæller. En familie var defineret i 
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overensstemmelse med en specifik amino syre sekvens (PW). Tre familier var defineret ved hjælp af m/z 
værdien af den mindste komponent i hver familie (219, 434 og 403). De tre sidstnævnte indeholdt ikke 
standard umodificerede amino syrer, hvilket indikerer peptider med modificerede amino syrer eller andre 
typer molekyler. 
For peptiderne i hydrolysaterne genereret ved hjælp af fordøjelsesproteaser i del II, viste analyse af <10 
kDa hydrolysaterne at fordøjelsesproteaser genererede peptider med en tydelig radikal scavenging aktivitet 
samt DPP-IV og ACE inhiberende aktivitet. Hydrolysater fra pepsin fordøjelse udviste den laveste EC50 værdi 
for radikal scavenging aktivitet og DPP-IV inhibering, hvorimod EC50 tiltog i hydrolysater efter efterfølgende 
nedbrydning med proteaser fra pancreatin og mucosa. Interessant, så blev EC50 værdierne for DPP-IV 
næsten ikke påvirket af sekventiel nedbrydning.  Muskel hydrolysatet viste både kompetitive og ikke-
kompetitiv inhibering, men en forlænget inkubation viste at inhiberingsegenskaberne var ustabile og ville 
derfor nedbrydes helt som kompetitive substrater af fordøjelsesproteaser. 
 Når hydrolysater blev fraktioneret ved hjælp af gel kromatografi, blev radikal scavenging aktivitet 
observeret i alle hydrolysaterne, dog udviste hydrolysaterne fra buglap muskel stærkere aktivitet end 
hydrolysaterne fra skind. DPP-IV og ACE inhiberende aktivitet blev observeret i næsten alle de 
fraktionerede hydrolysater, kun i det pepsin genererede hydrolysate blev ingen tydelig (eller måske ingen) 
DPP-IV aktivitet observeret. Dette er bemærkelsesværdigt, idet det ikke var i overensstemmelse med 
resultaterne fra EC50 værdierne fra tre-folds fortyndingskurverne. Dog er det interessant, idet det kan 
skyldes en synergi effekt som kun er til stede i hoved hydrolysatet, og som forsvinder når hydrolysatet 
separeres til fraktioner. 
Analyse ved hjælp af massespektrometri af de dominerende komponenter fra de aktive fraktioner fra 
buglap muskel og skind hydrolysaterne genereret af pancreatin/mucosa viste, at mange komponenter var 
til stede i flere fraktioner.  Det har endnu ikke været muligt at identificere mulige kandidat bioaktive 
komponenter som er ansvarlige for én bestemt bioaktivitet, idet en mere uddybende analyse og 
karakterisering er påkrævet.  
Dette PhD projekt viste et tydeligt potentiale for bioaktive peptider med sundhedsfremmende egenskaber 
fra marine sekundære produkter, både set i relation til fordøjelse og som et alternativ til anvendelse af 
industrielle proteaser. 
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ABBREVIATIONS 
ABTS: 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) 
ACE:   Angiotensin I-converting enzyme 
ACN:  Acetonitrile 
AMPs:  Antimicrobial peptides 
BCA:  Bicinchoninic acid 
BHA: Butylated hydroxyanisole 
BHT: Butylated hydroxytoluene 
BSA:  Bovine serum albumin 
DPPH: 2,2-diphenyl-1-picrylhydrazyl 
DPP-IV:  Dipeptidyl peptidase IV 
E/S ratio:  Enzyme/Substrate ratio 
EC50:  Half-maximal effective concentration 
EI complex:  Enzyme/Inhibitor complex 
ES complex:  Enzyme/Substrate complex 
FA:  Formic acid 
FPLC:  Fast protein liquid chromatography 
GIP:  Gastric inhibitory polypeptide 
GLP-1:  Glucagon-like peptide-1 
HPLC:  High pressure liquid chromatography 
IC50:  Measure of a compound's inhibition (50% inhibition) 
kDa: Kilodalton 
LC-MS:  Liquid chromatography - mass spectrometry 
m/z:  Mass to charge ratio 
MALDI: Matrix-assisted laser desorption/ionization  
MS/MS: Tandem mass spectrometry  
OPA: o-phthalaldehyde 
RFU: Relative fluorescence units 
ROS: Reactive oxygen species 
RP: Reverse phase 
Rt:  Retention time 
SEC: Size exclusion chromatography 
TOF: Time-of-flight mass spectrometer 
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CHAPTER  1      INTRODUCTION 
During the recent years there has been an increasing interest in bioprospecting i.e., the process of finding, 
developing and exploiting new biological compounds, especially for health and medical purposes. The 
starting point for bioprospecting may in fact sometimes be materials that traditionally have been regarded 
as waste, or they have been used for low-value purposes, like animal feed. This combined with animals 
living in extreme environments having developed functions to live under these extreme conditions can 
result in natural sources containing interesting bioactive components. If interesting bioactivities are found, 
and the bioactive compounds can be isolated and identified, valuable new products can be made 
(Chalamaiah et al, 2012; Harnedy & FitzGerald, 2012).  
The aquatic ecosystem represents a large number of organisms adapted to living conditions remarkably 
different from the land-living ones. Fish is expected to harbour a large number of bio-components as they 
must possess an eminent bioactive defence in order to protect them from the load of bacteria present in 
water (Harnedy & FitzGerald, 2012). 
Studies have shown that fish proteins hydrolysed with commercial proteases result in bioactive peptides 
with possible health promoting properties such as antioxidant effect (Je et al, 2008), immunostimulating 
effect (Yang et al, 2009) anticancer effect (Picot et al, 2006) antimicrobial activity (Liu et al, 2008) 
angiotensin I-converting enzyme (ACE) inhibiting activity (Bordenave et al, 2002) and diabetes 2 effect (Li-
Chan et al, 2012). Most of the research has focused on preparation and characterization of hydrolysates for 
commercial use in health and functional foods. An appropriate aspect is whether a gastrointestinal 
digestion of fish proteins generates peptides, which could have similar health promoting properties.  
Furthermore natural occurring antimicrobial peptides (AMPs) have been discovered in fish (Rajanbabu & 
Chen, 2011; Corrales et al, 2009). However, only few naturally occurring bioactive peptides have been 
characterized such as the antimicrobial polypeptide piscidines from gills (Corrales et al, 2010). It is 
therefore relevant to investigate if fish tissue also contains other natural occurring peptides with additional 
bioactive properties used as bioactive defense for harmful environments. 
Tissue and proteins from secondary products from fish e.g. fish gills, belly flap muscle and skin could 
therefore be a new source of peptides, which may have a nutritional and pharmaceutical value. These 
bioactive peptides could be used in health and functional foods, and thereby increasing the value adding of 
secondary marine products.  
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1.1.  Objectives and hypotheses 
The main objective of this PhD research was to discover and characterize novel bioactive peptides from 
marine secondary products. In order to achieve this main objective and to expand knowledge about 
bioactive peptides from marine secondary products, this PhD was divided into two more specific objectives 
in different parts:  
Part I. To investigate naturally occurring peptides extracted from untreated and heat-treated tissue of 
secondary products such as gills, belly flap muscle and skin from salmon (Salmo salar).  
Part II. To investigate peptides from salmon (Salmo salar) belly flap muscle and skin hydrolysed by 
gastrointestinal proteases.  
The hypotheses behind these parts are described as follows: 
Hypotheses in part I:  
 Do naturally occurring low molecular compounds in extracts from salmon tissues of secondary 
products possess bioactivities such as radical scavenging capacity, intestinal DPP-IV and angiotensin 
I-converting enzyme (ACE) inhibiting properties? 
 Do low molecular compounds in salmon extracts separated by size exclusion chromatography 
possess bioactivities as radical scavenging effect, intestinal DPP-IV and ACE inhibiting activity? 
 The extraction procedure has an effect on the composition of compounds from gills, belly flap 
muscle and skin. 
 Can it be showed that low molecular extracts consists of peptides with unmodified amino acids? 
 Can candidate bioactive compounds be identified?  
Hypotheses in part II: 
 Do low molecular compounds in hydrolysates obtained from an in vitro digestion of salmon muscle 
and skin with gastrointestinal proteases possess bioactivities such as radical scavenging capacity, 
intestinal DPP-IV and angiotensin I-converting enzyme (ACE) inhibiting properties?  
 The inhibitory stability and mechanisms of a low molecular hydrolysate towards ACE and DPP-IV 
activity can be evaluated. 
 Do low molecular compounds in hydrolysates from in vitro digestion of salmon muscle and skin 
with gastrointestinal proteases separated by size exclusion chromatography possess bioactivities 
such as radical scavenging effect, intestinal DPP-IV and ACE inhibiting activity? 
 Can candidate bioactive compounds be identified?  
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1.2. Thesis outline  
The present thesis is divided into three main parts. The first part consists of the introduction and 
background theory for the work presented in this thesis (chapter 1, 2, 3 and 4). The second part of the 
thesis describes the experimental work and the main methods used in the experiments (chapter 5). The 
third part presents the results and discussion (chapter 6). Conclusions based on the obtained results are 
furthermore drawn in the third part, where future perspectives also are discussed (chapter 7).  
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CHAPTER 2  BIOACTIVE PEPTIDES 
2.1. Bioactive peptide discovery 
For a long time food proteins have been recognized for their nutritional and functional properties, but for 
the last two decades there has been an increased interest in the research of food-derived bioactive 
peptides, especially on the identification of bioactive peptides from milk proteins (Ryan et al, 2011). In 1950 
the first food-derived bioactive peptide was identified by Mellander. He discovered that milk casein-derived 
peptides were able to enhance vitamin D-independent bone calcification in rachitic infants (Mellander, 
1950).  The bioactive peptides have been identified in different foods such as milk, muscle and plant, and 
proteins from these sources are a big potential as novel sources of bioactive peptides, - however, only few 
food products containing meat or marine derived bioactive peptides are available commercially (Ryan et al, 
2011). The food derived bioactive peptides display various physiological functions e.g. antioxidative, 
antimicrobial, prebiotic, antithrombotic and immunomodulatory effects, where the antihypertensive 
activity is the most widely reported, especially the peptides able to inhibit the ACE enzyme (Arihara, 
2006a). Commercial products containing bioactive peptides are in the marked, with Calpis (from Japan) and 
Evolus (from Finland), both from fermented milk proteins being perhaps the two most widely known 
products (Ryan et al, 2011).  
2.2. Bioactive peptides  
Bioactive peptides are specific protein fragments, and in addition to act as amino acids and nitrogen 
sources, they have numerous potential physiological functions within the body (Harnedy & FitzGerald, 
2012). Bioactive peptides can be naturally occurring biomolecules, produced by microbial fermentation or 
generated with a variety of different enzymes, such as commercially available enzymes or for instance 
gastro intestinal enzymes. The biologically active peptides or functional peptides (genuine or generated) 
can in addition to their nutritional value exert a physiological effect in the body (Vermeirssen et al, 2004). 
Thus, bioactive peptides are inactive or latent within the parent protein sequence, and can be released e.g. 
through either digestion with commercial enzymes, released during gastrointestinal digestion and during 
food processing in order to be in active form and thereby to exert an effect (Ryan et al, 2011). Two factors 
determine the generated bioactive peptide: the primary sequence of the protein substrate and the 
specificity of the enzyme(s) which is used to generate the peptide (Harnedy & FitzGerald, 2012). The size of 
bioactive peptides is usually 2-20 amino acid residues in length, but longer residues have been found. The 
bioactive peptides can be absorbed by the intestine and be transported out intact in the circulatory system, 
where they exert physiological effects, or they may stay in the digestive tract to produce local effects 
(Erdmann et al, 2008). The ability of bioactive peptides to exert physiological effects in vivo depends on the 
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peptides bioavailability, which is predominantly determined by the resistance to peptidase degradation of 
both the intestinal tract and serum, and its ability to intestinal absorption (Vermeirssen et al, 2004). 
The bioactive peptides have been detected in a wide range of food materials from plant and animal 
sources, fungi and microalgae (Agyei & Danquah, 2012). Animal sources as milk (Clausen et al, 2009; 
LaCroix & Li-Chan, 2012), cheese (Uenishi et al, 2012), eggs (Dávalos et al, 2004), fish (Pampanin et al, 2012; 
Raghavan et al, 2008), seafood (Hatanaka et al, 2009), pork (Escudero et al, 2010) and beef (Jang & Lee, 
2005), plant sources as wheat (Zhu et at, 2006), rice (Zhang et al, 2010) and amaranth seeds (Velarde-
Salcedo et al, 2013), from fungi such as brewer’s yeast (Kanauchi et al, 2005) and from microalgae (Sheih et 
al, 2009) and macroalgea (Tierney et al, 2013) just to point out a few sources from the wide range of food 
materials bioactive peptides originate from. The beneficial biological functionalities affects various systems 
in the body (see figure 1). Furthermore, some bioactive peptides may exhibit multifunctional properties, 
where specific peptide sequences may possess two or more different biological activities (Harnedy & 
FitzGerald, 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Beneficial biological functionalities of food derived peptides and the body system influenced (Agyei & Danquah, 2012). 
 
2.3. Naturally occurring bioactive peptides from marine sources 
Natural occurring antimicrobial peptides (AMPs) are widely distributed effectors in plants and animals 
innate immunity. The AMPs are small peptides (most less than 50 amino acids), and show a broad spectrum 
of antimicrobial activity. So far over 900 AMPs have been identified across species (McDermott, 2009). 
In order to isolate the naturally occurring peptides from the source e.g. extraction with buffers (Pampanin 
et al, 2012), acetic acid (Corrales et al, 2009), ethanol (Shirai et al, 1983), trichloroacetic acid (Suzuki et al, 
 6 
 
1990; Abe, 1983), 100% water, ethanol/water (80:20) and acetone/water (80:20) (Tierney et al, 2013) have 
been used. 
Many of the AMPs found in invertebrates have also been discovered in fish (Rajanbabu & Chen, 2011). Fish 
are adapted to living conditions which are much different from the land-living ones. In general fish must 
possess an outstanding bioactive defense in order to be able to protect them self from the high bacterial 
load in water, and are therefore expected to harbor bio-components such as bioactive peptides (Harnedy & 
FitzGerald, 2012). In addition, AMPs which are unique for fish have been identified, e.g. the antimicrobial 
polypeptides piscidines from gills (Corrales et al, 2009). Studies have shown that some of these peptides 
also exhibit immunomodulatory and antitumor activity (Rajanbabu & Chen, 2011). Pampanin et al (2012) 
detected a number of small peptides by LC-MS/MS in extracts from herring tissues and based on their 
sequence, a number of peptides with potential bioactivities, such as ACE, antioxidative, immunomodulatory 
have been identified. It is therefore possible that some of these peptides or peptide like molecules present 
in fish tissue are multifunctional and may exhibit other bioactivities like antioxidative activity. Like 
mammals, fish tissue already contains, in variable amounts, some known peptides/amino acids with 
antioxidative activity such as the imidazoles: anserine, carnosine, histidine (Abe et al, 1983; Shirai et al, 
1983; Suzuki et al, 1990) and glutathione (Bauchart et al, 2007). However, anserine is also found to have 
angiotensin converting enzyme (ACE) inhibiting properties (Hou et al, 2003).  
2.4. Hydrolysis generated bioactive peptides from marine sources 
The most commonly used method for producing bioactive peptides is enzymatic hydrolysis of proteins, 
where the enzymes applied could be from bacterial, fungal or plant sources or from gastrointestinal origin. 
The hydrolytic specificity of the enzyme determines which types of peptides are generated and production 
of bioactive peptides is furthermore performed at the optimal conditions for the enzyme. A combination of 
different enzyme treatments can produce various novel peptides. Furthermore, in order to mimic the 
peptides produced by the human digestive system, digestive proteases as trypsin, chymotrypsin and 
carboxypeptidase A can be used. By using these specific enzyme combinations it is possible to simulate the 
fate of a protein molecule when it passes through the digestive system (Agyei & Danquah, 2012).  
Marine bioactive peptides possess a variety of beneficial biological functionalities and have many 
physiological effects in the human body. Several studies have shown that fish protein hydrolysed with 
commercial proteases generates peptides with potential health promoting properties. Among them are 
effects towards hypertension (Balti et al, 2010; Hatanaka et al, 2009; Byun & Kim, 2001), diabetes 2 (Li-
Chan et al, 2012; Huang et al, 2012), antioxidative properties (Kim et al, 2001; Hsu et al, 2009; Farvin et al, 
2013) as well as anticarcinogen properties (Picot et al, 2006; Hsu et al, 2011).  
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Recent studies have shown that digestion of fish proteins with individual digestive proteases as pepsin and 
chymotrypsin to is to able produce ACE (Qian et al, 2007; Lee et al, 2010; Jung et al, 2006) and DPP-IV 
inhibiting peptides (Li-Chan et al, 2012), but knowledge on which peptides are produced during in vitro 
gastrointestinal digestion is more limited. A study by Escudera showed that an in vitro gastrointestinal 
digestion of pork muscle generated ACE inhibiting peptides mainly from the muscle protein titin (Escudero 
et al, 2010). 
2.5. Production and identification of bioactive peptides  
The most widely used technique to produce bioactive peptides is by enzymatic digestion using various 
proteolytic enzymes (Ryan et al, 2011). Methods include hydrolysis by plant, animal and bacterial proteases 
(Arihara, 2006a). Commercial enzymes from bacterial and fungal sources as well as digestive enzymes such 
as chymotrypsin, pancreatin, trypsin and pepsin have been used (Ryan et al, 2011). Extraction of naturally 
occurring peptides is furthermore a method for obtaining bioactive peptides (Tierney et al, 2013; Pampanin 
et al, 2012). So far the microbial fermentation of muscle proteins has not resulted in discovery of any 
bioactive peptides (Ryan et al, 2011). In order to identify bioactive peptides following hydrolysis, the crude 
hydrolysates are assayed for various bioactivities and size fractionated (figure 2).  
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Figure 2. Procedure for the isolation and identification of bioactive peptides from food proteins (modified from Arihara, 2006b). 
The size separated peptide fractions are then tested for bioactivities, and the fraction displaying the highest 
bioactivity is further purified with techniques as reverse phase high performance liquid chromatography. In 
order to identify individual peptide fractions a combination of HPLC and mass spectrometry (LC-MS) and 
protein sequencing are useful tools (Arihara, 2006b). Verification of the bioactivity can be done by 
repeating the assay with a synthetic version of the peptide of interest (Ryan et al, 2011). 
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CHAPTER 3 BIOACTIVIES INVESTIGATED IN THE PRESENT THESIS 
This project focuses on the three bioactivities: radical scavenging activity, angiotensin I-converting 
inhibition and dipeptidyl peptidase inhibition, which will be described in the following sections. 
The three bioactivities are highly relevant, very important and wide-ranging as they highly influence on 
serious illnesses as inflammation, hypertension and diabetes 2, which affect numerous people worldwide. 
3.1. Radical scavenging   
3.1.1. Radical scavenging mechanism 
Food quality and shelf-life of food products can be reduced by lipid perioxidation, and consumption of 
foods with lipid oxidation products has been linked to serious diseases. Antioxidants protect the body 
against reactive oxygen species (ROS), such as superoxide anion (O2-) and hydroxyl (OH-) radicals, which are 
molecules that can attack DNA, protein and membrane lipids. This can lead to different diseases as 
diabetes, cancer, Alzheimer’s and cardiovascular diseases. (Ryan et al, 2011). Free radicals are generated 
through normal reactions within the body during respiration, and they can provide defense against 
infections and exert diverse functions like signaling roles. The antioxidant system can under normal 
conditions remove reactive species through enzymatic (e.g. superoxide dismutase SOD) and non-enzymatic 
antioxidants (e.g. antioxidant vitamins and trace elements). Under certain circumstances, the endogenous 
defense system fails to protect the body on its own and this result in oxidative stress (Sarmadi & Ismail, 
2010). Oxidative stress is characterized by an increased level of reactive free radicals within cells (Mine & 
Katayama, 2008). This can induce cell damage causing inflammation e.g. in gut. One way to suppress 
oxidative stress is intake of dietary antioxidative peptides and amino acids that can act as radical 
scavengers (Katayama & Mine, 2007; Xu et al, 2012).  
When the free radical scavenger encounters a free radical it donates a single electron or a single proton to 
it, depending on the type of radical scavenger (figure 3). The reactive potentially harmful radical is now a 
non-radical and can now be metabolized and excreted without doing any harm. The free radical scavenger 
has become a radical, however, a more stable radical and therefore less harmful.   
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Figure 3. Radical scavenger mechanism. The radical scavenger donates an electron to the free radical, so it becomes an unharmful 
non-radical (http://chemwiki.ucdavis.edu). 
3.1.2. Antioxidant peptides 
In order to retard e.g. lipid peroxidation synthetic antioxidants such as butylated anisole (BHA) and 
butylated hydroxytoluene (BHT) are added to food products. However, the synthetic antioxidants are 
associated with some safety concerns and as a result of this, natural antioxidants such as bioactive peptides 
with no or little side-effects have gained interest due to their food quality prolonging abilities and potential 
health benefits (Harnedy & FitzGerald, 2012). Antioxidant peptides have been found in different foodstuffs 
such as milk (Clausen et al, 2009), egg (Dávalos et al, 2004), wheat (Zhu et al, 2006), rice (Zhang et al, 2010) 
and fish (Kim et al, 2001). In the resent years, a lot of research has focused on antioxidant peptides derived 
from fish sources (Ryan et al, 2011).  
Peptides and protein hydrolysates derived from food have in research shown to exert antioxidant activities 
against enzymatic (lipoxygenase-mediated) and non-enzymatic peroxidation of lipids and fatty acids. The 
exact mechanism by which peptides display antioxidant activity is not fully understood, however the 
antioxidant properties has been suggested to be due to free radical scavenging, metal ion chelation and 
singulet oxygen quenching (Erdmann et al, 2008). The type, hydrophobicity and position of amino acids in 
the peptide are believed to play an essential role regarding antioxidant activity of a peptide. Amino acid 
residues such as cystein, histidine, leucine, methionine and tyrosine have been found to be associated with 
radical scavenging activity. These amino acids donate protons to electron deficient radicals and thereby 
enhancing radical scavenging activity (Harnedy & FitzGerald, 2012). Furthermore, many antioxidative 
peptides have the hydrophobic amino acid residues valine or leucine at the N-terminus at the peptide (Kim 
et al, 2001). 
3.1.3. Radical scavenging peptides from marine hydrolysates 
Radical scavenging activity has been found in peptides derived from fish muscle but also from marine 
byproducts as skin, dark muscle and frame (Raghavan et al, 2008; Dong et al, 2008; Wu et al, 2003; Mendis 
et al, 2005; Hsu et al, 2010; Je et al, 2005; Kim et al, 2001; Kim et al, 2007). 
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Tilapia white meat protein hydrolysates generated from different enzymes were investigated for their 
ability to scavenge reactive oxygen species (ROS) and their reducing power. Hydrolysates prepared with 
Flavourzyme and Cryotin were most effective as in reducing ferric ions and to scavenge ROS, respectively. 
In general, the ability of the hydrolysates to scavenge ROS increased with degree of hydrolysis, in the 
means of low molecular peptides were better scavengers than high molecular peptides. It was suggested 
that the high activity of low molecular peptides could be due to the size of peptides, the composition of 
these or a combination of both (Raghavan et al, 2008).  
Dong et al (2008) found that hydrolysates from Silver carp muscle prepared from Alcalase and Flavourzyme 
exhibited significantly radical scavenging ability and were able to inhibit lineolic acid peroxidation. The 
obtained results showed that there was an association between the antioxidative activity of the 
hydrolysates and molecular weight, degree of hydrolysis and hydrolysis time (Dong et al, 2008). 
Peptides released from hydrolysis of mackerel meat with the commercial enzyme Protease N possessed 
noticeable antioxidative activities as they inhibited lineolic acid autoxidation, scavenged the DPPH free 
radical and reduced Fe3+ to Fe2+. The strongest in vitro antioxidant activity was found in peptide fraction 
with a molecular weight of 1400 Da. It was suggested that there was a correlation between the antioxidant 
activity and amount of peptides (Wu et al, 2003). The results from the different studies indicate that 
antioxidant activity depends of free amino acids present in the hydrolysates, of peptide size and of the 
amino acid composition of the peptide. This is also in accordance with Harnedy & FitzGerald (2012) and Kim 
et al (2001). 
Different digestive enzymes were used to hydrolyse hoki skin with and the trypsin derived hydrolysate was 
found to exhibit the highest scavenging activity. The hydrolysate was further purified and a derived peptide 
His-Gly-Pro-Leu-Gly-Pro-Leu with a MW of 797 Da acted as a strong radical scavenger. The peptide showed 
an inhibition of lipid peroxidation significantly greater than their control α-tocopherol and as effective as 
butylated hydroxytoluene (BHT), the synthetic antioxidant. Furthermore the peptide was presumed to be 
involved in maintaining the cell environment, as the expression of antioxidative enzymes in cultured human 
hepatoma cells in vitro were increased (Mendis et al, 2005). Peptides isolated from gelatin hydrolysates 
from Alaska pollack skin were found to have antioxidant activity. Peptides showing the strongest activity 
was further purified and characterized. One of the purified peptides furthermore had potent antioxidative 
effect on peroxidation of linoleic acid. The peptide was found to be composed of 16 amino acid residues, 
and containing a Gly residue at the C-terminus and the repeating motif Gly-Pro-Hyp (Kim et al, 2001). 
Six proteases were used for enzymatic hydrolysis in order to extract antioxidant peptides from hoki frame 
protein hydrolysate. Hydrolysates showing the highest antioxidant activity were further purified using 
chromatographic methods. The purified peptide had an amino acid sequence of Glu-Ser-Thr-Val-Pro-Glu-
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Arg-Thr-His-Pro-Ala-Cys-Pro-Asp-Phe-Asn and a MW of 1801 Da. The 16 amino acid long peptide effectively 
quenched different sources of free radical and inhibited lipid peroxidation higher than the positive control 
α-tocopherol. In addition the purified peptide protected free-radical-induced DNA damage and decreased 
radical-mediated cytotoxicity on human embryonic lung fibroblasts (Kim et al, 2007). 
Protein by-products as heads and viscera proteins from sardinelle were hydrolysed by different proteases. 
In general, all hydrolysates had different degrees of hydrolysis and varying degree of antioxidant activities. 
The hydrolysate showing the highest antioxidant activity was generated with a crude enzyme extract from 
sardine. This hydrolysate was further purified and seven novel antioxidant peptides with molecular weights 
below 600 Da were identified. The peptide displaying the highest radical scavenging activity was identified 
as Leu-His-Tyr It was suggested that the high activity may be due to the presence of both His and Tyr 
residues (Bougatef et al, 2010).  
Hsu et al (2009) isolated antioxidant peptides from tuna cooking juice hydrolysates. The obtained 
hydrolysate was subjected to size exclusion chromatography and the highest antioxidative activity was 
found in peptide fractions from 400 to 1500 Da. The peptide fractions was further isolated, and the final 
three antioxidative peptides which was investigated using both DPPH radical scavenging effect and lipid 
peroxidation inhibition assays, consisted of 4, 7 and 10 amino acid sequences with MW of 584, 938 and 
1305 Da (Hsu et al, 2009). 
Hsu (2010) also used another by-product, dark muscle from tuna, to hydrolyse with the commercial 
enzymes, protease XXIII and orientase. The hydrolysates were subjected to gel filtration chromatography, 
and both hydrolysates and fractions possessed strong DPPH radical scavenging activity and high antioxidant 
capacity (inhibition of lipid oxidation). Hsu found that peptide fractions with the highest antioxidative 
activity had molecular weights ranging from 390 to 1400 Da.  A further purification of the peptide fractions 
with HPLC revealed the sequences from the antioxidative peptides to be Leu-Pro-Thr-Ser-Glu-Ala-Ala-Lys-
Tyr and Pro-Met-Asp-Tyr-Met-Val-Thr, with molecular weights of 978 and 756 Da, respectively. Hsu 
furthermore suggested that the inhibition of lipid oxidation might be due to the radical scavenging activity, 
as the highly hydrophobic amino acids (such as leucine, valine, tyrosine, methionine) might possess the 
ability to interact with lipids and scavenge lipid-derived radicals by donating electrons. The results also 
confirm that amino acids such as Lys, His, Met, Trp and Tyr are generally accepted as antioxidants (Hsu, 
2010).  
Je et al (2005) reported an antioxidative peptide from Alaska pollack frame protein released by hydrolysis 
with a crude enzyme from mackerel intestine. The purified peptide had an amino acid sequence of Leu-Pro-
His-Ser-Gly-Tyr and a MW of 672 Da. Furthermore, at a concentration at 53.6µM, the peptide was able to 
scavenge 35% of available hydroxyl radicals.  It was suggested that the antioxidative activity of the peptides 
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was dependent on the molecular weight and amino acid residue (Je et al, 2005). This is in agreement with 
leucine, histidine and tyrosine residues are found to be associated with radical scavenging activity. The 
results from the different studies indicates that fish sources and fish by-products may be used in preventing 
the oxidation reactions observed in food processing and as natural antioxidants in order to enhance 
antioxidative properties of functional foods. 
3.2. Angiotensin I-converting enzyme inhibition 
3.2.1. Role in hypertension 
High blood pressure is a major risk for cardiovascular disease, including coronary heart disease, which is the 
leading cause of death in the developed industrialized countries (Arihara, 2006b). Angiotensin I-converting 
enzyme (ACE; EC 3.4.15.1) or kininase II is a nonspecific dipeptidyl carboxypeptidase located in many 
tissues and biological fluids (Shalaby et al, 2006). It is also known as dipeptidyl dipeptidase A because it 
removes C-terminal dipeptides from a wide variety of peptide substrates (Sentandreu & Toldrá, 2006). ACE 
belongs to the class of zinc proteases that need zink and chloride for its activation (Byun & Kim, 2001). 
Blood pressure is regulated by many factors; among them is the conversion of angiotensin I to angiotensin 
II by the angiotensin I-converting enzyme (ACE) which results in increased blood pressure. ACE plays a key 
role in the regulation of blood pressure and normal cardiovascular function and is associated with the 
blood pressure regulating renin-angiotensin system (Vermeirssen et al, 2002; Shalaby et al, 2006). 
In this system (figure 4) ACE catalyse the conversion of the inactive form of the decapeptide angiotensin I 
to the potent vasoconstrictor angiotensin II by hydrolytically splitting off the dipeptide His-Leu from the 
carboxyl end of angiotensin I (Ryan el al, 2011; Carmel & Yaron, 1978). 
 
 
 
 
 
 
 
Figure 4.  Angiotensin I-converting enzyme is associated with the blood pressure regulating renin-angiotensin system (Arihara, 
2006b). 
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The octapeptide angiotensin II brings several central effects like promoting salt retention among others and 
leads to a further increase in the blood pressure (Sentandreu & Toldrá, 2006). Being a multifunctional 
enzyme, ACE also catalyses the degradation of bradykinin, a blood pressure-lowering nonapeptide in the 
kallikrein-kinin system, into inactive fragments (Vermeirssen et al, 2002). By these actions ACE elevates the 
blood pressure. An inhibition of the ACE enzyme will therefore result in an overall antihypertensive effect 
(Shalaby et al, 2006).  
3.2.2. ACE inhibiting peptides 
In the treatment of high blood pressure one group of drugs are synthetic ACE inhibitors (Vermeirssen et al, 
2002). Since the discovery of the first ACE inhibitory peptides in snake venom, many synthetic ACE 
inhibitors have been produced (Ryan et al, 2011). Captopril is one of the most common ones, but this along 
with other synthetic ACE inhibitors can have various side effects due to their specificity and high activity 
(Vermeirssen et al, 2002). The use of synthetic ACE inhibiting drugs is under strict regulation due to the 
potential health hazards, and these health hazards and side effects, along with the fact that high blood 
pressure affects one third of the Western Worlds, contributes to the ongoing search for a healthier and 
natural alternative for the synthetic ACE inhibitory drugs. The food derived bioactive peptides may serve as 
source for antihypertensive agents in e.g. nutraceuticals and functional foods (Ryan et al, 2011). 
An inhibition of ACE can prevent hypertension (Fyhrquist & Saijonmaa, 2008). In general the potency of an 
ACE inhibitory component is denoted IC50 and expressed as the concentration of the component which 
inhibits 50% of ACE activity (Harnedy and FitzGerald, 2012). Ono et al (2003) showed that blood pressure in 
hypertensive rats were reduced after orally intake of salmon hydrolysates.  Furthermore research indicates 
at small and medium sized peptides can be absorbed intact through the intestine (Roberts et al, 1999).  
Hydrophobic amino acids such as proline play a role in inhibiting ACE activity (Byun & Kim, 2001). The 
information obtained from simulated gastrointestinal digestion studies and inhibition of ACE in vitro can 
only be used as an indicator for how the peptide acts in vivo. It is very important that the peptide reach its 
target in an active form, and in order to do that, it must resist degradation and modification in the 
gastrointestinal and vascular systems. Therefore, extensive in vivo studies are necessary in order to reliably 
assess the antihypertensive effects of a peptide (Harnedy and FitzGerald, 2012). 
3.2.3. Antihypertensive peptides from marine hydrolysates 
Suetsuna & Osajima identified the first ACE inhibiting peptides from fish sources. Their discovery in sardine 
meat was reported more than twenty-five years ago (Suetsuna & Osajima, 1986). ACE inhibitory peptides 
have been found in a variety of fish species like Atlantic salmon (Dragnes et al, 2009), Pacific hake 
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(Samaranayaka et al, 2010), Alaskan pollack (Byun & Kim, 2001), sardine (Suetsuna & Osajima, 1986) and 
tuna (Fujita & Yoshikawa, 1999) among others.  
From a simulated gastrointestinal digestion of Pacific hake fish protein the majority of the observed ACE 
inhibitory peptides were reported to be polar, short chained and to contain few hydrophobic amino acids in 
their sequence (Samaranayaka et al, 2010). Byun & Kim isolated antihypertensive peptides from Alaskan 
pollack skin that were composed of Gly-Pro-Leu and Gly-Pro-Met and showed IC50 values of 2.6 and 17.13 
µM, respectively. These results suggested that Gly-Pro-Leu would be useful as a new antihypertensive 
agent (Byun & Kim, 2001).  
Ahn et al (2012) used salmon byproduct from percoral fin for enzymatic hydrolysis using various proteases. 
The highest ACE inhibitory activity were found in Alcalase hydrolysates, where they purified three peptides 
with IC50 values of 9.10µM (A), 10.77µM (B) and 7.72µM (C). They furthermore analyzed the inhibition 
modes of the three purified ACE inhibitory peptides and found that (A) was a non-competitive inhibitor 
while (B) and (C) had mixed inhibition modes (Ahn et al, 2012). 
ACE inhibitory peptides from hydrolysates of sea bream scales were shown to decrease blood pressure 
significantly in hypertensive rats, which had been orally fed with the peptides. The amino acids sequences 
in the peptides demonstrating high ACE inhibitory activities in the hypertensive rats were determined to be 
Gly-Tyr, Val-Tyr, Gly-Phe and Val-Ile-Tyr (Fahmi et al, 2004).  
Tuna frame protein was also hydrolysed using various proteases and a potent ACE inhibitory peptide which 
consisted of 21 amino acids with a MW of 2.482Da and an IC50 of 11.28µM was isolated. The isolated ACE 
inhibitory peptide was shown to decrease blood pressure significantly in orally administrated 
spontaneously hypertensive rats. Furthermore the inhibition mode was analyzed using a Lineweaver-Burke 
plot and it suggests that the peptide was a non-competitive inhibitor against ACE (Lee et al, 2010).  
As mentioned above a number of rat studies using spontaneously hypertensive rats have shown a number 
of potential ACE inhibitory peptides, but there is lack of information from human studies with respect to 
the cardioprotective effect of marine waste (Harnedy & FitzGerald, 2012). However, all these findings 
suggests that hydrolysates from fish muscle and fish by-products contains compounds, that may be 
beneficial ingredients for pharmaceuticals and nutraceuticals against hypertension and the diseases related 
with it. 
 
One of the most extensively studied bioactivities, the ACE-inhibitory effect, has also been studied in salmon 
in both in vitro assays and in vivo in rats. In Atlantic salmon (Salmo salar L.) hydrolysates from rack 
(backbone and tail), skin, muscle, intestine and gills ACE inhibitory activity has been detected (Dragnes et al, 
2009; Ewart et al, 2009; Gu et al, 2011).  
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Gu et al (2011) found that the dipeptides Ala-Pro and Val-Arg from skin hydrolysates had the strongest 
activity with IC50 = 0.060 and 0.332 mg/ml, respectively. Ewart et al (2009) found the tripeptides Val-Leu-
Trp, Val-Phe-Tyr and Leu-Ala-Phe from rack had the strongest activity with IC50 = 10.0, 11.1 and 13.7 µg/ml, 
respectively. 
Enari et al (2008) have furthermore detected the ACE inhibitory effect in hydrolysates from pink salmon 
(Onchorhynchus gorbuscha) muscle. Some of the hydrolysates have been further purified with column 
chromatographic methods and mass spectrometry as liquid chromatography tandem mass spectrometry 
(LC/MS/MS) and reversed phase high performance liquid chromatography MS/MS (RP/HPLC/MS/MS) in 
order to identify the amino acid sequences.  Enari et al identified 20 active di-and tripeptides in pink salmon 
muscle, where the strongest activity was in the dipeptide Ile-Trp with IC50 = 0.38 µg/ml. Enari et al (2008) 
furthermore identified two new ACE-tripeptides, with the amino acid sequences Ile-Val-Phe and Phe-Ile-
Ale. These findings suggest that hydrolysates from salmon might be candidates for functional foods and as 
antihypertensive agents. IC50 is somewhat higher compared to e.g. captopril, but modification of the 
peptides can for instance lower IC50. 
3.3. Dipeptidyl peptidase IV (DPP-IV) inhibition 
3.3.1. Influence on insulin response 
In 2000 it was estimated that 171 million people was affected by the chronic metabolic disorder diabetes 
mellitus, and by 2030 the number is estimated to reach 366 million (Wild et al, 2004). Type 2 diabetes is 
one of the fastest growing health concerns worldwide, and it is furthermore the most prevalent form of 
diabetes, representing approximately 90-95% of all the diagnosed cases (Silveira et al, 2013). Type 2 
diabetes is characterized by a hyperglycemic chronic state due to several fundamental defects as insulin 
resistance in liver and muscle and an impaired insulin secretion by pancreatic β-cells (Velarde-Salcedo et al, 
2013). Dipeptidyl peptidase IV (DPP-IV, EC 3.4.14.5) influences the insulin response and a regulation of DPP-
IV, can therefore play a role in the treatment of diabetes 2.  
Dipeptidyl peptidase IV, a serine protease, has specificity for removing dipeptides from the N-terminus of 
proteins and substrate peptides by cleaving postproline or alanine residues in the second amino terminal 
position (Huang et al, 2012; Silveira et al, 2013). DPP-IV is expressed in both membrane and in soluble 
forms in a variety of cells, especially in the epithelial tissues as liver, intestine and kidney. DPP-IV belongs to 
the prolyl oligopeptidase family and plays numerous roles in several biological processes, including 
proteolytic action which results in inactivation or activation of cytokines, growth factors and peptides 
(Lacroix & Li-Chan, 2012). It has been shown to degrade many hormones, such as the two main incretin 
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hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide- 1 (GLP-1), which 
stimulate the insulin response (Flatt et al, 2008). 
During a meal as illustrated in figure 5, the incretin hormones, as GIP and GLP-1, are released from the 
small intestine in the gut to the bloodstream (Velarde-Salcedo et al, 2013). They act by stimulating glucose-
dependent insulin secretion in the pancreatic β-cells (Silveira el al, 2013). The insulin secretion leads to a 
lowering of the plasma glucose concentrations (Flatt et al, 2008). It has been estimated that the incretin 
hormones are responsible for over 50% of the total insulin secreted during a meal, mainly by the combined 
effects of GIP and GLP-1 (Velarde-Salcedo et al, 2013; Silveira el al, 2013). However, the enzyme DPP-IV 
inactivates these incretine hormones and as a consequence of this there is no stimulation of insulin-release 
in the pancreas and thereby no lowering of the glucose concentration in the plasma (Flatt et al, 2008).  
 
Figure 5. Overview of the DPP-IV regulation in relation to the glucose level (Flatt et al, 2008). 
DPP-IV cleaves and inactivates GIP and GLP-1 within a few minutes, which result in loss of their 
insulinotropic activities (Li-Chan et al, 2012). The concept of DPP-IV inhibitors is to prevent this rapid 
inactivation of the incretin hormones, thus enhancing endogenous incretin activity and improving glucose 
tolerance and can thereby be used as a way to prevent diabetes 2 (Flatt el al, 2008). 
3.3.2. DPP-IV inhibiting peptides 
In order to help in the management of type 2 diabetes different strategies have been developed, - 
inhibition of DPP-IV is one of them (Lacroix & Li-Chan, 2012). Inhibition of DPP-IV is seen as way to increase 
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incretin effect on insulin secretion and prevent diabetes 2 (Deacon & Holst, 2006). To be able to utilize the 
beneficial effects of GLP-1 in the treatment of e.g. type 2 diabetes, orally active dipeptidyl peptidase IV 
inhibitors have been developed (Deacon & Holst, 2006). Synthetic peptides with inhibitory properties are 
developed, where some are approved as therapeutic agents in diabetes 2 treatment (Thornberry & 
Gallwitz, 2009). In the recent years focus has been on natural inhibitory peptides from hydrolysates from 
various natural sources as an alternative to the synthetic inhibitors. 
Recent studies have shown that peptides generated with specific proteases and derived from different 
sources such as salmon skin, tuna cooking juice, gouda-type cheese, whey protein concentrate and milk 
proteins possess DPP-IV inhibiting activity (Li-Chan et al, 2012; Huang et al, 2012; Uenishi et al, 2012; 
Silveira et al, 2013; Nongonierma & FitzGerald, 2013).  
Lacroix & Li-Chan (2012) showed that in vitro gastrointestinal digestion using pepsin and pancreatin on 
different dairy proteins generated DPP-IV inhibiting peptides, and that inhibiting activity already was 
generated after pepsin digestion. Even though a peptic digestion of whey protein isolate hydrolysates had 
the greatest DPP-IV inhibitory activity (IC50 value of 75 µg/ml), the hydrolysates produced from sodium 
caseinate generally displayed higher DPP-IV inhibitory than most whey protein isolate hydrolysates. Their 
findings show a potential of dairy proteins to serve as natural precursors of DPP-IV inhibitory peptides and 
could therefore be used as a natural complementary approach in the management of type 2 diabetes 
(Lacroix & Li-Chan, 2012). 
Other studies have been made on whey proteins, which also indicate they are a source of DPP-IV inhibitory 
peptides (Tulipano et al, 2011; Silveira et al, 2013). Silveira et al (2013) hydrolysed a whey protein 
concentrate rich in β-lactoglobulin with trypsin, and further separated and analysed the fractions with RP-
HPLC-MS/MS. The peptide with the sequence Ile-Pro-Ala-Val-Phe showed high inhibitory activity (IC50 value 
of 44.7µM), and it is therefore proposed that β-lactoglobulin, as source of bioactive peptides with DPP-IV 
inhibitory activity, may be a beneficial natural ingredient of foods against type 2 diabetes (Silveira et al, 
2013).  
Uenishi et al (2012) was the first to report, that DPP-IV inhibitory peptides, casein-derived from gouda-type 
cheese, have an effect on plasma glucose in rat models. Their studies showed that the peptide with the 
identified sequence Leu-Pro-Gln-Asn-Ile-Pro-Pro-Leu had the highest DPP-IV inhibitory activity. This peptide 
was synthesized and orally administered to female rats in a glucose tolerance test. Results showed that 
their blood glucose concentrations were suppressed by the oral administration of the peptide. Even 
though, the IC50 value of the peptide Leu-Pro-Gln-Asn-Ile-Pro-Pro-Leu and its derivative peptides are more 
than 100 times lower compared to commercially DPP-IV inhibitory drugs, their research indicates the 
beneficial functions of dairy products (Uenishi et al, 2012). 
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A recent study from Velarde-Salcedo et al (2013) report the in vitro DPP-IV inhibitory activity of peptides 
released from amaranth seed proteins after simulated gastrointestinal digestion. Other seeds as wheat, 
soybean and black bean were also tested, however, the highest inhibition of DPP-IV was found in peptides 
from amaranth seed proteins. Results from in silico prediction of the bioactive peptides binding modes 
showed, that the possible mechanism of globulin peptides to inhibit DPP-IV was through blocking the active 
dimer formation. Beyond their nutritional properties, this study presents a new perspective of cereal 
benefits and their potential use as novel functional food ingredients in the prevention of type 2 diabetes 
(Velarde-Salcedo et al, 2013). 
3.3.3. DPP-IV inhibiting peptides from marine hydrolysates and other sources 
Only a few studies have been made on DPP-IV inhibitory peptides from fish hydrolysates, and therefore the 
information on this subject is sparse. However, studies on DPP-IV inhibitory peptides have been made on 
other sources such as dairy protein hydrolysates and whey protein hydrolysates as before mentioned.  
Li-Chan et al (2012) showed that hydrolysis of Atlantic salmon skin gelatin with the proteases alcalase, 
bromelain and flavourzyme generated DPP-IV inhibiting peptides. The greatest DPP-IV inhibitory activity 
was found in the flavourzyme hydrolysates with the E/S ratio of 6%. This hydrolysate was further 
fractionated by ultrafiltration with cutoff membranes and the UF-fraction under 1 kDa was purified by 
HPLC. The fraction yielding the highest DPP-IV rate had an IC50 value of 57.3µl/ml. Moreover 2 peptides 
were identified in the fraction with amino acid sequences Gly-Pro-Gly-Ala (300.4Da) and Gly-Pro-Ala-Glu 
(372.4Da). These two peptides may be useful for the prevention of or for the therapy of type 2 diabetes (Li-
Chan et al, 2012).  
Huang et al (2012) isolated three DPP-IV inhibiting peptides from tuna cooking juice hydrolysed by protease 
XXIII and orientase. The greatest DPP-IV inhibitory peptide fraction was found to have a molecular weight 
of over 1422Da. The amino acid sequences of the three isolated peptides were identified by MALDI-
TOF/TOF MS/MS, and were found to be comprised of 13-15 amino acid residues. This is much longer than 
the preferable DPP-IV inhibitory peptides, which usually have a length of 3-7 amino acids. However, the 
identified peptides all comprised at least one proline in the sequence and were composed of many 
hydrophobic amino acid residues such as Val, Leu and Ile, these results are in accordance with reports in 
patents concerning characteristics of DPP-IV-inhibitory peptides. The results show, that the DPP-IV 
inhibitory activity of bioactive peptides is not determined by the length, but by the sequence and 
composition of the amino acids. Moreover, the results from Huang et al (2012) suggests, that tuna cooking 
juice may be a cost-free and good protein source to produce DPP-IV inhibitory peptides by hydrolysis with 
commercial proteases. 
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3.4. Bioactive peptides from salmon  
Various peptides with different bioactivities besides the three described in the previous sections have so far 
been isolated from salmon; however, most of them have been hydrolyzed with proteases and are not 
naturally occurring peptides.  
Pei et al (2010) have in a study shown that oligopeptides between 300 and 860 kda isolated from protease 
hydrolyzed marine collagen from chum salmon (Onchorhynchus keta) skin facilitates learning and memory 
in aged mice through reducing oxidative damage in the brain. This finding suggests that marine collagen 
peptides could be a functional food candidate in order to relieve memory deficits which are associated with 
aging. 
Another study on chum salmon suggests that marine oligopeptides with a MW 300 and 860 kda prepared 
from fish meat by enzymatic hydrolysis is a possible immune stimulant and may strengthen the immune 
response. This study was conducted in female mice which were fed the marine oligopeptide preparation for 
a certain amount of time (Yang et al, 2009). 
Zhang et al (2011) have also studied marine collagen peptides hydrolyzed from chum salmon skin, and 
found that it enhances cutaneous wound healing and angiogenesis in rats. This suggests marine collagen 
peptides to be a therapeutically beneficial method to treat wounds in clinical practice. Furthermore Saito et 
al (2009) have shown that collagen hydrolysates from chum salmon skin affect lipid absorption and 
metabolism in rats, which may be useful in suppressing the transient increase of plasma triglycerides. 
Fish protein hydrolysates may also be a potential source of anticancer peptides, as Picot et al (2006) in 
Atlantic salmon (Salmo salar) by-products found antiproliferative activity towards two human breast cancer 
cell lines. 
The above mentioned studies clearly suggest a great potential for bioactive peptides from salmon 
hydrolysates.  
3.5. Inhibition modes of ACE and DPP-IV inhibiting peptides                                                                          
An interesting aspect is whether generated peptides inhibit DPP-IV and ACE by a competitive or non- 
competitive mechanism. The inhibitory mechanism of bioactive peptides towards e.g. ACE and DPP-IV can 
be studied by enzyme inhibition. 
 In a competitive inhibition, the inhibitor (in this case the bioactive peptide) acts as though it competes with 
the substrate for binding to an enzymatic binding site. The enzyme can bind substrate and form an ES 
complex or the inhibitor (EI), but not both of them (ESI). A competitive inhibitor resembles the substrate 
and bind to the active site of the enzyme, thereby preventing the substrate from binding to the same active 
 21 
 
site. The catalytically inactive EI complex is formed, when the inhibitor binds to the enzyme. A competitive 
inhibition can be overcome by a sufficiently high concentration of substrate. 
In an uncompetitive inhibition, the inhibitor binds only to the enzyme-substrate complex (ES), but not to 
the free enzyme. The inhibitor decreases the maximum enzyme activity, as it takes longer for the substrate 
to leave the active site. 
In a mixed inhibition, the inhibitor is able to bind to the enzyme, whether or not the enzyme has already 
bound to the substrate, but where it has higher affinity for binding the enzyme in one state or the other. It 
is kind of a mixture of a competitive inhibition, where the inhibitor only is able to bind enzyme if the 
substrate has not already bound to it, and an uncompetivtive inhibition, where the inhibitor bind only to 
the enzyme, if the substrate has already bound and formed an ES complex. 
In a non-competitive inhibition, the inhibitor acts by decreasing the activity of the enzyme (turnover 
number) rather than reducing the proportion of enzyme molecules bound to the substrate. The inhibitor 
binds equally well to the enzyme whether or not the substrate has already bound to it, and they may bind 
simultaneously at different binding sites (Voet & Voet, 2004). 
 
Peptides inhibiting ACE in a competitive, non-competitive and uncompetitive mode, respectively, has been 
found in various sources and that inhibition mode apparently is dependent on sequence and length of the 
peptide (Jao et al, 2012) Only few studies has reported inhibition mode of peptides from fish muscle.  
Ahn et al (2012) analyzed the inhibition modes of three purified ACE inhibitory peptides salmon byproduct 
from percoral fin and found that the sequence of C-terminal residue with Lys-Phe-Asp was a non-
competitive inhibitor while the sequences of C-terminal residues Ser-Cys-Phe and  Leu-Tyr-Glu had mixed 
inhibition modes (Ahn et al, 2012). A potent ACE inhibitory peptide from tuna frame protein which 
consisted of 21 amino acids with was analysed for the inhibition mode by using a Lineweaver-Burke plot 
and it suggests that the peptide was a non-competitive inhibitor against ACE (Lee et al, 2010). Ono et al 
(2006) reported that the inhibitory mechanism of ACE by different dipeptides from salmon muscle 
hydrolysates is dependent on the nature of amino acid on C-terminal and N-terminal, respectively, and that 
peptides with Trp on the C terminal exhibited non-competitive inhibition. This agrees with Jung et al (2006), 
who isolated an ACE non-competitive inhibiting peptide from yellowfin sole with a hydrophobic C terminal 
end. Several synthetic peptide competitive inhibitors of DPP-IV have been developed (Thornberry & 
Gallwitz, 2009). However, there have been no reports on the inhibition mode of DPP-IV inhibiting peptides 
from protein hydrolysates.  
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CHAPTER 4 PEPTIDES GENERATED BY GASTROINTESTINAL DIGESTION 
In the present study hydrolysis of salmon with gastrointestinal proteases has been performed. The 
proteases pepsin, pancreatin (mixture of several digestive enzymes especially trypsin) and intestinal 
mucosa have been used as enzyme sources, and these enzymes will therefore be described in the 
following.  
The digestive enzymes of the pancreas play a central role in digestion, and the major source of proteases in 
the digestive system is the pancreas. Even though the major products of the pancreatic cells are proteases, 
a variety of additional proteases are expressed throughout the digestive tract, and especially in the small 
intestine and in the stomach. The gastrointestinal system contains endopeptidases and exopeptidases 
(Whitcomb & Lowe, 2007).  
Pepsin initiates the digestion of proteins in the stomach, which breaks down proteins to peptides.  Pepsin is 
formed at low pH from the inactive zymogen pepsinogen, where pepsinogen is activated by hydrochloric 
acid and converted to pepsin. Pepsin is known to have a broad specificity and cleaves therefore very 
broadly. Hydrochloric acid also maintains a low pH in the stomach at app. 2.0, which is the pH value where 
pepsin exhibit maximal activity.  Pepsinogen is released by chief cells in the stomach and the production of 
pepsinogen is stimulated by the presence of the hormone gastrin in the blood (Gregory, 2013).   
The primary proteases as trypsin and chymotrypsin are synthesized as inactive precursors in the pancreas 
by protein biosynthesis and secreted into the lumen of the intestine, where the degradation of proteins 
continues. The inactive precursors are called chymotrypsinogen and trypsinogen. Trypsinogen is activated 
into trypsin by enterokinase, which is embedded in the intestinal mucosa or by auto catalysis by trypsin. 
Once trypsin is formed it activates chymotrypsinogen, which is cleaved into the active protease 
chymotrypsin. The two proteases trypsin and chymotrypsin are endopeptidases and belong to the serine 
protease family of enzymes, which are enzymes that share important structural functions including a serine 
at the catalytic site. Even though the structure of the serine proteases are highly homologous, the 
proteases have different specificity pockets which allows only selected peptide bonds to be hydrolysed. 
Chymotrypsin preferentially hydrolyses peptides involving aromatic amino acids as tryptophan, 
phenylalanine and tyrosine, whereas trypsin-like proteases hydrolyse the carboxyl groups of the basic 
amino acids arginine or lysine residues of peptides.  
Among proteases in the pancreatic juice, trypsin and chymotrypsin makes up about 19% and 9% of the 
protein, where trypsin is the most abundant of all pancreatic digestive enzymes. As trypsin plays a central 
role in regulating all the other digestive peptides, it is furthermore the most important of all the digestive 
enzymes (Whitcomb & Lowe, 2007). Following the peptic degradation of the proteins, the pancreatic 
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proteases trypsin, chymotrypsin, carboxypeptidase A and B and elastase cleaves the polypeptides, which 
results in a mixture of free amino acids and oligopeptides. By the action of a number of brush border 
peptidases, the oligopeptides undergo further hydrolysis which results in a mixture consisting of free amino 
acids and di- and tri-peptides (Vermeirssen et al, 2004). After digestion, bioactive peptides can either 
produce local effects in the gastrointestinal tract or be absorbed through the intestine in order to enter the 
blood circulation intact and exert systemic effects (Erdmann et al, 2008). As mentioned earlier, the peptides 
can, depending on the amino acid sequence, exhibit diverse biological functions.  
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CHAPTER 5 EXPERIMENTAL WORK 
5.1. Experimental outline 
The experimental set up is shown in figure 6. The experimental work is divided between naturally occurring 
peptides extracted with and without heat treatment and peptides generated by hydrolysis with selected 
proteases. Tissues regarded as secondary products from salmon (Salmo salar), in this case gills, belly flap 
muscle and skin, has been used as protein sources. In order to select <10 kDa molecules the extracts and 
hydrolysates were either ultra filtrated or dialysed with 10mW cut off. Selected bioassays were used in 
order to investigate the <10 kDa extracts and hydrolysates for radical scavenging activity capacity, 
angiotensin I-converting (ACE) and intestinal DPP-IV inhibiting properties. The <10 kDa extracts and 
hydrolysates were further analysed size exclusion chromatography (SEC), where compounds were 
separated by Fast Performance Liquid Chromatography (FPLC). Fractions from the SEC were analysed for 
peptide content and for the bioactivities by the selected bioassays as previous mentioned. Based on 
peptide content and their bioactivity in the various assays, extract fractions and hydrolysate fractions were 
further selected for analysis by LC-MS and MS/MS. 
 
Figure 6. Overview of experimental outline of the experiment with extraction of naturally occurring peptides from salmon. 
 25 
 
 
5.2. Methodology - Principles behind the in vitro assays 
The three chosen bioactivities; radical scavenging activity, ACE and DPP-IV inhibition  have been measured 
with in vitro assays, which are based on the principles described in the following sections. 
5.2.1. Radical scavenging activity 
In order to determine the radical scavenging effect of the bioactive peptides, 2,2’-azinobis(3-
ethylbenzthiazoline-6-sulfonic acid) (ABTS) radical scavenging assay is used. The principle is a decolorization 
technique which measures the ability of antioxidative peptides to donate electron to the stable ABTS•+ 
radical. The reaction is seen in figure 7. The radical is a blue/green chromophore, which will loose its color 
when it accepts an electron. The absorption at 734 nm is followed and antioxidants reduce this absorbance 
as can be seen on the spectra. 
 
                                                                Antioxidant (e-) 
ABTS•+ (dark green)                                   ABTS (colorless) 
 
Figure 7. The absorption spectra of ABTS•+ and ABTS measured at 734nm. ABTS•+ is the dark green line, while ABTS is the black line. 
When the antioxidants donates electrons to the radical ABTS•+, the radical is inactivated and will loose its color. 
The shift in color can be measured by spectroscopy at 734 nm, and the decolorization depends on the 
concentration of antioxidant and in some degree the time. The reaction between the stable ABTS•+ radical 
and the antioxidants happens rather fast, which makes it possible to measure the absorbance shortly after 
the reaction is started (Re et al, 1999). 
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5.2.2. ACE activity 
ACE inhibiting activity is measured with a method based on the intramolecular quenched tripeptide o-
aminobenzoylglycyl-p-nitro-L-phenylalanyl-L-proline (Abz-Gly-Phe-Pro). When the fluorogenic synthetic 
substrate Abz-Gly-Phe-Pro is hydrolysed, it results in a fluorescent clevage product o-aminobenzoylglycine 
(Abz-Gly), which can be measured in a fluorescence spectrophotometer (Excitation λ = 355, Emission λ = 
405) (Sentandreu & Toldra, 2006). The reaction (figure 8) will be decreased by ACE inhibiting peptides.   
                                                                  ACE enzyme 
    Abz-Gly-Phe-Pro (ACE substrate)                                       Phe-Pro  + Abz-Gly (fluorescent product) 
Figure 8. The ACE enzyme hydrolyses the synthetic substrate Abz-Gly-Phe-Pro and results in a fluorescent product Abz-Gly. 
5.2.3. DPP-IV activity  
DPP-IV inhibiting activity in this study was performed in 96-well microplates and to measure the increase in 
absorbance the synthetic substrate Gly-Pro-p-nitroanilide was used.  DPP-IV cleaves the colorless substrate 
and the resulting product p-nitroaniline has a yellow/green color which absorbs at 405 nm. The reaction 
(figure 9) will be decreased by DPP-IV inhibitor peptides (Sarath et al, 2001).  
                                                         DPP-IV enzyme 
Gly-Pro-p-nitroanilide  (colorless)                                     Gly-Pro + p-nitroaniline (yellow/green) 
Figure 9.  DPP-IV cleaves the substrate Gly-Pro-p-nitroanilide and the resulting product p-nitroaniline absorbs at 405nm.  
5.3. Materials 
Gills, skin and belly flap muscle from fresh Atlantic salmon (Salmo salar) obtained from commercial fish 
farms were vacuum packed and stored at - 40°C until use.  
 
Pig intestine was used as enzyme source for DPP-IV and ACE activity. 
Pig intestine (1 m jejunum) from a Danish landrace/Yorkshire cross that had been fasted overnight, and 
stored at - 20°C was filled with 100 mL of 0.1 M Tris-HCl buffer, pH 8 (22˚C ) and inverting briefly 5 times. 
The crude extract was filtered through a fine-meshed sieve and centrifuged at 4000xg for 30 minutes at 
4˚C. The supernatant was saved and 40 mL was dialysed for 24 h at 2˚C in 10 kDa dialysis tubing against 100 
x volume of 0.1 M Tris-HCl buffer pH 8. Protein content of the recovered dialysed mucosal extract was 7.2 
mg/mL determined with Pierce BCA protein assay kit from Thermo Scientific (Rockford, IL, USA)   using BSA 
as standard. The recovered dialysed mucosal extract was frozen in aliquots at -20˚C until use. This extract 
was used both for digestion experiments and as enzyme source in DPP-IV and ACE activity measurements. 
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2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), Gly–Pro-p-nitroanilide, captopril, diprotin 
(Ile-Pro-Ile), pancreatin, pepsin, Sodium dodecyl sulphate (SDS), DL-Dithiothreitol 99% (DTT), O-
Phthaldialdehyde 97% (OPA), Cytochrome c (12.3 kDa), Aprotinin (6.5 kDa), Lys5 (659 Da), Gly3 (189 Da), Gly 
(75 Da) and protease type XIV from Streptomyces griseus ≥ 3,5 units pr mg (pronase) were all purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Abz-Gly-Phe(NO2)-Pro was purchased from Bachem AG 
(Bubendorf, Switzerland). L-Serine was from Merck chemicals (Darmstadt, Germany). All other reagents 
used were analytical grade chemicals. 
5.4. Experimental approach  
5.4.1. Naturally occurring peptides (extracts) 
5.4.1.1. Pre-experiment 
A number of aqueous extracts were made from gills, belly flap muscle and skin from salmon (Salmo salar). 
In order to preserve the bioactivity of the peptides mild extraction procedures as acidic, alkaline and 
aqueous solutions were used. Combination of different extraction conditions such as with/without boiling, 
with/without inhibitor and variation of pH resulted in a total of 36 extracts.  
The extracts were then size fractionated by ultrafiltration using a 10 kDa filter, and relevant fractions below 
10 kDa from gills, belly flap muscle and skin were further fractionated by gelfiltration on a Superdex peptide 
HR 10/30 column. The fractionation profile from the different extraction conditions did not differ much 
(results not shown), and the largest variation of the fractionation profiles was seen in the various tissues. It 
was therefore decided that for following experiments with naturally occurring peptides to use aquaous 
solutions and with/withouth boiling for the three different tissues from salmon. 
5.4.1.2. Extraction with and without heat treatment 
The thawed gills, skin and belly flap muscle from salmon were cut into small pieces and mixed with 3 
volumes of water (w/v) (e.g. 20 g fish tissue + 60 ml water) and was either boiled in a 100°C for 10 min or 
not. After heating the fish/water suspension were homogenized with an ultraturrax T25 (IKA 
Labortechnich) at 13.500 rpm for 5 min on ice. The suspensions were centrifuged for 45 min at 21.000xg at 
4°C. The supernatant was filtered through a 150 mm filter paper (Frisenette), followed by filtration through 
0.45 and 0.20µm filters (Sartorius) on ice. The obtained filtered extracts were kept on ice until ultra 
filtration.  
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5.4.1.3. Ultrafiltration 
The filtrate was fractionated by ultrafiltration with Vivaspin 10 kDa cut off filters (Sartorius) at 4000g at 4°C 
for 45 min. Both filtrate and retentate were stored at -20°C until use.  
5.4.2. Hydrolysis generated peptides (hydrolysates) 
5.4.2.1. In vitro digestion - Pretreatment 
The thawed skin and belly flap muscle from salmon were cut into small pieces and mixed with water to a 
final protein concentration of 6.3% and 6.6% of skin and belly flap muscle respectively. This is based on a 
protein content of 15.4% and 31.3% for belly flap muscle and skin, respectively, determined by Kjeldahl 
analysis. The total amount of fish/water suspension was 42 ml. The fish/water suspension was heated to 
95˚C in loosely capped blue cap bottles in a water bath. After reaching 95˚C, the fish/water suspension was 
left there for 10 min and afterwards cooled down to room temperature. 
5.4.2.2. In vitro digestion with gastrointestinal proteases 
Digestion study was carried out with seven different combinations of pepsin (45 mg/ml), pancreatin (30 
mg/ml) and small intestine mucosa extract (7.2 mg/ml), respectively (table 1).  
Table 1. Experimental design of in vitro digestion of salmon belly flap muscle and skin with gastrointestinal proteases.  
 
Treatment No. Designation Enzyme 
Enzyme 
added (mL) 
Start of 
digestion
Digestion pH 
Digestion time, 
(hours) 
Control 1 
 
─ ─ ─ 
 
None - - 8 24 
Pepsin only 2 
 
+ ─ ─ 
 
Pepsin 1 Time zero 2 2.5 
Pepsin 
+ pancreatin 
3 
 
+ + ─ 
 
Pancreatin 1 
After  3.5 
hours 
8 21,5 
Pepsin 
+ pancreatin 
+ mucosal extract 
4 
 
+ + + 
 
Pancreatin 
Mucosal 
extract 
1 
1 
After  3.5 
hours 
8 21.5 
Mucosal extract 
only 
5 
 
─ ─ + 
 
Mucosal 
extract 
1 Time zero 8 24 
Pancreatin only 6 
 
─ + ─ 
 
Pancreatin 1 Time zero 8 24 
Pancreatin 
+ mucosal extract 
7 
 
─ + + 
 
Pancreatin 
Mucosal 
extract 
1 
1 
Time zero 8 24 
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Digestion was performed in a water bath with shaker (Hetofrig CB60VS) at 37˚C. Before addition of 
enzymes, pH for treatment 2 was adjusted to 2 with 6 N HCL  and pH for treatment 1, 5, 6 and 7 was 
adjusted to 8 with 2 N NaOH.  A 10 kDa cut off dialysis bag containing 10 ml of water was added to the fish 
tissue suspension for each treatment at time zero. Treatment 2, 3 and 4 was carried out sequential as 
treatment 2 was adjusted to pH 8 with 4 N NaOH after 2.5 hours. After one hour more the dialysis bag was 
removed and a new dialysis bag was added together with pancreatin (treatment 3) and pancreatin + 
mucosal extract (treatment 4), respectively. Water was added so all seven suspensions had the same final 
volume. 
When digestion time ended, dialysis bags were removed and flushed with water and carefully wiped with 
paper tissue. Contents of the dialysis bags were transferred to eppendorf tubes and frozen at -20˚C until 
use. Digestion controls with enzyme(s) alone were also carried out. 
5.4.2.3. Digest yield  
Digest yields in the hydrolysates were measured by the OPA (o-phthaldialdehyde)-method modified after 
Nielsen et al (2001) using L-serine as standard. 25µl properly diluted hydrolysate samples so absorbance did 
not exceed 0.8, standard solution (0.1mg L-Serine/ml) and water, respectively, was added to a microtiter 
plate in eightfold determination. 200µl OPA reagent prepared according to Nielsen et al (2001), was added 
to each well and the plate was inserted in the plate reader (Biotek, Synergy 2) with automatic shaking. The 
plate was left for two min in the plate reader before the absorbance was measured at 340nm. 
5.4.3. Peptide content  
Peptide content in the <10 kDa extracts filtrates was measured with the Pierce Modified Lowry Protein 
Assay (Thermo Fisher Scientific, Rockford, IL, USA). The lower peptide content in the fractions obtained 
from size exclusion chromatography was measured with the Pierce BCA Protein Assay Kit (Thermo Fisher 
Scientific, Rockford, IL, USA) with a lower detection limit.  For both methods bovine serum albumin (BSA) 
was used as standard and peptide content is expressed as mg protein pr. ml. 
5.4.4. Pronase treatment of extracts (only extracts) 
Pronase (1 mg/mL) was mixed with <10 kDa extracts in the ratio 120 µl to 480 µl (pronase 5 times dilution) 
in a microcentrifuge tube. Control samples without pronase but with water were made the same way.  A 
sample containing only pronase (1 mg/mL) was made to indicate elution of pronase and corresponding 
autolytic peptides, if any. The microcentrifuge tubes were placed in a 37˚C waterbath over night. The 
filtrate/protease solution, filtrate/water solution and protease solution was injected on a 200µl coil into 
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SuperdexTM peptide 10/300 GL column (GE Healthcare) using 100mM ammonium acetate buffer pH 8 as 
with a flow rate at 0.500 ml/min. Compounds were detected at 215nm and 280 nm. 
5.4.5. ABTS●+ radical scavenging activity (modified after Clausen et al, 2009) 
50µl of <10 kDa extract, hydrolysate or standard or dilutions thereof were combined in 96 well microplates 
with  200µl of ABTS●+ solution (0.37 mM in 0.1 M borate buffer, pH 8.0), which had been prepared from 
18.7mM ABTS and 8.8mM ammoniumpersulfate in water that had incubated overnight at room 
temperature. All dilutions were done in borate buffer. Absorbance was measured on a plate reader (Biotek, 
Synergy 2) at 734nm and free radical scavenging activity defined as decrease in absorbance after 30 min. 
The known antioxidant Gluthathione was used as positive control and as a reference inhibitor. 
5.4.6. DPP-IV activity  
50µl of <10 kDa extract, hydrolysate or standard or dilutions thereof were combined with 50 µl of intestinal 
mucosal extract (diluted 27 times in 100mM Tris-HCl buffer pH 8.0) in 96 well microplates and prewarmed 
to 37˚C. 200µl of prewarmed DPP-IV substrate (2.5 M Gly-Pro-Nitroanilide, 0.1 M Tris-HCl buffer, pH 8.0, 
25°C.) was added and absorbance measured at 405 nm (and 600nm to correct for light scatter) every two 
minutes for 20 minutes in the microplate reader (Synergy 2, Biotek) at 37°C. DPP-IV activity was calculated 
as ∆ mOD 405 nm/min as initial rate for the linear part of the curve and scatter subtracted if present. All 
dilutions were done in 0.1 M Tris-HCl buffer, pH 8.0, 25°C. The tripeptide Ile-Pro-Ile (Diprotin A) was used as 
a positive control and as a reference inhibitor. 
5.4.7. ACE activity (modified after Sentandreu & Toldra, 2006) 
50µl of <10 kDa extract, hydrolysate or standard in 3-fold dilution was added to a well in 96 well 
microplate. 50µl intestinal mucosal extract (10 times diluted in 150mM tris buffer pH 8.3) was added to the 
wells. Before addition of substrate, the microplate was preincubated at 37˚C for 10 minutes in the 
fluorescence spectrophotometer (Gemini max, Molecular Devices) with automatic mixing. The substrate 
working solution (light sensitive) (0.45mM Abz-Gly-Phe(NO2)-Pro in 150mM Tris-HCl buffer pH 8.3, 25°C 
with 1.125M NaCl) was also incubated at 37˚C for 10 minutes in a waterbath. Subsequently, 200µl of 
substrate solution was added and fluorescence was measured as Relative Fluorescence Units (RFU) after 
automatic shaking  every minute for 40 minutes at λ (excitation) = 355 nm and λ (emission) = 405 nm. ACE 
activity is defined as ∆ RFU per min. The well known ACE-inhibitor Captopril is used as reference (positive 
control) in the ACE inhibiting assay. 
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5.4.8. Stability of DPP-IV and ACE inhibition by belly flap +++ hydrolysate, diprotin and captopril 
Stability of DPP-IV and ACE inhibitiory property by belly flap muscle +++ hydrolysate, diprotin or captopril 
was measured in diluted and undiluted mucosal extract, respectively. Hydrolysate (3 times diluted), 
diprotin (0.22mM) and captopril (4µM) was mixed with either mucosal extract (9 times diluted) or 
undiluted mucosal extract in ratio 1:1.  
 All dilutions regarding DPP-IV inhibition was done with 100mM Tris-HCl buffer, pH 8 and all dilutions 
redarding ACE inhibition was done with 150mM Tris-HCl buffer, pH 8.3. To prevent any microbial growth, 
sodium azide was added to the Tris-HCl buffer to a final concentration in hydrolysates/mucosal extract 
mixture of 0.05%. 
All samples were done in eppendorf tubes and incubated in water bath at 37°C. Diluted mucosal extract 
incubated alone was used as control to measure effect of incubation on the extract.  
Sampling was done at time zero, ½ hour, 1½ hour, 4½ hour and 24 hour. At each sampling the following 
was transferred to a microtiterplate: 100 µl of samples with diluted mucosal extract, 11 µl of samples with 
undiluted mucosal extract + 89 µl of Tris-HCl buffer. DPP-IV and ACE activity was immediately measured 
thereafter using the assay previous described. Measurement was done as a triplicate. 
As reference to maximal activity and inhibition the following controls was at each sampling point. 50 µL 
fresh mucosal extract 9x diluted + water, 50 µL of fresh mucosal extract 9x diluted + either 50 µL of fresh 
+++ hydrolysate, diprotin, or captopril. 
5.4.9. Inhibition kinetics (only belly flap muscle +++ hydrolysates) 
A Lineweaver-Burk plot for determination of inhibition mode of belly flap muscle +++ hydrolysate against 
DPP-IV and ACE activity, respectively, was carried out as a cross titration experiments in microtiterplates. 
Hydrolysates diluted three times in water were used as strongest hydrolysates concentrations which 
subsequently were diluted twofold with water to 64 times as final dilution. Concentration range of the DPP-
IV substrate Gly-Pro-p-nitroanilide and the ACE substrate Abz-Gly-Phe(NO2)-Pro was 2 mM to 0.016 mM  
and 10 mM to 0.16 mM, respectively. The substrate concentration range was based on [Vmax] versus [S] 
plot using water as sample. Substrate concentrations below and above an estimated Km value was used. 
50 µl of hydrolysates dilutions were transferred to a microtiterplate containing 50 µl mucosal extract 50 
times diluted with tris 100mM pH 8 for DPP-IV, and tris 150mM pH 8.3 for ACE in each well.  Eight wells 
contained 50 µl of water instead of mucosal extract. DPP-IV and ACE activity was measured immediately 
after adding 200 µl of substrate dilutions using the assay procedures previous described. 200 µl of substrate 
dilutions added to 100 µl of water was used as blank.  
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5.4.10. Size exclusion chromatography (SEC) 
Compounds in the <10 kDa extracts and from the <10 kDa hydrolysates were separated by FPLC (Fast 
Performance Liquid Chromatography) using an Äkta Purifier system with FRAC 950 collector. 200µl 
undiluted filtrate was injected into a SuperdexTM peptide 10/300 GL column (GE Healthcare) using 100mM 
ammonium acetate buffer pH 8 with a flow rate at 0.500 ml/min. Ammonium acetate is a volatile buffer 
that minimally affects later steps of mass spectrometry.  Compounds were detected at 215nm and 280 nm. 
Fractions of 1 ml each were collected (35 total) and stored at -20°C until use. Cytochrome c (12.3 kDa), 
Aprotinin (6.5 kDa), Lys5 (659 Da), Gly3 (189 Da), and Gly (75 Da) (Sigma-Aldrich, St. Louis, Missouri, USA) 
was used as molecular weight markers. 
5.4.11. Peptide-content, ABTS●+ radical scavenging, DPP-IV and ACE activity in fractions from SEC 
The above mentioned assays (described earlier) were used in order to analyse the fractions.  
For fractions from extracts only ABTS●+ inhibiting activity and peptide content was measured, as the 
undiluted extractions showed neither DPP-IV nor ACE inhibiting activity. 
5.4.12. LC-MS and MS/MS (In extracts and - + + hydrolysates from belly flap muscle and skin)  
1 ml fractions from the size exclusion chromatography that showed antioxidative capacity (extracts from 
Section 5.4.1) and high peptide content (the belly flap muscle and skin -++ hydrolysates from Section 5.4.2) 
were dried in a SpeedVac (Thermo Scientific Savant SPD1010) and reconstituted in 50 µl buffer A (5% 
acetonitrile [ACN] + 0.1% formic acid [FA]), vortexed, centrifuged at room temperature at 14,000xg for 10 
min and transferred to LC vials. Buffer B was 90% ACN + 0.1% FA. A nanoHPLC (EASY nLC; Proxeon, Odense, 
Denmark) was used. The samples were trapped on an EASY reverse phase pre-column (2 cm length, ID 100 
µm, 5 µm C18 beads) and separated on an EASY reverse phase analytical column (10 cm length, ID 75 µm, 3 
µm C18 beads). Flow rate was 300nL/min. The time from mixer to elution was 3 min, corresponding to a 
dead volume of around 900 nL. The components were eluted by a gradient  (0 min 100%A, 0.05 min 99%A, 
2 min 90%A, 21 min 45%A, 23 to 26 min 0%A,  28 min  95%A, 30 min 0%A) into a micrOTOF-QII mass 
spectrometer (Bruker Daltonik, Bremen, Germany) through the standard nanosprayer into the electrospray 
ion source. Nitrogen was used as nebulizer (pressure at 1 bar) and drying gas (5 L/min at 150 °C) in the ion 
source. Argon 5.0 was used as collision gas, and the collision energy was automatically adjusted to the 
selected m/z values using default options. Infusion of electrospray calibrant solution (Fluka) by a syringe 
pump was used as external calibration for the samples. Additionally, a standard peptide mixture from 
bovine serum albumin was run for every fifth LC-MS/MS sample, and was used for more detailed external 
calibration. The MS instrument was controlled by instrument-specific software (Compass 1.3 micrOTOF 
control v2.3), where the acquisition parameters were set (positive mode, low mass limit at m/z 50, MS/MS 
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auto in the m/z range 70 to 800, 4 precursor ions with absolute intensity > 2000 counts, exclude after 4 
spectra, release after 1 min). The data were initially analyzed in the Compass 1.3 DataAnalysis v4.0 
software to generate the compounds and externally calibrate the spectra. The software extracted 
compounds using intensity threshold at 1000, retention time window 1 min, S/N threshold 3, and relative 
area and intensity thresholds at 3%. 
5.4.13. Determination of EC50 values 
Values for the half maximal effective concentration EC50 was determined using non linear regression – 
global curve fitting (Sigmaplot 11, Systat software Inc.) 
Statistical analysis was performed by one-way ANOVA followed Tukey’s multiple comparison test 
(Graphpad Prism ver. 4.03, Graphpad Software Inc.)  
CHAPTER 6 RESULTS AND DISCUSSION  
In this chapter the experimental findings are presented and discussed in connection to the hypothesis 
stated in Chapter 1 and relevant literature. The experimental findings are the basis for the papers listed in 
the appendix, thus some of the results are not intended for publishing (section 6.3). 
The chapter is divided into main sections: 
 Naturally occurring peptides (section 6.1 - Paper I) 
 Peptides from digestion with gastrointestinal proteases (section 6.2 - Paper II) 
 Bioactivities in sequential digested hydrolysate fractions from SEC (section 6.3) 
  Bioactivities and LC-MS MS/MS in belly flap muscle and skin hydrolysate -++ fractions from SEC 
(section 6.4 – Paper III) 
 
6.1. Naturally occurring peptides (Paper I) 
The following results are the basis for paper I “Extraction and characterization of candidate bioactive 
compounds in different tissues from salmon (Salmo salar)” which is submitted to International Journal of 
Applied Research in Natural Products.  
Three different tissues from salmon were analysed for low molecular weight compounds (<10 kDa) with 
radical scavenging activity and ACE and DPP-IV inhibitory properties. Extraction of compounds was done 
with heat treatment in order to prevent endogenous proteolysis and bacterial growth. An extraction was 
also carried out without heat treatment, as heat treatment also may affect relevant compounds such as 
peptides. Boiling did not affect the peptide content in <10 kDa extract from gill compared to extract 
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prepared without boiling when analysed with a Lowry assay (table 2). An increase in peptides was observed 
in both belly flap muscle and skin extract after boiling, which could be due to a more efficient extraction 
from these tissues.  
Table 2. Peptide content and EC50 values for radical scavenging activity in <10 kDa extracts from different tissues from salmon. BSA 
was used as standard. 
Treatment Tissue mg/mL  EC50   (mg/mL) 
Boiling Gills 0.838 0.0039 
 Belly flap muscle 0.425 0.0082 
 Skin 0.769 0.01 
No Boiling Gills  0.847 0.0053 
 Belly flap muscle 0.256 0.0087 
 Skin 0.434 0.012 
6.1.1. Bioactivities 
All <10 kDa extracts exhibited nearly maximal ABTS radical scavenging activity with around 95% 
decolorisation of ABTS at 734 nm (figure 10). Three-fold dilution curves did not show any clear effect of 
boiling on radical scavenging activity as no difference in EC50 values was observed.  
In both cases gill extract result in the lowest EC50 value (table 2), and therefore indicate that extract from 
gill contain compounds with more potent radical scavenging activity than extracts from either belly flap 
muscle or skin.  
None of the <10 kDa filtrates inhibited DPP-IV and ACE (results not shown). This is surprisingly, as Pampanin 
et al (2012) found that herring skin contained small peptides with potential bioactive properties such as 
ACE inhibiting properties for reducing hypertension. This compound may also be present in extracts tested 
in this study, but in such low concentration that DPP-IV and ACE inhibiting activity cannot be measured.   
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Figure 10.  ABTS radical scavenging activity in <10 kDa boiled (A) and not boiled (B) extracts from gill (●, ○); belly flap muscle (■, □); 
and skin (▲,∆) at various concentrations when diluted three fold. 
 
6.1.2. Size exclusion chromatography 
Size exclusion chromatography of <10 kDa extracts showed very different elution profiles of compounds 
from gills, belly flap muscle and skin, detected at 215 and 280 nm (figure 11). This indicates different 
compositions of low molecular weight compounds. A common feature for the boiled extracts is that 
compounds did not elute before at 18 ml, which correspond to the molecular weight of Gly3. This indicates 
that the largest compounds eluting were in the 400-500 Da range. Between 3 and 5  peaks eluted after Gly 
at both at 280 nm and  215 nm, - this indicate that all extracts may contain compounds with hydrophobic 
moieties with a molecular weight larger than Gly3, that are able to absorb to the column. Only the control 
extract from gills contain compounds which elute with void volume, this suggest a molecular weight larger 
than 7 kDa. This may be due to compounds which could have precipitated during boiling and therefore not 
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present in the filtrate. In belly flap muscle an increase in compound eluting between 20 and 22 ml was 
observed, this could be due to boiling. No effect of boiling was observed for skin. 
 
Figure 11. Size exclusion  chromatograms at 215 and 280 nm (Superdex peptide) of <10 kDa extracts (boiled and not boiled) from 
the 3 different tissues, gills, belly  flap muscle and skin. Peptide standard is shown on the “gill” figure.  
 37 
 
6.1.3. Test of peptide content in peaks from size exclusion chromatography 
A test of peptide content was made by addition of protease to the <10 kDa boiled extracts and analysed by 
size exclusion chromatography. The peaks that were affected by the treatment with protease indicated 
presence of peptides consisting of standard amino acids. 
 
Figure 12. Effect of pronase (Streptomyces griseus protease XIV) on elution profile of compounds <10 kDa from boiled salmon 
tissue suspension. A: Gills, B: Belly flap muscle, C: Skin.              Without pronase;                    With pronase. 
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 The elution profiles of <10 kDa extract from from gills, belly flap muscle and skin with and without protease 
are shown in figure 12. Pronase eluted at 9 mL corresponding to the void volume as expected. No 
significant peaks eluting later was observed in the pronase control. In general, the pronase treatment had 
surprisingly little effect on the extracts, which indicate presence of other compounds than peptides or 
modified peptides resistant to proteolysis. The main effect on the gill extract was on a peak eluting after 22 
mL, which was reduced considerably, while a peak eluting after 24 mL correspondingly increased (figure 
12A).  
The pronase treatment on belly flap muscle extract (figure 12B) mainly resulted in a decrease of a major 
peak eluting after 19 mL. An increase in a peak eluting after 19.5 mL could be a result of cleavage products 
from peptides eluting after 19 mL. Three peaks eluting after 20.5, 22 and 26 mL also decreased after 
pronase treatment. Interestingly, the decrease of these peaks did not result in increase in new peaks 
eluting later. The effect of pronase treatment on skin extract seemed somewhat smaller than on gill and 
belly flap muscle extract (figure 12C). As for belly flap muscle extract, a decrease in peaks eluting at 19 and 
26 mL was seen.  
6.1.4. ABTS●+ radical scavenging activity and peptide content in fractions from boiled salmon 
Peptide content and radical scavenging activity were measured in fractions from the size exclusion 
chromatography of boiled <10 kDa extracts from gills, belly flap muscle and skin (figure 13). In fractions 
eluting from 0-16 mL, no ABTS●+ activity was detected. In the fraction eluting at 18 mL, a weak ABTS●+ 
radical scavenging activity was observed for gills and skin. This could be due to peptides in the low 
molecular weight range (between Gly3 and Lys5). As figure 13 show, there is not a full correlation between 
peptide content and radical scavenging activity. This indicates the presence of other type of compounds 
contributing to the activity or inactive peptides. In fractions eluting between 21 and 22 mL the strongest 
ABTS●+ radical scavenging activity was detected for all three tissues. The gill extract was found to have the 
strongest activity, where also the highest peptide content was detected. This correlates with the lower EC50 
value for gill extract compared to the two other tissue extracts. These fractions eluted after glycine and 
suggest the presence of compounds with strong affinity to the column material. In fractions from gills and 
skin eluting at 28 and 33 mL, respectively, radical scavenging activity was also detected. This indicates 
stronger interaction with the column.  Fractions from untreated salmon extracts have also been analysed 
with the ABTS●+ radical scavenging assay, and these profiles match the profiles from boiled salmon extract 
(results not shown).  
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Figure 13. Peptide content and ABTS●+ radical scavenging activity in fractions from size exclusion chromatography of <10 kDa 
extract from boiled salmon tissue . (●): Gills, ( ○):  Belly  flap muscle, (+): Skin. 
 
6.1.5. LC–MS and MS/MS 
The fractions from the boiled samples which showed the highest ABTS●+radical scavenging activity were 
selected for analysis by mass spectrometry. Focus was on the major compounds in the fractions (se figure 
14a, b and c), which gave MS/MS spectra of reasonable quality. C18 reverse phase columns were used in 
the LC-MS analyses. The very hydrophilic compounds are not retained on such columns, and will therefore 
not be detected.   
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Figure 14a. Base peak ion chromatograms from nanoLC reverse phase separation of size exclusion fractions (A) 18 mL (B) 21 mL, (C) 
22 mL, (D) 28 mL, (E) 29 mL (cf. Fig 13) with ABTS●+ radical scavenging activity from salmon gill <10 kDa extract.               Sample;                           
;              Blank; Arrows indicate peaks containing components mentioned in the text and tables.  
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Figure 14b. Base peak ion chromatograms from nanoLC reverse phase separation of size exclusion fractions (A): 21 mL, (B) 22 mL. 
(cf. Fig 13) with ABTS●+ radical scavenging activity from salmon belly flap muscle <10 kDa extract.              Sample;                Blank; 
Arrows indicate peaks containing compounds mentioned in the text and tables. 
 
 
Figure 14c. Base peak ion chromatograms from nanoLC reverse phase separation of size exclusion fraction “21 mL” (cf. Fig 13) with 
ABTS●+ radical scavenging activity from salmon skin <10 kDa extract.                 Sample                  Blank; Arrows indicate containing 
components mentioned in the text and tables.  
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The mass spectrometric analyses showed three conspicuous features. First, some compounds were found 
in several fractions and from different tissues. Second, several families of chemically related compounds 
were evident. In fact, most compounds belonged to one or another multimember family, here called the 
"PW family", "434 family"  "403 family" and "219 family", as recognized by similarities of the MS/MS 
spectra within each family (table 3, 4, 5 and 6). The families are named according to a specific amino acid 
sequence (PW) or by the lowest m/z value reported in each family. Third, there were only few compounds 
with standard amino acids as major constituents. No proteolytic treatment was performed for the fractions 
analyzed by MS and endogenous proteases were inactivated by the heat treatment. Thus, the detected 
compounds were likely small compounds or peptides freely present in the tissues, although the boiling 
procedure may have resulted in heat-induced chemical modifications.  
Table 3.  Two compounds in the PW family and two unrelated compounds as detected by reverse phase LC-MS/MS. These 
compounds were only found in gills.  
Obs. m/z, 
charge  
Rt (min) MS(2) fragments Found in Comments 
399.20/z=1 15.7-15.9 146.06, 159.09, 188.07, 205.10, 302.15 Gills fraction 21 PPW (theoretical m/z 
399.20). PW family. 
486.24/z=1 15.0-15.3 157.10, 188.08, 205.10, 302.15 Gills fraction 21 SPPW or PSPW 
(theoretical m/z 
486.24). PW family 
417.25/z=1 17.6-17.8 132.08, 141.10, 144.08, 159.09, 170.06, 
227.16, 287.14 
Gills fractions 21 
and 22 
WVL/I or VWL/I? 
(theoretical m/z 
417.25) 
247.06/z=1 19.5-19.6 125.02, 141.08, 143.03, 152.07, 183.04, 
203.07 
Gills fraction 28
Table 4. Compounds in the 434 family as detected by reverse phase LC-MS/MS. These compounds were only found in gills.  
Obs. m/z, 
charge  
Rt (min) MS(2) fragments Found in Comments 
434.19/z=1 16.3-16.6 116.02, 129.07, 133.10, 141.07, 142.03, 
144.01, 155.09, 162.02, 167.09, 170.03, 
185.10, 199.07, 233.06 
Gills fraction 18  
436.21/z=1 19 116.02, 129.07, 133.10, 142.03, 144.01, 
157.10, 162.02, 170.03, 187.11, 199.07, 
233.07 
Gills fraction 18  
448.20/z=1 19.5 116.02,127.06, 129.07, 142.03, 144.01, 
155.09, 162.03, 170.03, 173.10, 199.11, 
216.14, 233.06 
Gills fraction 18  
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Table 5. Compounds in the 403 family as detected by reverse phase LC-MS/MS. These compounds were only found in gills.  
Obs. m/z, 
charge 
Rt (min) MS(2) fragments Found in Comments 
403.09, z=3 8.7-8.9 112.05, 119.04, 136.06, 162.07, 176.00, 
193.05, 250.10, 288.05, 306.05, 348.07, 
420.09, 462.08 
Gills fraction 21 Likely  the same  as 
the coeluting 604 
427.61, z=2 9.4-9.6 112.05, 119.04, 136.06, 152.06, 161.06, 
192.08, 216.09, 290.06, 332.08 
Gills fraction 22  
439.62, z=2 9.8-10.1 119.03, 135.03, 152.06, 161.06, 216.09, 
234.10, 314.07, 33208, 394.10 
Gills fraction 21  
447.62, z=2 9.4-9.7 119.03, 135.04, 136.06, 152.06, 161.06, 
216.09, 232.09, 312.05, 332.08, 348.09 
Gills fraction 21  
451.60, z=2 8.7-9.1 112.05, 119.03, 136.06, 143.04, 152.06, 
163.05, 176.80, 191.04, 250.09, 312.05, 
330.05 
Gills fraction 22  
455.59, z=2 8.4-8.6 112.05, 119.04, 136.06, 152.06, 161.06, 
192.08, 216.09, 290.06, 332.07 
Gills fraction 18 Probably different 
from 455 in fraction 
22 
455.59, z=2 9.7-10 119.04, 135.04, 136.06, 152.06, 161.06, 
216.09, 232.08, 332.07, 348.08 
Gills fraction 22 Probably different 
from 455 in fraction 
18 
459.60, z=2 8.8-9.0 112.05, 119.04, 135.03, 136.06, 152.06, 
177.00, 193.05, 232.08, 250.10, 312.04, 
330.07, 348.07 
Gills fraction 22  
467.59, z=2 8.5-8.8 112.05, 119.03, 136.06, 139.95, 152.06, 
161.06, 192.08, 216.09, 234.09, 290.06, 
314.07, 332.07 
Gills fraction 18  
475.59, z=2 9.0-9.3 112.05, 119.03, 126.07, 135.02, 136.06, 
152.06, 161.07, 176.99, 192.08, 216.09, 
232.08, 314.06, 332.09 
Gills fraction 18  
604.13, z=2 8.6-9.0 112.06, 136.06, 193.05, 208.07, 226.09, 
232.08, 250.09, 268.10, 288.05, 291.06, 
306.05, 330.06, 348.07, 420.08, 462.11 
Gills fraction 21 Likely the same as
the coeluting 403 
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Table 6. Compounds in the 403 family as detected by reverse phase LC-MS/MS. These compounds were found in all tissues 
investigated.  
Obs. m/z, 
charge 
Rt (min) MS(2) fragments Found in Comments 
219.06/z=1 18.5-19.3 128.06, 133.02, 141.01, 154.08, 159.02, 
171.03, 173.05, 183,04, 201.05 
Gills fraction 21, 22, 28, 29 
Belly flap fraction 21, 22 
Skin fraction 22 
M +H+ 
437.11/z=1 18.7-18.9 141.01, 159.02, 201.05, 219.06 Gills fraction 21, 22
Belly flap fraction 22 
2M + H+ 
261.07/z=1 19.6-19.8 129.07, 133.02, 154.08, 171.04, 173.05, 
183.04, 201.05, 219.06 
Gills fraction 21  
655.08/z=1 18.1-18.4 141.01, 159.02, 201.05, 219.06 Gills fraction 22 3M + H+ 
349.12/z=1 20.4-20.6 159.02, 173.05, 201.05, 219.06, 259.09 Gills fraction 22
Belly flap fraction 21, 22 
 
293.06/z=1 19.8-20.7 141.02, 159.03, 171.03,173.06, 201.05, 
219.07 
Gills fraction 28, 29  
448.13/z=1 19.9-20.1 165.01, 201.04, 219.06, 243.06 Belly flap fraction 21  
 
The only compounds that consisted of identifiable amino acids were found in fraction 21 and to a lesser 
degree in fraction 22 from gills. M/z 399 (figure 15) could be explained as the peptide PPW (theoretical m/z 
399.203, observed m/z 399.202), member of the PW family (table 3). The compound m/z 486 was 
apparently related to m/z 399 (MS/MS fragments at m/z 188, 205 and 302), although the former had a 
somewhat poor MS/MS spectrum.  The mass difference between 399 and 486 could suggest an additional 
Ser, thus giving the sequence SPPW or PSPW (theoretical m/z 486.235, observed m/z 486.235). Comparing 
with zebrafish sequences (the salmon genome is not yet available), the PPW sequence is found in 
numerous proteins, but we are not aware of any previous reports indicating that it may be present as a free 
peptide. Also the sequences SPPW or PSPW can be found in several tens of zebrafish proteins. The PPW 
and SPPW/PSPW could be responsible for part of the radical scavenging activity observed in fraction 21 of 
gill and could represent new antioxidative peptides natural present in fish tissue.  
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Figure 15. MS/MS spectrum of compound m/z 399.202 from gills fraction 21, and its identification as PPW. The MS/MS fragments 
with the suggested structures are also generated from free Trp (corresponding to the y1 fragment; data not shown). The m/z values 
of these fragments from free Trp are also found in the databases Metlin (metlin.scripps.edu) and MassBank (www.massbank.jp), 
and together with the Trp-specific y1 fragment at m/z 205, they are probably indicative of a C-terminal Trp. W
i: immonium ion of 
Trp; P: proline. The small diamond () to the right indicates the m/z value of the intact ion. 
A compound of m/z 417 was found in fractions 21 and 22 from gills (table 3). MS/MS fragments show a 
strong peak at 159.09, potentially fitting with the immonium ion of Trp. The remaining mass of the original 
ion could fit with presence of Val and Leu/Ile. Leu/Ile in C-terminal position would give an y1-ion of 132, 
which is present. Thus, a tripeptide consisting of Trp, V, and Leu/Ile, is a possibility (WVL/I or VWL/I), but 
there are still a number of unexplained fragments left. Thus, this compound is presently considered as 
unidentified.  
All other compounds contained mainly of units that were not standard amino acids (i.e., modified amino 
acids or some other kinds of molecules).  
The 434 family was found in fraction 18 from gills (table 4), with compounds of m/z 434, 436 and 448 
(distinct from 448 in the 219 family). The three compounds eluted at different positions in the gradient, and 
contained a number of fragment ions in common. Additionally, there was one series of fragments that had 
the same mass difference as the intact ions (m/z 185, 187, 199, respectively). 
The 403 family was found in fractions 18, 21 and 22 from gills (table 5), and these compounds tended to 
elute early in the gradient (8 to 11 min). The members were characterized by a strong MS/MS fragment at 
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m/z 136.06 (a value close to the immonium ion of Tyr), and a number of additional common fragments. 
However, no other data directly supported the presence of Tyr.  
The 219 family gave the major chromatographic peak(s) in all shown fractions, except in figure 14a (fraction 
18 from gills). The family consisted of compounds with m/z 219, 261, 293, 349, 437, and 655.  These 
compounds had at least 4 MS/MS fragments in common with m/z 219 (figure 16 and table 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. MS/MS spectra of representatives in the 219 family. (A) 219. (B) 437. (C) 349. Note the common fragments:  m/z 219, 
201, 159 in all three spectra, m/z 141 in A and B, and m/z 173 in A and C. The small diamond () to the right indicates the m/z 
value of the intact ion. 
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M/z 219, 437 and 655 probably corresponded to the same compound (as M + H+, 2M + H+, and 3M + H+, 
respectively).  Being the common basis of the most prominent family of compounds found in these 
experiments, m/z 219 was selected for further analyses. The chemical composition that most closely 
approximated the mean isotopic distribution was C10H10N4O2.  
The presence of the 219 compound or its family members in most dominating fractions with radical 
scavenging activity indicates that these compounds contribute in general to the observed radical 
scavenging activity in the different tissues. Thus, the 219 compound could be an interesting new candidate 
to a natural radical scavenging agent. The 219 compound is further discussed below in section 6.1.6. 
Many bioactive peptides contain amino acids that are consistent with ring and unsaturated bonds. Trp can 
exhibit radical scavenging activity as the phenolic group can serve as hydrogen donors (Pihlanto, 2006). 
Saito et al (2003) studied radical scavenging activity of different combinations of tripeptides and found that 
tripeptides with a Trp at the C-terminus exhibited the highest radical scavenging activity. The hydrophobic 
part of Trp could also explain that the investigated peptides elute after Gly when fractionated on the size 
exclusion column. 
Anserine and carnosine, two modified dipeptides with a methylhistidine moiety possessing antioxidant and 
ACE inhibiting activities (Hou et al, 2003), have previously been detected in fish tissue (Shirai et al, 1983; 
Bauchart et al, 2007). In the studied fractions, we did not find any evidence for the presence anserine or 
carnosine, or any other compound with a methylhistidine moiety.  
6.1.6. Database searches 
Searches in chemical databases might in some cases be of considerable help in identifying unknown 
compounds (Little et al, 2012; Wolf et al, 2010). External calibration with known samples run for every fifth 
fish sample, gave a range of m/z between 219.0580 and 219.0627 (average 219.0600) for the 219 molecule.  
The NIST08 database was searched with the data for m/z 219, but no reasonable hits were found. The 
compound was then analyzed by MetFrag (Wolf et al, 2010), using the three databases KEGG, PubChem 
and ChemSpider in a range from m/z 219.050±25 ppm to 219.100±25 ppm.  MetFrag suggested several 
compounds, where most of the hits could be excluded. However, it is possible that the chemical 
composition with the best calculated fit, C10H10N4O2, could be a close approximation to the real compound 
with m/z 219. 
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6.2. Peptides from digestion with gastrointestinal proteases (Paper II) 
The following results are the basis for paper II “Enhanced free radical scavenging and inhibition of DPP-4 
and ACE activities by compounds from salmon tissues digested in vitro with gastrointestinal proteases”, 
which is submitted to Journal of Agricultural Science and Technology A & B. 
In this study the formation of peptides from an in vitro digestion of salmon tissue with gastrointestinal 
proteases were investigated regarding ABTS●+ radical scavenging activity, intestinal DPP-IV and angiotensin 
I-converting enzyme (ACE) inhibiting properties. The in vitro digestion included both a sequential hydrolysis 
with combination of digestive proteases simulating a gastrointestinal digestion and hydrolysis with the 
different protease preparations alone. 
6.2.1. Digest yield 
Peptides below 10 kDa were collected and total yield in the hydrolysates are shown in figure 17. The tissue 
controls with no proteases added show that a small part of the peptides are naturally originating from belly 
flap (9.3·10-3M) and skin (2.6·10-3M), respectively. The In vitro digestion with GI proteases of belly flap 
muscle resulted in general in higher yield than corresponding digestion of skin. Pepsin digestion of belly flap 
muscle resulted in a 3 fold larger yield that pepsin digestion of skin. The addition of pancreatic proteases 
after pepsin digestion results in 2.5 to 6 fold increases (2.5 for skin and 6 for belly flap muscle) whereas 
addition of mucoasal extract did not result in any further formation of peptides. Digestion of belly flap 
muscle with only pancreatin resulted in yield similar to pepsin digestion while pancreatin alone degrades 
skin much more efficient than pepsin and mucosal extract only gives a small degradation in both belly flap 
and skin. However combination of pancreatin and mucosal extract did result in a large increase in 
formation of peptides after digestion of belly flap muscle and skin, respectively. This indicates that protease 
in mucosal extracts together with pancreatin has a higher digestive efficiency than they have after pepsin 
digestion. 
The pepsin and pancreatin preparations used did not result in any formation of peptides but enzyme 
preparation with both pepsin, pancreatin and mucosal extract added did result in formation in a small 
formation of peptides.  
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Figure 17. Recovery of peptides <10 kDa after in vitro digestion with gastrointestinal proteases was measured as serine equivalents 
using the OPA method. The diagram shows the recovery after treatment of belly flap muscle, skin and enzyme controls with or 
without proteases. Errorsbars show SD of eight determinations. 
  
6.2.2. ABTS●+ radical scavenging, ACE and DPP-IV inhibiting activity of <10 kDa hydrolysates  
ABTS●+ radical scavenging activity, ACE and DPP-IV inhibiting activity of the <10 kDa generated hydrolysates 
were tested with in vitro assays at various concentrations. The potency of hydrolysates from the in vitro 
sequential digestion of belly flap muscle and skin are shown in figure 18 and estimated EC50 values are 
shown in table 7.  All six hydrolysates obtained from digestion of belly flap muscle and skin, respectively, 
gives maximal ABTS●+ radical scavenging activity (zero absorbance at 734 nm) and nearly complete ACE and 
DPP-IV inhibition. Controls which represent <10 kDa compounds naturally present in tissue show clear 
ABTS●+ radical scavenging activity for both belly flap muscle with approx. 95% reduction in 734 nm 
absorbance and for skin with approx. 70% reduction, respectively. Control for belly flap muscle also show 
clear ACE inhibiting activity with approx. 50% inhibition, while control for skin only shows a weak ACE 
inhibiting activity. Both control for belly flap muscle and skin, respectively, only indicate weak DPP-IV 
inhibiting activity.  
The three fold dilution curves for hydrolysates recovered from digestion with pepsin shows the highest 
potency compared to control regarding ABTS●+ radical scavenging activity; - this applies for both belly flap 
muscle and skin which exhibit the same potency with EC50 = 0.069 mM for belly flap muscle and EC50 = 
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0.073 mM for skin, respectively. The ABTS●+ radical scavenging activity potency decreases significantly 
when digestion proceed and peptides recovered from digestion with pepsin/pancreatin/mucosal extract 
(+++ hydrolysate) shows the lowest potency and increasing the EC50 value two times to 0.13 mM. Notable is 
that dilution curves of peptides or other compounds below 10 kDa naturally present in both belly flap 
muscle and skin tissue not treated with enzymes exhibit a clear ABTS●+ radical scavenging activity  with EC50 
= 0.37 mM and 0.28 mM, respectively. Hydrolysates from belly flap muscle made with pancreatin alone 
result in the same EC50 as pepsin generated hydrolysates while mucosal extract generated hydrolysates 
result in very low radical scavenging activity with an EC50 higher than the controls (table 8). 
The three fold dilution curves for belly flap muscle hydrolysates in relation to ACE inhibition show that 
pepsin digestion also results in highest inhibition efficiency with a EC50 value of 0.15 mM and that EC50 value 
increases significantly by a factor of four when digestion proceed with pepsin/pancreatin digestion. In 
contrast to radical scavenging activity digestion, the combination of all three protease preparations 
decreases EC50 value for ACE inhibiting activity again all though not to the same level as the pepsin 
generated hydrolysate. Again it is notable that peptides or other compounds obtained from not hydrolysed 
belly flap muscle exhibit ACE inhibiting activity with an estimated EC50 value of 1.6 mM. The dilution curves 
for skin hydrolysates in relation to ACE inhibition show same pattern as belly flap muscle hydrolysates and 
pepsin digestion of skin result in similar EC50 as belly flap muscle hydrolysates. However, the one-way 
ANOVA analysis could not show a significant difference between the EC50 values of the three skin 
hydrolysates (table 7), but show significant difference between the EC50 values between the hydrolysates 
and the estimated EC50 value for the control. In contrast to ABTS●+ radical scavenging activity and ACE 
inhibiting activity, none of the three hydrolysates neither from belly flap muscle or skin exhibit different 
potency in their ability to inhibit DPP-IV with no significant difference between EC50 values. But EC50 values 
for all three hydrolysates were significantly different from the estimated EC50 value for compounds 
naturally present in both belly flap muscle and skin tissue not treated with enzymes.  
EC50 value for ABTS●+ radical scavenging activity, ACE and DPP-IV inhibiting activity for belly flap muscle 
hydrolysate from digestion with pancreatin alone (table 8) are similar to the EC50 value for hydrolysates 
from pepsin digestion alone and thereby result in more potent peptides than sequential digestion by pepsin 
and pancreatin. However, the combination of pancreatin and mucosal extract result in a very high increase 
of the EC50 values. This suggests that proteases in the mucosal extract may decreases formation of bioactive 
peptides generated by pancreatin digestion of belly flap muscle. Skin hydrolysates generated by pancreatin 
digestion gave in contrast an eight-fold higher EC50 value for ABTS radical scavenging activity than for pepsin 
generated hydrolysates and a four-fold higher EC50 value and ACE inhibition, while the EC50 value for DPP-IV 
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is lower. But also for skin the combination of pancreatin and mucosal extract result in much higher EC50 
values. 
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Figure 18. ABTS●+ radical scavenging activity, ACE and DPP-IV inhibiting activity of <10 kDa hydrolysates from sequential in vitro 
digestion with gastrointestinal proteases of salmon belly flap muscle and skin at various concentrations. DPP-IV activity is Δ Abs 405 
 52 
 
nm/min, ACE activity is ∆ RFU/min and radical scavenging activity is absorbance at 734 nm after 30 min. Absorbance or enzymatic 
activity in absence of hydrolysates were normalized to 1. All activities are measured at standard assay condition. 
 
Table 7. EC50 values for ABTS●+ radical scavenging activity, ACE and DPP-IV inhibiting activity of <10 kDa hydrolysates from 
sequential in vitro digestion with pepsin, pancreatin and mucosal extract from salmon belly flap muscle and skin. Values and SD are 
shown in mM.  
Treatment 
 
Belly flap muscle Skin 
Pe
ps
in
 
Pa
nc
re
at
in
 
M
uc
os
al
 e
xt
ra
ct
. 
ABTS●+ ACE DPP-IV ABTS●+ ACE DPP-IV 
─ ─ ─ 0.37±0.01a 1.6±0.1a 31±10a 0.28±0.02a 5±2a 8±3a 
+ ─ ─ 
 
0.069±0.003b 0.15±0.01b 1.0±0,1b 0.073±0.005b 0.13±0.02b 0.84±0.07b 
+ + ─ 0.089±0.003b 0.67±0.05c 1.2±0,1b 0.12±0.01c 0.42±0.06b 0.92±0.09b 
+ + + 0.13±0.005c 0.39±0.03d 0.9±0,1b 0.13±0.01c 0.30±0.04b 0.73±0.07b 
Statistical analysis of EC50 values between enzyme treatments were performed by one-way ANOVA followed Tukey’s multiple 
comparison test. Values with different letters differs significantly (P<0.05), values with same letters do not differ significantly 
(P>0.05). EC50 values in italics were determined by extrapolation. 
 
Table 8. EC50 values for ABTS●
+ radical scavenging activity, ACE and DPP-IV inhibiting activity of <10 kDa hydrolysates from in vitro 
digestion of salmon belly flap muscle and skin with pancreatin and mucosal extract and in combination. Values and SD are shown in 
mM. 
EC50 values in italic are determined by extrapolation.  
Treatment 
 
Belly flap muscle Skin 
Pe
ps
in
 
Pa
nc
re
at
in
 
M
uc
os
a ABTS●+ ACE DPP-IV ABTS●+ ACE DPP-IV 
─ ─ + 
 
1.30±0.09d 2.7±0.6e 20±7c 0.47±0.03d 3.4±0.6c 4±2c 
─ + ─ 
 
0.069±0.005b 0.17±0.04b 0.69±0.08b 0.56±0.04e 0.50±0.08b 0.37±0.1db 
─ + +   0.32±0.02e 0.9±0.2f 1.4±0.2b 0.70±0.05f 1.4±0.2d 1.8±0.6eb 
Statistical analysis of EC50 values between enzyme treatments were performed by one-way ANOVA followed Tukey’s multiple 
comparison test. Values with different letters differs significantly (P<0.05), values with same letters do not differ significantly 
(P>0.05). EC50 values in italics were determined by extrapolation. 
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6.2.3. Stability of DPP-IV and ACE inhibition of belly flap +++ hydrolysate, diprotin and captopril 
Stability of DPP-IV and the ACE inhibiting properties of belly flap +++ hydrolysate was further investigated 
when incubated with mucosal ACE and DPP-IV for 24 hours (figure 19A and B). This was to investigate how 
stability of competitive and non-competitive property of the +++ hydrolysates is in comparison with 
diprotin and captopril.  As reference to maximal activity a control with fresh mucosal extract 9x diluted + 
water measured at each sampling point with the same level of ACE and DPP-IV activity through the 24 
hours. The hydrolysate was incubated with either 9x diluted mucosal extract or undiluted mucosal extract 
for 24h at 37°C.  
In figure 19A mucosal extract 9x diluted + hydrolysate show low DPP-IV activity at time 0 and after 1½h, 
which means almost full inhibition, subsequently the inhibitory effect slowly decreases over time. Mucosal 
extract 9x diluted + diprotin (reference) shows full inhibition until 1½h, after 1½h the inhibitory effect 
decreases rapidly, and almost no inhibitory effect of diprotin was observed after 4½hNo change in DPP-IV 
activity is observed in the controls with mucosal extract 9x diluted + fresh hydrolysate and with mucosal 
extract 9x diluted + fresh diprotin. Both of them show constant and almost full inhibition during the entire 
incubation. . Undiluted mucosal extract + diprotin only show partly inhibition already at 0h, at the following 
measurements no inhibition is observed when compared to the control, suggesting that diprotin most likely 
was degraded quickly by DPP-IV. Undiluted mucosal extract + hydrolysates show low inhibition at 0h which 
decrease further after 1½h. This indicates that DPP-IV inhibiting peptides will be degraded or inactivated if 
incubation period was extended. 
In figure 19B the results from the stability experiment of ACE inhibiting properties follows the same pattern 
as observed for the DPP-IV experiment even though a slower decrease in inhibitory effect is observed. The 
two controls, mucosal extract 9x diluted + fresh captopril and mucosal extract 9x diluted + fresh 
hydrolysate show, as expected, completely inhibition during the entire incubation. The control with fresh 
mucosal extract 9x diluted + water, measured at each sampling point show the same ACE activity during 
24h. Mucosal extract 9x diluted + captopril show full inhibition until 4½h and thereafter the inhibitory 
effect slightly decrease to approximately 50% inhibition after 24h. 9x diluted mucosal extract + 
hydrolysates show full inhibition of the ACE activity until 1½h, at the following measurements the inhibitory 
effect slowly decreases and at 24h partly inhibition is observed. Undiluted mucosal extract + the reference 
captopril, show completely inhibition until ½h, thereafter the inhibitory effect of captopril decreases and 
after 24h no inhibition is observed. Undiluted mucosal extract + hydrolysates partly inhibit the ACE activity 
at 0h, after that the inhibitory effect decreases over time. As observed for DPP-IV no inhibition was 
observed when incubated with undiluted mucosal extract for 24 hours, indicating that ACE inhibiting 
peptides also will be degraded or inactivated with a longer incubation time.  
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Figure 19. Stability of DPP-IV (A) and ACE (B) inhibiting properties of <10 kDa +++ hydrolysate  from in vitro digestion of belly flap 
muscle with gastrointestinal proteases when incubated with mucosal extract for 24 hours at 37°C. Reference is diprotin (A) and 
captopril (B). 
Mucosal extract 9x diluted and +++hydrolysate;               Mucosal extract 9x diluted and diprotin or captopril.               
Mucosal extract undiluted and +++ hydrolysate;               Mucosal extract undiluted and diprotin or captopril.  
Controls:              
Mucosal extract 9 x diluted tested with fresh +++ hydrolysate;         Mucosal extract 9x diluted and fresh diprotin or 
captopril;                  Fresh mucosal extract 9x diluted and water.   Measurement was done in triplicate. 
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6.2.4. Inhibition kinetics of belly flap muscle +++ hydrolysates 
The inhibitory mechanism of +++ hydrolysate from belly flap muscle towards ACE and DPP-IV was studied 
further by a Lineweaver Burk plot (figure 20a and b). In the Lineweaver Burk plot for DPP-IV (figure 20a) all 
the lines intersect to the left of the V-1 axis and this indicate that +++ hydrolysate can give a mixed 
inhibition towards DPP-IV with both competitive and non-competitive inhibition. This agree with the result 
from the stability study (figure 19a) where the weak inhibition of DPP-IV by the +++ hydrolysate during 24h 
could be due to peptides with non-competitive inhibition properties.  DPP-IV inhibition with different 
peptide sequences showed both competitive a mixed inhibition and showed that DPP-IV have at least two 
inhibitor binding sites (Rahfeld et al, 1991).  
In the plot for ACE (figure 20b) all the lines intersect in the same x-intercept, but with different slopes and 
y-intercept, and this indicate that the +++ hydrolysate behaved as non-competitive inhibitor towards ACE. 
As the stability of +++ hydrolysates inhibition decreases over time (figure 19b), it could indicate a reversible 
non-competitive inhibition. Other studies have identified small ACE non-competitive inhibitory peptides 
from fish hydrolysates prepared with digestive proteases. Jung et al (2006) isolated non-comp peptide Tyr-
Phe-Pro from yellowfin sole protein digested with chymotrypsin. Shiozaki et al (2010) identified an ACE 
non-competitive inhibiting dipeptide Asp-Tyr from in vitro digestion of oyster hydrolysates with pepsin and 
pancreatin. Ono et al (2006) isolated an ACE non-competitive inhibiting dipeptide Phe-Leu from hydrolysed 
salmon muscle, but found that the reverse sequence Leu-Phe showed competitive inhibition. This strongly 
suggests that both competitive and non-competitive inhibiting peptides can be presence in fish muscle 
hydrolysates.  
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Figure 20. Lineweaver-Burk plot of DPP-IV (a) and ACE (b) activity in presence of various concentrations of <10 kDa (+++) 
hydrolysate from in vitro digestion of salmon belly flap muscle with gastrointestinal proteases. Concentration of hydrolysates (mM 
serine equivalents) ● 28; ▼ 14; ■ 7; ◊ 3.5 ▲ 1,8;  Δ 0.9; □ 0.45. Control:○ H2O 
 
6.3. Bioactivities in sequential digested hydrolysate fractions from SEC 
In this study hydrolysates <10 kDa from the in vitro sequential digestion of salmon tissue with 
gastrointestinal proteases (from section 5.4.2) were fractionated by size exclusion chromatography. The 
fractions were investigated regarding peptide content, ABTS●+ radical scavenging activity, angiotensin I-
converting (ACE) and intestinal DPP-IV inhibiting properties (figure 21 and 22). The observed bioactivity 
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from the fractionated hydrolysates are not in agreement with the results from the three fold dilution 
curves in figure 18 and the EC50 in table 7 in section 6.2.2, as the fractions from both tissues digested with 
pepsin show no pronounced (or maybe none) DPP-IV inhibitory activity. This is surprisingly, however 
interesting, as it might be due to a synergy effect only present in the main hydrolysates, which then 
vanishes when the hydrolysates are separated into fractions.  
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Figure 21. Size exclusion chromatograms at 215 nm (Superdex peptide) of <10 kDa hydrolysates from the sequential digestion of 
belly flap muscle. Peptide content, ABTS●+ radical scavenging activity, DPP-IV and ACE inhibiting activity in fractions from SEC. 
Green: belly flap muscle control, no protease added (- - -); Blue: pepsin added (+ - - ); Red: pepsin + pancreatin added (+ + -); Black: 
pepsin + pancreatin + mucosa added (+ + +). 
 
Size exclusion chromatography of fractions from belly flap muscle hydrolysates from sequential digestion 
showed overall differences in elution profiles, but they do have a similar pattern of compounds, detected at 
215 nm (figure 21). This indicates similar compositions of low molecular weight compounds. Furthermore 
are the patterns from the two hydrolysates generated with pepsin/pancreatin and pepsin/pancreatin/ 
mucosa the most alike. 
Some differences are detected in the elution profile between the peptide content measured in fractions 
and in peaks detected at 215 nm. Especially in the hydrolysates generated with pepsin/pancreatin and 
pepsin/pancreatin/mucosa where no peptide concentration was detected from 22 to 27 ml, but where 
peaks at 215 nm were detected. The elution pattern for the BCA content in three hydrolysates are similar, 
even though the fractions from the hydrolysate generated with pepsin and pancreatin seems to contain the 
highest peptide content. 
ABTS●+ radical scavenging activity in the two before mentioned hydrolysates generated with pepsin/ 
pancreatin and pepsin/pancreatin/mucosa are similar.  A strong ABTS●+ radical scavenging activity was 
found in a broad peak eluting from 12-24 ml, and in a narrow peak from 28-31 ml. This corresponds with 
the peptide content detected, even though the peptide content in the narrow peak from 28-31 ml was 
rather limited in contrast to the strong ABTS●+ radical scavenging activity detected in that specific peak. The 
fractions from the hydrolysate generated only with pepsin also display ABTS●+ radical scavenging activity, all 
though in a lower degree compared to the two other hydrolysates.  A rather strong ABTS●+ radical 
scavenging activity was found in a broad peak from 12-22 ml, whereas no ABTS●+ radical scavenging activity 
was detected after 22 ml. This is in agreement with the peptide content. For the protease free control, only 
a weak ABTS●+ radical scavenging activity was found in a narrow peak eluting from 23-24 ml and at 32-34 
ml. These activities correspond to the elution profile at 215 nm, and suggest ABTS●+ radical scavenging 
activity naturally occurring in belly flap muscle, which also is detected in section 6.1.4. 
No pronounced DPP-IV inhibiting activity was observed in the fractions from the hydrolysates. Again the 
two hydrolysates generated with pepsin/pancreatin and pepsin/pancreatin/mucosa showed similar 
profiles, and it was furthermore in fractions from these hydrolysates the DPP-IV inhibitory activity was 
found. A peak eluting from 15 to 20 ml displayed DPP-IV inhibitory activity, which also corresponds with the 
peptide content. For the hydrolysate generated with only pepsin no pronounced DPP-IV inhibitory activity 
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(or maybe none) was detected, and in the control no DPP-IV inhibitory activity was found. The absence of 
DPP-IV inhibitory activity in the pepsin generated hydrolysate, is as earlier pointed out not in agreement 
with the observed results in section 6.2.2. 
As expected no ACE inhibitory activity was observed for the control. The three hydrolysates show similar 
activity profiles, and in a peak eluting from 13 to 20 ml, ACE inhibiting activity was detected. The ACE 
inhibitory activity detected in the fractions from the three hydrolysates was alike. ACE inhibitory activity 
from the hydrolysate obtained with pepsin was somewhat weaker than the two other hydrolysates, which 
display similar ACE inhibiting activity. The ACE inhibiting activity for all three hydrolysates corresponds with 
the high peptide content observed in the peak eluting first in the chromatogram for BCA protein. 
Size exclusion chromatography of fractions from skin hydrolysates from sequential digestion showed similar 
pattern in elution profiles of compounds, detected at 215 nm (figure 21), as the case was for belly flap 
muscle. This indicates similar compositions of low molecular weight compounds. The elution profile for the 
two hydrolysates generated with pepsin/pancreatin and pepsin/pancreatin/mucosa was again alike.  
The elution profiles for belly flap muscle hydrolysates versus skin hydrolysates showed many similarities in 
elution patterns. However, the fractions from the skin hydrolysates elute earlier in the chromatogram, and 
indicate a greater content of high molecular compounds. The hydrolysates generated with pepsin/ 
pancreatin and pepsin/pancreatin /mucosa are the most alike for both tissues, even though peaks from the 
skin hydrolysates are detected just before 35 ml. This could indicate hydrophobic compounds, interacting 
with the column material. The two controls (belly flap muscle and skin with no protease added) showed 
quite different elution profiles. This indicates a different composition of low molecular weight compounds, 
which also support the findings in section 6.1.2.  
As was the case for the belly flap muscle hydrolysates, some differences are detected in the elution profile 
between the peptide content measured in fractions and peaks detected by 215 nm. Especially in the 
hydrolysates generated with pepsin/pancreatin and pepsin/pancreatin/mucosa, where no peptide 
concentration was detected from 22 to 27 ml, but where peaks at 215 nm were detected. In contrast to the 
findings from the belly flap muscle hydrolysates, there was a pronounced difference in the peptide content 
for the three skin hydrolysates. The peptide content in two hydrolysates generated with pepsin/pancreatin 
and pepsin/pancreatin/mucosa are alike, whereas the pepsin generated hydrolysates seemed to have a 
much lover peptide concentration.  This indicates very different peptide concentrations in the two tissues, 
when digested with pepsin only. 
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Figure 22. Size exclusion chromatograms at 215 nm (Superdex peptide) of <10 kDa hydrolysates from the sequential digestion of 
skin. Peptide content, ABTS●+ radical scavenging activity, DPP-IV and ACE inhibiting activity in fractions from SEC. Green: belly flap 
muscle control, no protease added (- - -); Blue: pepsin added (+ - - ); Red: pepsin + pancreatin added (+ + -); Black: pepsin + 
pancreatin + mucosa added (+ + +). 
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As for belly flap muscle, the ABTS●+ radical scavenging activity in the two skin hydrolysates generated with 
pepsin/pancreatin and pepsin/pancreatin/mucosa are similar. ABTS●+ radical scavenging activity was found 
in a broad peak eluting from 15-20 ml, and in peaks eluting from 22-24 ml and from 28-31 ml. The strongest 
ABTS●+ radical scavenging activity was found in the peak elution from 22-24 ml. This corresponds with the 
peptide content detected, even though the peptide content in the narrow peak from 28-31 ml was rather 
limited in contrast to the strong ABTS●+ radical scavenging activity detected in that specific peak. The 
hydrolysate generated with pepsin also display ABTS●+ radical scavenging activity, all though to a lower 
degree compared to the ABTS●+ radical scavenging activity observed in the two other hydrolysates. 
However, this is in agreement with the peptide content. Interesting, all the skin hydrolysates display a 
much weaker ABTS●+ radical scavenging activity compared to all the hydrolysates from belly flap, even 
though the same proteases has been used. This indicates the difference of bioactive compounds generated 
in the two tissues. For the protease free control, only a weak ABTS●+ radical scavenging activity was found 
in a narrow peak eluting 32-34 ml. This activity correspond to a peak in the elution profile at 215 nm, and 
suggest ABTS●+ radical scavenging activity naturally occurring in skin, which also is detected in section 6.1.4. 
No pronounced DPP-IV inhibiting activity was observed in the fractions from the hydrolysates, which also 
was the case for the belly flap muscle hydrolysates. Again the two hydrolysates generated with pepsin/ 
pancreatin and pepsin/pancreatin/mucosa show similar activity profile pattern, and it is furthermore in 
these hydrolysates DPP-IV inhibitory activity was found.  It was in a peak eluting from 15-20 ml, which also 
corresponded with the peptide content. This is also in agreement with the results obtained for belly flap 
muscle. For the hydrolysate generated only with pepsin and the control, no DPP-IV inhibitory activity was 
detected. As before mentioned for the pepsin generated belly flap hydrolysate, this result is notable and 
not in agreement with the findings in section 6.2.2. 
As expected no ACE inhibitory activity was observed for the control, which also is in agreement with the 
finding for belly flap muscle and from section 6.1.1. The two hydrolysates generated with pepsin/ 
pancreatin and pepsin/pancreatin/mucosa show similar profiles, and in a peak eluting from 13 to 20 ml, 
ACE inhibiting activity was detected. The ACE inhibitory activity detected in the fractions from the two 
hydrolysates was quite alike. This is similar to the hydrolysates from belly flap muscle. ACE inhibitory 
activity from the hydrolysate obtained with pepsin was somewhat weaker than the inhibitory activity from 
the two other hydrolysates.  The inhibitory effect was furthermore weaker when compared to the same 
hydrolysates from belly flap muscle. The ACE inhibiting activity for all three hydrolysates corresponds with 
the peptide content observed in the peak eluting first in the BCA protein chromatogram. 
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In conclusion, many similarities are seen for the hydrolysates from belly flap muscle and skin generated 
with sequential digestion. In general are the patterns for the observed bioactivities from the fractionated 
hydrolysates similar, but differences in intensities of bioactivities between the digestion treatments are 
observed.  The elution profiles show overall differences, however, the patterns in elution profiles of 
compounds detected at 215 nm are similar. The ABTS●+ radical scavenging activity was found in all obtained 
hydrolysates, though hydrolysates from belly flap muscle showed a much stronger activity compared to 
skin hydrolysates. DPP-IV and ACE inhibiting activity was observed in nearly all hydrolysates, only in the 
pepsin generated hydrolysates no pronounced (or maybe none) DPP-IV inhibitory effect was found.  This is 
notable, as it is not in agreement with the results from section 6.2.2., where both belly flap muscle and skin 
hydrolysates digested with pepsin display DPP-IV inhibitory activity, and furthermore where no difference 
in DPP-IV inhibitory activity was observed between the sequential digested hydrolysates.  
 In general, the results from the bioactivities observed in fractions from the pepsin digested tissues are not 
in agreement with the results from section 6.2.2. The fractions from the pepsin generated showed the 
overall lowest inhibitory effect in the three assays, whereas as the pepsin generated hydrolysates in section 
6.2.2. overall showed the highest inhibitory effect when displayed in the three fold dilution curves and in 
EC50 values. 
The results from the fractionation also show that hydrolysates obtained with pepsin/pancreatin and 
pepsin/pancreatin/mucosa are alike, indicating no pronounce effect of the degradation of mucosa. The skin 
hydrolysate from pepsin degradation differs markedly from the other hydrolysates. A pronounced 
difference in peptide concentration was observed only between the belly flap muscle and skin hydrolysates 
generated with pepsin. The content was much higher in belly flap muscle. As in agreement with the findings 
in section 6.1.4., both belly flap muscle and skin control (not degraded by proteases) display ABTS●+ radical 
scavenging effect, which may be due to naturally occurring peptides. 
The results from the DPP-IV assay are marked by a variation between the fractions primarily after 20 ml 
eluted, this is mainly due to scatter during the measurements and these results are therefore marked by a 
lack of uncertainty; - however, this does not change the overall findings for the fractionated hydrolysates. 
6.4. Bioactivities and LC-MS MS/MS in belly flap muscle and skin - + + hydrolysates 
fractions from SEC (Paper III - under preparation) 
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CHAPTER 7 CONCLUSION AND PERSPECTIVES 
The main objective of this PhD research was to discover and characterize novel bioactive peptides from 
marine secondary products. Gills, belly flap muscle and skin from salmon (Salmo salar) were chosen for the 
research. Both naturally occurring peptides from extracts from salmon tissue and peptides from 
hydrolysates generated by gastrointestinal proteases were investigated. The studies included in this PhD 
thesis have touched upon research areas where previous publications are scarce or non-existing. 
The hypothesis whether naturally occurring low molecular compounds in extracts from salmon tissues of 
secondary products possess bioactivities such as radical scavenging capacity, intestinal DPP-IV and ACE 
inhibiting properties in part I was only partly confirmed. ABTS●+ radical scavenging activity was detected in 
<10 kDa extracts of gills, belly flap muscle and skin, whereas none of the extracts showed ACE and DPP-IV 
inhibiting activity. This could be due to low peptide content in the extracts and an up-concentration of the 
extracts by e.g. freeze-drying might be feasible, and may reveal if the extracts possessed ACE and DPP-IV 
inhibiting properties.  
Low molecular compounds from salmon extract separated by size exclusion chromatography showed 
ABTS●+ radical scavenging activity. The strongest ABTS●+ radical scavenging activity was detected in 
fractions eluting between 21-22 ml for all three tissues with strongest activity in the gill extract. There was 
not a full correlation between ABTS●+ radical scavenging activity and peptide content, which may indicate 
presence of inactive peptides or other compounds contributed to the activity. Fractions were not analysed 
with ACE and DPP-IV assays as the extracts did not show any activity in these assays.  Again, if the extracts 
were up-concentrated it might have been possible to reveal, if the extracts and fractions hereof possessed 
ACE and DPP-IV inhibiting properties.  
The extraction procedure was observed to have no effect on the composition of compounds from skin. For 
gills an effect was observed, as the elution profiles of compounds by size exclusion chromatography with 
and without heat treatment showed differences. This indicated that compounds could have precipitated 
during boiling. The extraction procedure also influenced the composition of compounds from belly flap 
muscle as an increase in compounds was observed.   
Mass spectrometry analysis of dominating compounds in active fractions from size exclusion 
chromatography showed that families of related compounds were found in several fractions from different 
tissues, but most pronounced in gills. It was possible to identify a candidate bioactive compound, and it was 
defined according to content of a specific amino acid sequence (PW). Three families were defined by the 
m/z value of the smallest compound reported in each family (219, 434 and 403). The three latter families 
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did not contain standard unmodified amino acids, and thus not confirming the hypothesis that low 
molecular extracts consists of peptides with unmodified amino acids. 
It would be advantageous to do MS analysis with di-and tripeptides, which have been modified in various 
ways, in order to know how they behave by MS, MS/MS and LC-MS/MS before doing further MS analysis on 
the naturally occurring peptides. Internal standards could also be useful e.g. in order to find the number of 
components and their m/z values by MS, and also to get a much more exact m/z value in order to generate 
better possible chemical formulas as the precision would be higher. 
For the low molecular compounds in  the hydrolysates generated by gastrointestinal proteases investigated 
in part II, analysis of <10 kDa hydrolysates showed that gastrointestinal proteases generated peptides with 
clear ABTS●+ radical scavenging activity and DPP-IV and ACE inhibiting activity as well.  These results confirm 
the stated hypothesis on that subject. Furthermore, hydrolysates from pepsin digestion exhibited the 
lowest EC50 values for ABTS●+ radical scavenging activity and ACE inhibition, whereas EC50 increased in 
hydrolysates after subsequent digestion with pancreatic and mucosal proteases.  
It was possible to evaluate the inhibitory stability and mechanism of a low molecular hydrolysate towards 
ACE and DPP-IV activity. Inhibition modes for the muscle hydrolysates were found to be both competitive 
and non-competitive, but prolonged incubation showed that the inhibitory properties were unstable, and 
therefore properly digested as competitive substrates by gastrointestinal proteases. 
The hypothesis whether  low molecular compounds in hydrolysates from in vitro digestion of salmon 
muscle and skin with gastrointestinal proteases separated by size exclusion chromatography possess 
bioactivities as radical scavenging effect, intestinal DPP-IV and ACE inhibiting activity in part II was almost 
fully confirmed. In general are the patterns for the observed bioactivities from the fractionated 
hydrolysates similar, but differences in intensities of bioactivities between the digestion treatments are 
observed. When fractionated by size exclusion chromatography, ABTS●+ radical scavenging activity was 
found in all obtained hydrolysates, though hydrolysates from belly flap muscle showed a much stronger 
activity compared to skin hydrolysates. DPP-IV and ACE inhibiting activity was observed in nearly all 
fractionated hydrolysates, only in the pepsin generated hydrolysates no pronounced (or maybe none) DPP-
IV inhibitory effect was observed. This is surprising and notable, as it was not in agreement with the results 
from the three-fold dilution curves, where both belly flap muscle and skin hydrolysates digested with 
pepsin display DPP-IV inhibitory activity, and furthermore where no difference in DPP-IV inhibitory activity 
was observed between the sequential digested hydrolysates. However, it is interesting, as it might be due 
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to a synergy effect only present in the main hydrolysates, which vanishes when the hydrolysates are 
separated into fractions.  
Finally, mass spectrometry analysis of dominating compounds in active fractions from size exclusion 
chromatography from belly flap and skin hydrolysate generated from pancreatin/mucosa digestion showed 
that many compounds were present in several fractions. Currently it has not been possible to identify 
candidate bioactive compounds responsible for a certain bioactivity as a more thorough analysis and 
characterization is required. Hopefully, the work regarding this can be completed in the nearest future.  
It would be interesting to carry out further studies regarding other bioactivities than the three investigated 
in the low molecular weight molecules; this applies for both the obtained extracts and the various 
hydrolysates obtained with gastrointestinal proteases. Furthermore, a step further would be in vivo assays, 
and  test of candidate bioactive compounds in animal models. 
Mass spectrometry analysis of the other obtained hydrolysates would also be appropriate to carry out, as 
this might reveal other candidate bioactive compounds or confirm the findings for the already analysed 
compounds in active fractions.  
The findings from the present thesis clearly suggest a potential for bioactive peptides with health 
promoting properties from fish secondary tissues, especially when generated with gastrointestinal 
proteases, both in relation to gastrointestinal digestion and as an alternative to the use of industrial 
proteases.  
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Summary. There is an interest in bioprospecting organisms from the aquatic environment to find novel bioactive compounds with health 
promoting or other functional properties. The aim of this study was to evaluate extracts from  untreated and heat-treated salmon tissues for their 
radical scavenging activities and for their ability to inhibit activity of the proteases angiotensin I-converting enzyme (ACE) and dipeptidyl 
peptidase 4 (DPP-4). In vitro assays were used to detect these activities and the corresponding candidate bioactive compounds were characterized 
by LC-MS/MS.  
Radical scavenging activity was detected in <10kDa extracts of gills, belly flap muscle and skin with EC50 values of 39, 82 and 100 µg/mL, 
respectively. No ACE or DPP-4 inhibiting activity could be detected. LC-MS/MS analysis of dominating compounds in active fractions from size 
exclusion chromatography showed that families of related compounds were found in several fractions from different tissues but most pronounced 
in gills. One family was defined according to content of a specific amino acid sequence (PW). Three families were defined by the m/z value of 
the smallest compound reported in each family (219, 434 and 403). The three latter families did not contain standard unmodified amino acids, 
indicating peptides with modified amino acids or other kinds of molecules. 
Industrial relevance. Bioprospecting in fish tissue traditionally regarded as waste can lead to detection of novel natural bioactive compounds 
including peptides, which could have nutritional, pharmaceutical or other functional value and be used in health and functional foods, thus 
increasing the value adding of secondary marine products. A number of  naturally occurring antimicrobial  peptides have been characterized from 
fish skin and gills, such as piscidins, but these and other fish tissues may contain numerous other compounds with bioactive properties. Such 
compounds could be extracted by the subsection of the fish industry that processes marine secondary products and further developed to 
commercial products. Thus, the identification of novel bioactive compounds could be utilized by the pharmaceutical and biotech industry to 
develop new products. 
Keywords. Salmon tissue; natural compounds; radical scavenging; marine by-products 
 
INTRODUCTION 
 
Fish are adapted to living conditions utterly different from land-living organisms. For instance, fish must in general possess an 
eminent bioactive defense to protect them from the high bacterial load in water, and may thus be expected to harbor bioactive 
molecules for this purpose (Harnedy & FitzGerald 2012). Bioprospecting in fish tissues that traditionally has been regarded as 
waste, or has been used for low-value purposes, like animal feed, can lead to detection of novel natural bioactive compounds 
including peptides with health promoting and functional properties.   
A large number of natural antimicrobial peptides (AMPs) are found in invertebrates, and such peptides have also been 
identified in a number of fish species (Rajanbabu & Chen 2011). Some AMP families are unique for fish such as the antimicrobial 
polypeptides piscidins from gills (Corrales et al., 2009, Corrales et al., 2010). Studies have shown that some of these peptides 
also exhibit immunomodulatory and antitumor activity (Rajanbabu & Chen 2011). It is therefore possible that some of these 
peptides are multifunctional and may exhibit other highly relevant bioactivities with health promoting properties eg., oxidative 
stress that can be suppressed by radical scavenging molecules (Katayama & Mine 2007), hypertension that can be reduced by 
angiotensin I-converting enzyme (ACE) inhibiting molecules (Fyhrquist & Saijonmaa 2008) and insulin secretion that can be 
influenced by dipeptidyl peptidase IV (DPP-4) inhibiting molecules (Flatt et al., 2008). The past two decades, the identification 
of possibly bioactive compounds, present in marine secondary products, has been an emerging area of research (Kim and Mendis 
2006). Several investigations have shown that processing leftovers contain significant levels of proteins, cryptides and peptides 
with bio-functional and techno-functional properties.  Peptides derived from marine proteins (cryptides)  have proved to be 
effective against several ailments, such as hypertension (Enari et al. 2008, Gu et al. 2011), osteoporosis (Kanis 2002), 
cardiovascular diseases  (Wergeland et al. 2004), and cancer (Picot et al. 2006). However, like mammals, fish tissue also 
contains, in variable amounts, some peptides or amino acids with antioxidative activity such as the imidazoles anserine, carnosine 
and histidine (Abe et al., 1983; Shirai et al., 1983; Suzuki et al., 1990) and glutathione (Bauchart et al., 2007). Additionally, one 
study has shown that anserine possesses angiotensin converting enzyme (ACE) inhibiting properties (Hou et al., 2003).  
Falkenberg et al.  
12 
Recently, Pampanin et al. (2012) compared peptides with known bioactivities, such as ACE inhibition, antioxidative, or 
immunomodulatory activities, with small peptides from herring tissues detected by LC-MS/MS. Based on their sequences, a 
number of herring peptides with potential bioactivities were suggested. None of the peptides appeared to contain modified amino 
acids. However, a review by Harnedy & Fitzgerald (2013) shows salmon and salmon by-products, compared to many other 
marine organisms, have not been subjected to the same extent of bio-prospective multifaceted research activities.  
Furthermore, only few studies have isolated and characterised novel naturally occurring low molecular compounds in fish 
tissue that can exhibit radical scavenging activity or act as inhibitors toward ACE. To our knowledge studies investigating 
compounds from fish tissues with DPP-4 inhibiting properties have not previously been carried out. Farmed salmon is nutritional 
and healthy and has become a popular food worldwide. The market is not satiated yet and the scale of production is still 
increasing. According to FAO FishStat, the global aquaculture annual production of Salmo salar (Linnaeus, 1758) in 2012 was 
approx. 2 million tons. The remaining processing leftovers from salmon production amounting to hundreds of thousand tons per 
annum include trimmings, frames, fins, heads, skin, shells and viscera. These secondary products are normally used for 
production of fish oil, essential fatty acids, fishmeal, fish silage and animal feed, but can also be utilized for production of high-
priced products. The extraction and subsequent exploitation of marine by-products for components with bioactive properties 
represents an excellent strategy for added-value generation. 
The aim of this study is to evaluate radical scavenging activity, ACE and DPP-4 inhibiting activities in extracts from skin, belly 
flap muscle and gills from salmon, and characterize the corresponding candidate bioactive compounds to observed activities.  
 
MATERIALS AND METHODS 
 
Salmon tissues. Gills, skin and belly flap muscle from fresh Atlantic salmon (Salmo salar) (Fig. 1) obtained from a 
commercial fish farm were vacuum packed and stored at - 40°C until use.  
Preparation of tissue extracts with and without heat treatment. Thawed gills, skin and belly flap muscle from salmon were 
cut into small pieces (approx. 0.5x0.5x0.5 cm for gill and belly flap muscle and 0.5x0.5x0.1cm for skin). For each tissue two 
samples were prepared where tissue pieces were mixed with 3 volumes of water (w/v) (e.g. 20 g fish tissue + 60 mL water). One 
sample was boiled in a water bath at 100°C for 10 min. The other sample was not boiled but kept on ice for 10 min. After 
heating, the tissue/water suspensions were homogenized with an ultraturrax T25 (IKA Labortechnich) at 13500 rpm for 5 min on 
ice. The suspensions were centrifuged for 45 min at 21000xg at 4°C. The supernatant was filtered through a 150 mm filter paper 
(Frisenette nr. 201), followed by filtration through 0.45 and 0.20 µm filters (Sartorius) on ice. The obtained filtered extracts were 
kept on ice until ultra filtration.  
Chemicals. 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), Gly–Pro-p-Nitroanilide, captopril, 1-methyl-L-
tryptophan, 5-methyl-DL-tryptophan, diprotin and protease type XIV from Streptomyces griseus ≥ 3,5 units pr mg (pronase) 
were purchased from Sigma Aldrich (St. Louis, MO, USA). Abz-Gly-Phe(NO2)-Pro was purchased from Bachem AG 
(Bubendorf, Switzerland).  
Preparation of mucosal extract. Mucosal extract from pig intestine was used as enzyme source for DPP-4 and ACE activity. 
Pig intestine was obtained from a Danish landrace/ Yorkshire cross that had been fasted overnight before slaughter and then 
stored at - 20°C. Jejunum (1 m) was filled with 100 mL of 0.1 M Tris-HCl buffer, pH= 8.0 (22˚C) and inverted briefly 5 times. 
The crude extract was filtered through a fine-meshed sieve and centrifuged at 4000xg for 30 minutes at 4˚C. The supernatant was 
saved and 40 mL was dialysed for 24 h at 2˚C in 10 kDa dialysis tubing against 100 x volume of 0.1 M Tris-HCl buffer pH 8. 
Protein content of the recovered dialysed mucosal extract was 7.2 mg/mL as determined with Pierce BCA protein assay (Thermo 
Scientific, Rockford, IL, USA)   using bovine serum albumin (BSA) as standard. The recovered dialysed mucosal extract was 
frozen in aliquots at -20˚C until use.  
Ultrafiltration of extracts. The filtered extracts were fractionated by ultrafiltration with Vivaspin 10 kDa cut off filters 
(Sartorius) at 4000xg at 4°C for 45 min. The filtrates named as <10 kDa extracts were stored at -20°C until use.  
Peptide content. Peptide content in the <10 kDa extracts was measured with the Pierce Modified Lowry Assay (Thermo Fisher 
Scientific, Rockford, IL, USA). The lower peptide content in the fractions obtained from size exclusion chromatography was 
measured with the more sensitive Pierce BCA Protein Assay.  For both methods BSA was used as standard and peptide content is 
expressed as mg protein per mL. 
ABTS●+ radical scavenging activity (modified after Clausen et al., 2009). A volume (50 µl) of <10 kDa extracts or dilutions 
thereof were combined in 96 well microplates with  200 µl of ABTS●+  solution (0.37 mM in 0.1 M borate buffer, pH=8.0), 
which had been prepared from 18.7 mM ABTS and 8.8 mM ammonium persulfate in water that had been incubated overnight at 
room temperature. All dilutions were done in borate buffer. Absorbance was measured at 734 nm in a microplate reader (Biotek, 
Synergy 2). ABTS●+ free radical scavenging activity was defined as decrease in absorbance after 30 min. 50 µl of water was used 
as control for 100% absorbance. 
DPP-4 inhibitory activity (modified after Li-Chan et al., 2012). A volume (50 µl) of <10 kDa extracts or dilutions thereof 
were combined with 50 µl of intestinal mucosal extract (diluted 27 times in 100 mM Tris-HCl buffer pH=8.0) in 96 well 
microplates and prewarmed to 37˚C. All dilutions were done in 0.1 M Tris-HCl buffer, pH 8.0, 25°C. Prewarmed DPP-4 
substrate (200 µl of 2.5 mM Gly-Pro-Nitroanilide, 0.1 M Tris-HCl buffer, pH 8.0, 25°C) was added and absorbance measured at 
405 nm (and 600 nm to correct for light scatter) every two minutes for 20 minutes in a microplate reader (Synergy 2, Biotek) at 
37°C. 50 µl of water was used as control for 100% activity and 2 mM diprotin was used as reference inhibitor. DPP-4 activity 
was calculated as ∆ mOD 405 nm/min as initial rate for the linear part of the curve and scatter subtracted if present. Inhibition 
was calculated as activity in % of activity in control. 
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ACE inhibitory activity (modified after Sentrandreu & Toldra 2006). A volume of 50µl of <10 kDa extracts in 3-fold 
dilution was added to a well in 96 well microplate. Intestinal mucosal extract (50 µl of 10 times diluted extract in 150 mM Tris-
HCl buffer pH 8.3) was added to the wells. Before addition of substrate, the microplate was preincubated at 37˚C for 10 minutes 
in the fluorescence spectrophotometer (Gemini max, Molecular Devices) with automatic mixing. The substrate working solution 
(light sensitive) (0.45 mM Abz-Gly-Phe(NO2)-Pro in 150 mM Tris-HCl buffer pH 8.3, 25°C with 1.125 M NaCl) was also 
incubated at 37˚C for 10 minutes in a water bath. Subsequently, 200 µl of substrate solution was added. 50 µl of water was used 
as control for 100% activity and 0.12 µM captopril was used as reference inhibitor. Fluorescence was measured every minute as 
Relative Fluorescence Units (RFU) after automatic shaking for a total of 40 minutes at λ (excitation) = 355 nm and λ (emission) 
= 405 nm. ACE activity was defined as ∆ RFU per min and inhibition was calculated as activity in % of activity in control. 
 
 
 
Figure 1. Picture of the salmon tissues used for extraction of bioactive compounds. (A) Gill, (B) Skin, ( C) Belly flap muscle 
Experimental design 
 
 
 
Figure 2. Schematic flowchart showing the experimental design of analyzing bioactive compounds in tissues from salmon 
 
Determination of EC50 values. EC50 values were determined by dose-response experiments, where ABTS●+ radical scavenging 
and ACE and DPP-4 inhibitory activity were measured with 3-fold dilutions of extracts. Non-linear regression for estimation of 
EC50 values was performed using sigmoidal dose-response curves with individual Hillslope coefficients (y=min+ (max-
min)/(1+10^(EC50-x)Hillslope) built into Sigmaplot v. 11 graphing and statistics software (Systat software Inc)  
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Size exclusion chromatography (SEC). Compounds in <10 kDa extracts were separated by FPLC (Fast Performance Liquid 
Chromatography) using an Äkta Purifier system with FRAC 950 collector. Undiluted filtrate (200 µl) was injected into a 
SuperdexTM peptide 10/300 GL column (GE Healthcare) using 100 mM ammonium acetate buffer pH 8 with a flow rate at 0.5 
mL/min. Ammonium acetate is a volatile buffer that minimally affects subsequent steps of mass spectrometry.  Compounds were 
detected at 215 nm and 280 nm. Fractions of 1 mL each were collected (35 fractions in total) and stored at -20°C until use. 
Cytochrome c (12.3 kDa), aprotinin (6.5 kDa), Lys5 (659 Da), Gly3 (189 Da), and Gly (75 Da) (Sigma-Aldrich, St. Louis, 
Missouri, USA) were used as molecular weight markers. 
 Pronase treatment of extracts. Pronase (1 mg/mL) dissolved in 100 mM Tris-HCl pH 8 was mixed with <10 kDa extracts in 
the ratio 120 µl to 480 µl (pronase 5 times dilution, Enzyme:Substrate ratio 1:4 (v:v)) in a microcentrifuge tube. Control samples 
without pronase but with water were made the same way. A sample containing only pronase (1 mg/mL) was made to indicate 
elution of pronase and corresponding autolytic peptides, if any. The microcentrifuge tubes were placed in a 37˚C water bath 
overnight (16 hours) and immediately analysed by SEC as described above.  
LCMS and LCMS/MS. Fractions from the size exclusion  chromatography that showed antioxidative capacity were dried in a 
SpeedVac (Thermo Scientific Savant SPD1010) and reconstituted in 50 µl buffer A (5% acetonitrile [ACN] + 0.1% formic acid 
[FA]), vortexed, centrifuged at room temperature at 14,000xg for 10 min and transferred to LC vials. Buffer B was 90% ACN + 
0.1% FA. A nanoHPLC (EASY nLC; Proxeon, Odense, Denmark) was used. The samples were trapped on an EASY reverse 
phase pre-column (2 cm length, ID 100 µm, 5 µm C18 beads) and separated on an EASY reverse phase analytical column (10 cm 
length, ID 75 µm, 3 µm C18 beads). Flow rate was 300 nL/min. The time from mixer to elution was 3 min, corresponding to a 
dead volume of around 900 nL. The components were eluted by a gradient  (0 min 100%A, 0.05 min 99%A, 2 min 90%A, 21 
min 45%A, 23 to 26 min 0%A,  28 min  95%A, 30 min 100%A) into a micrOTOF-QII mass spectrometer (Bruker Daltonik, 
Bremen, Germany) through the standard nanosprayer into the electrospray ion source. Nitrogen was used as nebulizer (pressure 
at 1 bar) and drying gas (5 L/min at 150 °C) in the ion source. Argon 5.0 was used as collision gas, and the collision energy was 
automatically adjusted to the selected m/z values using default options. Infusion of electrospray calibrant solution (Fluka) by a 
syringe pump was used as external calibration for the samples. Additionally, a standard mixture of tryptic peptides made from 
BSA (Agilent) was run for every fifth LC-MS/MS sample, and was used for more detailed external calibration. The MS 
instrument was controlled by instrument-specific software (Compass 1.3 micrOTOF control v2.3), where the acquisition 
parameters were set (positive mode, low mass limit at m/z 50, MS/MS auto in the m/z range 70 to 800, 4 precursor ions with 
absolute intensity > 2000 counts, exclude after 4 spectra, release after 1 min). The data were initially analyzed in the Compass 1.3 
DataAnalysis v4.0 software to generate the compounds and externally calibrate the spectra. The software extracted compounds 
using intensity threshold at 1000, retention time window 1 min, S/N threshold 3, and relative area and intensity thresholds at 3%. 
 
RESULTS AND DISCUSSION  
 
In the last decade a large number of small antimicrobial peptides have been identified in fish tissue like gills, skin and organs 
(Hoang & Kim, 2013). Studies have shown that some of these peptides also can have other bioactive properties like anticancer 
activity (Chang et al., 2011) and immunomodulatory activity (Hsieh et al., 2010). This suggests that salmon tissue could have 
unidentified endogenous peptides or other compounds that possess other bioactive properties apart from antimicrobial activity. 
This is supported by the study by Pampanin et al. (2013), who showed that extracts from herring skin and internal organs 
contained many small peptides with potential bioactive properties. The present study analysed three different tissues from salmon 
for low molecular weight compounds (<10 kDa) with radical scavenging activity and ACE and DPP-4 inhibitory properties based 
on the hypothesis that salmon tissue contains novel bioactive compounds. Extraction of compounds was done in water with heat 
treatment to prevent endogenous proteolysis and also to prevent bacterial growth. However as heat treatment may also affect 
relevant compounds such as peptides, an extraction was also carried out without heat treatment. Analysis with Lowry assay 
showed that boiling did not affect the peptide content in <10 kDa extract from gill compared to extract prepared without boiling 
(Table 1). An increase in the amount of recovered peptides was observed in both belly flap muscle and skin extract after boiling 
(Table 1), which could be due to a more efficient extraction from these tissues.  
 
Table 1. Peptide contents and radical scavenging activity in <10 kDa extracts of different tissues from salmon. Peptide content was measured in 
duplicates by the Lowry method using bovine serum albumin (BSA) as standard, and is given as mg protein/mL. Radical scavenging activities are 
reported as the peptide concentrations that were able to remove 50% of the ABTS●+ radicals (EC50, half maximal effective concentration). EC50 
values were estimated by non-linear regression (sigmoidal dose-response curve) with 95% confidence intervals. 
Treatment Tissue mg protein /mL EC50   (mg/mL) EC50   (mg/mL) 95% 
confidence interval 
Boiling Gills 0.84 3.5 x 10-3 2.9 x 10-3 - 4.2 x 10-3
 Belly flap muscle 0.43 8.1 x 10-3 Not analysed 
 Skin 0.77 1.0 x 10-2 9.8 x 10-3 - 1.1 x 10-3 
No Boiling Gills 0.85 5.2 x 10-3 4.6 x 10-3 - 5.7 x 10-3 
 Belly flap muscle 0.26 8.3 x 10-3 7.7 x 10-3 - 8.8 x 10-3 
 Skin 0.43 1.2 x 10-2 9.9 x 10-3 - 1.6 x 10-2 
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Bioactivities. All <10 kDa extracts showed clear  ABTS●+ radical scavenging activities with 95% decrease in absorbance  at 
734 nm (Fig. 3). Dose-response data from analyses of three-fold dilutions of the extracts are shown in Fig. 3. There were 
relatively small differences between the tissues, with gill extracts apparently giving the lowest EC50 value estimated by non-linear 
regression analysis (Table 1), which may suggest that this extract contained compounds with more potent radical scavenging 
activity than extracts from either belly flap muscle or skin.  
 
 
Figure 3. Concentration dependencies of ABTS●+ radical scavenging activities in extracts (<10 kDa) from salmon tissues. Extracts were from (A) 
boiled tissues (filled symbols) or from (B) control (not boiled) tissues (open symbols). The tissues were gill (●,○); belly flap muscle (■,□ ) and 
skin (▲,∆). The curves were fitted by nonlinear regression – global curve fitting. Absorbance was normalized to 1 based on absorbance of water 
as control. 
 
 
None of the <10 kDa extracts inhibited DPP-4 and ACE activity when compared to water as control (results not shown). This is 
notable as Pampanin et al. (2012) found that extracts of herring skin with PBS buffer contained several small peptides with 
potential bioactivity on the cardiovascular system such as reducing hypertension. 
Size exclusion chromatography. Size exclusion chromatography of <10 kDa extracts showed very different elution profiles of 
compounds from belly flap muscle, gills, and skin, respectively, as detected by absorbance at 215 and 280 nm (Fig. 4), indicating 
different compositions of low molecular weight compounds in these tissues. A common feature for boiled extract from all three 
tissues was that compounds did not elute before 18 mL, which corresponds to the MW of Gly3. This indicated that even though 
extracts were fractionated by 10 kDa cut-off ultrafiltration, the largest compounds eluting were in the range of 400-500 Da 
assuming that there was no extraneous interaction between the compounds and column matrix. Both at 280 nm and 215 nm 
between 3 and 5 peaks eluted after Gly. This indicates that all extracts contained compounds that adsorbed to the column and 
therefore could have an MW larger than Gly. Only control extracts from gills contained compounds that eluted with void volume, 
which suggested a MW larger than 7 kDa. These compounds could have precipitated during boiling as they were not detected in 
the filtrate. Boiling also influenced the profile of belly flap muscle as shown by an increase in compounds eluting between 20 and 
22 ml. In contrast no effect of boiling was observed for skin. 
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Figure 4. Size exclusion chromatography (SuperdexTM peptide 10/300 GL column) of <10 kDa extracts (boiled and not boiled) from three 
different salmon tissues: gills (top row), belly flap muscle (middle row) and skin (bottom row). Designation of peptide standards markers is 
shown on figure “Gill” (top row, left column). Eluting components were detected by absorbance at 215 and 280 nm. 
Test of peptide content in peaks from size exclusion chromatography. A test of peptide content was made by addition of 
pronase to the boiled < 10 kDa extracts and analysed by SEC. Peaks  that were affected by the treatment with pronase indicated 
presence of peptides consisting of standard amino acids.  
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Figure 5. Effect of pronase (Streptomyces griseus protease XIV) on Size exclusion chromatography elution profile of < 10 kDa extracts from 
boiled salmon tissue. (A) Gills, (B) Belly flap muscle, (C) Skin. ― Without pronase; ······ with pronase.  Pronase (1 mg/mL in 100 mM Tris-HCl 
pH 8) was mixed with extract in ratio 1:4 (v:v) and incubated 16 hours before analyses by SEC. 
 
Fig. 5 shows the elution profiles of < 10 kDa extracts from gills, belly flap muscle and skin with and without pronase. Pronase 
eluted as a single peak at 9 mL corresponding to the void volume. In general, the pronase treatment had surprisingly little effect 
on the extracts. The resistance to proteolysis indicated the presence of compounds other than unmodified peptides. The main 
effect of pronase on the gill extract was on a peak eluting at 22 mL, which was reduced considerably, while a peak eluting at 24 
mL correspondingly increased (Fig. 5A). The pronase treatment on belly flap muscle extract (Fig. 3B) mainly resulted in a 
decrease of a major peak eluting at 19 mL. An increase in a peak eluting at 19.5 mL could be a result of cleavage products from 
peptides eluting at 19 mL. Three peaks eluting at 20.5, 22 and 26 mL also decreased after pronase treatment. Interestingly, the 
decrease of these peaks did not result in increase in new peaks eluting later, possibly because pronase destroyed the peptide 
bonds. The effect of pronase treatment on skin extract seemed somewhat smaller than on gill and belly flap muscle extract (Fig. 
5C). As for belly flap muscle extract, a decrease in peaks eluting at 19 and 26 mL was seen.  
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ABTS●+ radical scavenging activity and peptide content in fractions from boiled salmon. Peptide content and radical 
scavenging activities were measured in fractions from the size exclusion chromatographed samples of boiled < 10 kDa extracts 
from salmon gills, belly flap muscle and skin (Fig. 6). There was no ABTS●+ scavenging activity in fractions eluting from 0-
16mL. In the fraction eluting  at 18 mL, a weak ABTS●+  radical scavenging activity  was observed for gills and skin, which 
could be due to peptides in the low molecular weight range (between Gly3 and Lys5). Pampanin et al. (2013) identified small 
peptides in extracts from herring skin that could have antioxidative properties, suggesting that fish skin in general contains small 
peptides with antioxidative properties. However, there is not a full correlation between peptide content and radical scavenging 
activity indicating the presence of inactive peptides or that other types of compounds were contributing to the activity. The 
strongest ABTS●+ radical scavenging activity was detected in fractions eluting between 21 and 22 mL for all three tissues with 
strongest activity in the gill extract, where also the highest peptide content was detected. This is in agreement with the lower EC50 
value for gill extract compared to the two other tissue extracts. These fractions eluted after glycine and suggest the presence of 
compounds with some affinity to the column material. Radical scavenging activity was also detected in fractions eluting at 28 and 
33 mL for gill and skin, respectively, indicating even stronger interaction with the column. Fractions from untreated salmon 
extracts were also analyzed with the ABTS●+ radical scavenging assay, and the activity profiles matched those from boiled 
salmon extract (results not shown).  
 
 
 
Figure 6. Peptide content (A) and ABTS●+ radical scavenging activity (B) in fractions from size exclusion chromatography of <10 kDa extract 
from boiled salmon tissue. (●) Gills,( ○) Belly flap muscle, (+) Skin. Peptide standards markers are shown in A. Peptide content was analysed 
with bicinchoninic acid assay (Pierce BCA Protein Assay) with bovine serum albumin as standard. 
 
LC-MS and MS/MS. The fractions from the boiled samples that showed the highest ABTS●+radical scavenging activity were 
selected for analysis by mass spectrometry. Focus was on the major compounds in the fractions (Fig. 5a, b and c) that gave 
MS/MS spectra of reasonable quality. C18 reverse phase columns were used in the LC-MS analyses. Very hydrophilic 
compounds are not retained on such columns, and will therefore not be detected.   
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Figure 7a. Base peak ion chromatograms from nanoLC reverse phase separation of fractions from salmon gill. The fractions were from size 
exclusion chromatography (SEC) performed on <10 kDa extract from salmon gill, and collected in 1 ml portions at (A) 18 mL (B) 21 mL, (C) 22 
mL, (D) 28 mL, (E) 29 mL (cf. Fig 4), corresponding to the fractions showing the highest ABTS●+  radical scavenging activity.   ― Sample; --- 
Blank; Arrows indicate peaks containing components that have been characterized by MS/MS and are mentioned in text and tables.  
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Figure 7b. Base peak ion chromatograms from nanoLC reverse phase separation of fractions from belly flap muscle. The fractions were from 
size exclusion chromatography (SEC) performed on <10 kDa extract from salmon belly flap muscle, and collected in 1 ml portions at (A): 21 mL, 
(B) 22 mL. (cf. Fig 4), corresponding to the fractions showing the highest ABTS●+  radical scavenging activity.   ― Sample; --- Blank; Arrows 
indicate peaks containing components that have been characterized by MS/MS and are mentioned in text and tables. 
 
 
Figure 7c. Base peak ion chromatograms from nanoLC reverse phase separation of fractions from salmon skin. The fractions were from size 
exclusion chromatography (SEC) performed on <10 kDa extract from salmon skin, and collected in 1 ml portions at 22 mL (cf. Fig 4), 
corresponding to the fraction showing the highest ABTS●+  radical scavenging activity.   ― Sample; --- Blank; Arrow indicate peak containing 
components that have been characterized by MS/MS and are mentioned in text and tables. 
 
The mass spectrometric analyses showed three conspicuous features. First, some compounds were found in several fractions 
and from different tissues. Second, several families of chemically related compounds were evident. In fact, most compounds 
belonged to one or another multimember family, here called the "PW family", "434 family"  "403 family" and "219 family", as 
recognized by similarities of the MS/MS spectra within each family (Tables 2, 3, 4 and 5). The families are named according to a 
specific amino acid sequence (PW) or by the lowest m/z value reported in each family. Third, there were only few compounds 
with standard amino acids as major constituents. No proteolytic treatment was performed on the fractions analyzed by MS and 
endogenous proteases were inactivated by the heat treatment. Thus, the detected compounds were likely small compounds or 
peptides freely present in the tissues, although the boiling procedure may have resulted in heat-induced chemical modifications.  
The only compounds that consisted of identifiable amino acids were found in fraction 21 and to a lesser degree in fraction 22 
from gills. M/z 399 (Fig. 8) could be explained as the peptide PPW (theoretical m/z 399.203, observed m/z 399.202), member of 
the PW family (Table 2). The compound m/z 486 was apparently related to m/z 399 (both having MS/MS fragments at m/z 188, 
205 and 302), although the former had a somewhat poor MS/MS spectrum. The mass difference between 399 and 486 could 
suggest an additional Ser, thus giving the sequence SPPW or PSPW (theoretical m/z 486.235, observed m/z 486.235). Comparing 
with zebra fish sequences (the salmon genome is not yet available), the PPW sequence is found in numerous proteins, but we are 
not aware of any previous reports indicating that it may be present as a free peptide. Also the sequences SPPW or PSPW can be 
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found in several tens of zebra fish proteins. The PPW and SPPW/PSPW could be responsible for part of the radical scavenging 
activity observed in fraction 21 of gill and could represent new antioxidative peptides naturally present in fish tissue.  
 
Table 2.  Two compounds in the PW family and two unrelated compounds detected by reverse phase LC-MS/MS. These compounds were only 
found in <10 kDa extract from salmon gills. 
 
Obs. m/z, charge Rt (min) MS(2) fragments Found in Comments 
399.20, z=1 15.7-15.9 146.06, 159.09, 188.07, 205.10, 302.15 Gills fraction 21 PPW (theoretical m/z 
399.20). PW family. 
486.24, z=1 15.0-15.3 157.10, 188.08, 205.10, 302.15 Gills fraction 21 SPPW or PSPW 
(theoretical m/z 486.24). 
PW family 
417.25, z=1 17.6-17.8 132.08, 141.10, 144.08, 159.09, 170.06, 
227.16, 287.14 
Gills fractions 21 and 22 WVL/I or VWL/I? 
(theoretical m/z 417.25) 
247.06, z=1 19.5-19.6 125.02, 141.08, 143.03, 152.07, 183.04, 
203.07 
Gills fraction 28  
 
Table 3. Compounds in the m/z 434 family detected by reverse phase LC-MS/MS. These compounds were only found in <10 kDa extract from  
salmon gills. 
 
Obs. m/z, charge Rt (min) MS(2) fragments Found in Comments 
434.19, z=1 16.3-16.6 116.02, 129.07, 133.10, 141.07, 142.03, 
144.01, 155.09, 162.02, 167.09, 170.03, 
185.10, 199.07, 233.06 
Gills fraction 18  
436.21, z=1 19 116.02, 129.07, 133.10, 142.03, 144.01, 
157.10, 162.02, 170.03, 187.11, 199.07, 
233.07 
Gills fraction 18  
448.20, z=1 19.5 116.02,127.06, 129.07, 142.03, 144.01, 
155.09, 162.03, 170.03, 173.10, 199.11, 
216.14, 233.06 
Gills fraction 18  
 
Table 4. Compounds in the m/z 403 family detected by reverse phase LC-MS/MS. These compounds were only found in <10 kDa extract from 
salmon gills. 
 
Obs. m/z, charge Rt (min) MS(2) fragments Found in Comments 
403.09, z=3 8.7-8.9 112.05, 119.04, 136.06, 162.07, 176.00, 
193.05, 250.10, 288.05, 306.05, 348.07, 
420.09, 462.08 
Gills fraction 21 Likely the same as the co-
eluting 604; here as (M+3H+)/3 
427.61, z=2 9.4-9.6 112.05, 119.04, 136.06, 152.06, 161.06, 
192.08, 216.09, 290.06, 332.08 
Gills fraction 22  
439.62, z=2 9.8-10.1 119.03, 135.03, 152.06, 161.06, 216.09, 
234.10, 314.07, 33208, 394.10 
Gills fraction 21  
447.62, z=2 9.4-9.7 119.03, 135.04, 136.06, 152.06, 161.06, 
216.09, 232.09, 312.05, 332.08, 348.09 
Gills fraction 21  
451.60, z=2 8.7-9.1 112.05, 119.03, 136.06, 143.04, 152.06, 
163.05, 176.80, 191.04, 250.09, 312.05, 
330.05 
Gills fraction 22  
455.59, z=2 8.4-8.6 112.05, 119.04, 136.06, 152.06, 161.06, 
192.08, 216.09, 290.06, 332.07 
Gills fraction 18 Probably different from 455 in 
fraction 22 
455.59, z=2 9.7-10 119.04, 135.04, 136.06, 152.06, 161.06, 
216.09, 232.08, 332.07, 348.08 
Gills fraction 22 Probably different from 455 in 
fraction 18 
459.60, z=2 8.8-9.0 112.05, 119.04, 135.03, 136.06, 152.06, 
177.00, 193.05, 232.08, 250.10, 312.04, 
330.07, 348.07 
Gills fraction 22  
467.59, z=2 8.5-8.8 112.05, 119.03, 136.06, 139.95, 152.06, 
161.06, 192.08, 216.09, 234.09, 290.06, 
314.07, 332.07 
Gills fraction 18  
475.59, z=2 9.0-9.3 112.05, 119.03, 126.07, 135.02, 136.06, 
152.06, 161.07, 176.99, 192.08, 216.09, 
232.08, 314.06, 332.09 
Gills fraction 18  
604.13, z=2 8.6-9.0 112.06, 136.06, 193.05, 208.07, 226.09, 
232.08, 250.09, 268.10, 288.05, 291.06, 
306.05, 330.06, 348.07, 420.08, 462.11 
Gills fraction 21 Likely the same as the co-
eluting 403; here as (M+2H+)/2 
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Table 5. Compounds in the m/z 219 family detected by reverse phase LC-MS/MS. These compounds were found in all <10 kDa extracts from 
salmon tissues (gills, belly flap muscle and skin).  
 
Obs. m/z, 
charge 
Rt (min) MS(2) fragments Found in Comments 
219.06, z=1 18.5-19.3 128.06, 133.02, 141.01, 154.08, 159.02, 
171.03, 173.05, 183,04, 201.05 
Gills fraction 21, 22, 28, 29 
Belly flap fraction 21, 22 
Skin fraction 22 
M + H+ 
437.11, z=1 18.7-18.9 141.01, 159.02, 201.05, 219.06 Gills fraction 21, 22 
Belly flap fraction 22 
2M + H+ 
261.07, z=1 19.6-19.8 129.07, 133.02, 154.08, 171.04, 173.05, 
183.04, 201.05, 219.06 
Gills fraction 21  
655.08, z=1 18.1-18.4 141.01, 159.02, 201.05, 219.06 Gills fraction 22 3M + H+ 
349.12, z=1 20.4-20.6 159.02, 173.05, 201.05, 219.06, 259.09 Gills fraction 22 
Belly flap fraction 21, 22 
 
293.06, z=1 19.8-20.7 141.02, 159.03, 171.03,173.06, 201.05, 
219.07 
Gills fraction 28, 29  
448.13, z=1 19.9-20.1 165.01, 201.04, 219.06, 243.06 Belly flap fraction 21  
 
 
 
Figure 8. MS/MS spectrum of compound m/z 399.202 from  fraction 21 mL from SEC of gill extract, and its identification as PPW. The MS/MS 
fragments with the suggested chemical structures are also generated from free Trp (corresponding to the y1 fragment; data not shown). The m/z 
values of these fragments from free Trp are also found in the databases Metlin (metlin.scripps.edu) and MassBank (www.massbank.jp), and 
together with the Trp-specific y1 fragment at m/z 205, they are probably indicative of a C-terminal Trp. Wi, immonium ion of Trp; P, proline. The 
small diamond () to the right indicates the m/z value of the intact ion. 
A compound of m/z 417 was found in fractions 21 and 22 from gills (Table 2). MS/MS fragments show a strong peak at 
159.09, potentially fitting with the immonium ion of Trp. The remaining mass of the original ion could fit with presence of Val 
and Leu/Ile. Leu/Ile in C-terminal position would give an y1-ion of 132, which is present. Thus, a tripeptide consisting of Trp, 
Val, and Leu/Ile, is a possibility (WVL/I or VWL/I), but there are still a number of unexplained fragments left. Thus, this 
compound is presently considered as unidentified.  
All other compounds contained mainly units that were not standard amino acids; i.e., modified amino acids, or some other 
kinds of molecules.  
The 434 family was found in fraction 18 from gills (Table 3), with compounds of m/z 434, 436 and 448 (distinct from 448 in 
the 219 family). The three compounds eluted at different positions in the gradient, and contained a number of fragment ions in 
common. Additionally, there was one series of fragments that had the same mass difference as the intact ions (m/z 185, 187, 199, 
respectively). 
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The 403 family was found in fractions 18, 21 and 22 from gills (Table 4), and these compounds tended to elute early in the 
gradient (8 to 11 min). Most analyzed members in this family were doubly charged (in contrast to all compounds mentioned 
above).  The members were characterized by a strong MS/MS fragment at m/z 136.06 (a value close to the immonium ion of 
Tyr), and a number of additional common fragments. However, no other data directly supported the presence of Tyr.  
 
  
Figure 9. MS/MS spectra of representatives in the m/z 219 family. (A) m/z 219. (B) m/z 437. (C) m/z 349. Note the common fragments:  m/z 
219, 201, 159 in all three spectra, m/z 141 in A and B, and m/z 173 in A and C. The small diamond () to the right indicates the m/z value of the 
intact ion. 
The 219 family gave the major chromatographic peak(s) in all shown fractions, except in Fig 5a (fraction 18 from gills). The 
family consisted of compounds with m/z 219, 261, 293, 349, 437, and 655.  These compounds had at least 4 MS/MS fragments in 
common with m/z 219 (Fig. 9 and Table 5). M/z 219, 437 and 655 were co-eluting, and the latter was only found in fractions 
where 219 was very intense. They probably corresponded to the same compound (as M + H+, 2M + H+, and 3M + H+, 
respectively).  Also m/z 448 (fraction 21 from belly flap muscle; note that there was also another compound with m/z 448 as 
indicated below) probably belonged to this family, although it only showed two fragments in common with the remaining family 
(fragments 219 and 201). 
Being the common basis of the most prominent family of compounds found in these experiments, m/z 219 was selected for 
further analyses. The isotopic envelope of the intact compound 219 showed intensities of the second and third peaks of 12.84% 
(mean; range 12.27-13.44%) and 1.17% (mean; range 1.08-1.29%). The chemical composition that most closely approximated 
the mean isotopic distribution was C10H10N4O2 (as neutral compound; theoretical m/z for MH+ is 219.0877; theoretical peak 
intensities of 12.82 and 1.16% as calculated by the NIST08 database software).  
There are some biologically relevant compounds that have theoretical m/z values close to the detected in the range 219.05-
219.07. Potassium adducted glucose (theoretical m/z 219.027) can easily be excluded based on both its hydrophilicity and its 
isotopic envelope distribution. Another candidate could be methylated Trp (theoretical m/z 219.113; chemical composition for 
neutral compound is C12H14N2O2). If so, this could suggest 261 as the acetylated methyl-Trp. The spectra of 1-methyl-L-Trp and 
5-methyl-DL-Trp were therefore investigated. The two methyltrypthophans showed very similar spectra (not shown). Only the 
MS/MS fragment at 173 was common for the methyltryptophans and compound 219. Furthermore, some of the major fragments 
showed a 1 Da difference between compound 219 (see also Fig. 9A) and the methyltryptophans (201 vs 202, 183 vs 184, 159 vs 
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160, 133 vs 132). Theoretical peak intensities for methylated Trp are 14.35 and 1.35% for second and third peak, and observed 
intensities were 13.9 and 1.5%, respectively. Thus, the 219 compound is not methyltryptophan, although some kind of chemical 
relationship cannot be excluded. 
The presence of the 219 compound or its family members in most dominating fractions with radical scavenging activity 
indicate that these compounds contribute in general to the observed radical scavenging activity in the different tissues. Thus, the 
219 compound could be an interesting new natural radical scavenging agent. The 219 compound is further discussed below in the 
section "Database searches". 
Many of the characterized compounds exhibited low fractional masses (the numbers after the decimal point). If the analyzed 
compounds consist of the common elements of organic biomolecules, they must contain several rings and unsaturated bonds, in 
addition to oxygens or phosphorus (sulfur can be excluded based on the isotopic peak distributions). Many bioactive peptides 
contain amino acids that possess ring and unsaturated bonds. Trp can exhibit radical scavenging activity as the indolic group can 
serve as hydrogen donor (Pihlanto, 2006). Saito et al. (2003) studied radical scavenging activity of different combinations of 
tripeptides and found that tripeptides with a Trp at the C-terminus exhibited the highest radical scavenging activity. The presence 
of Trp could also explain that these peptides elute after Gly when fractionated on the size exclusion column. The aromatic amino 
acids Phe, Tyr and Trp have been analysed on the SEC column using the previously described method and all three eluted after 
Gly (results not shown). 
Anserine and carnosine, two modified dipeptides with a methylhistidine moiety possessing antioxidant and ACE inhibiting 
activities (Hou et al. 2003), have previously been detected in fish tissue (Shirai et al 1983, Bauchart et al 2007). In the studied 
fractions, we did not detect anserine or carnosine, or any other compound with a methylhistidine moiety.  
Database searches. Searches in chemical databases might in some cases be of considerable help in identifying unknown 
compounds (Little et al., 2012; Wolf et al., 2010). External calibration with known samples run for every fifth fish sample, gave a 
range of m/z between 219.0580 and 219.0627 (average 219.0600) for the 219 molecule.  
The NIST08 database was searched with the data for m/z 219, but no reasonable hits were found. The compound was then 
analyzed by MetFrag (Wolf et al., 2010), using the three databases KEGG, PubChem and ChemSpider in a range from m/z 
219.050±25 ppm to 219.100±25 ppm in steps of 0.01, and using the 9 peaks indicated in Table 5. MetFrag suggested several 
compounds with theoretical fragments covering 5 to 7 of the observed fragments, but when screened against the isotopic 
distribution, most of the hits could be excluded. Compounds with neutral composition C12H11O2P (e.g., PubChem ID 17841952), 
C11H10N2O3 (e.g., PubChem IDs 4268466, 13290790), and C10H10N4O2 (e.g., PubChem ID 28412031) showed 5 to 6 hits with the 
observed fragments, and reasonable fits with the isotopic contribution. However, none of them appeared as obvious candidates 
for being immediately accepted as the presently observed compound, as some of the major peaks were lacking for all hits. 
The theoretical isotopic peak intensities may depend somewhat on the software used in the calculations (we have used the 
calculator in the NIST08 database software). In principle, the isotopic distribution may slightly change according to food and 
trophic level of the organism (McCutchan et al., 2003; Newsome et al., 2007; Henry et al., 2012), although it would not be 
expected that such changes should be detected by the present type of MS. Still, we have compared observed and theoretical peak 
intensities for some salmon peptides identified in other analyses (Falkenberg et al., in prep). Most of the observed intensities were 
92 to 100% of the theoretical intensities, with a few instances (for the third peak in the isotopic envelope) up to 120% of 
theoretical intensity. Thus, it is possible that the chemical composition with the best calculated fit, C10H10N4O2 for the neutral 
compound, could be a close approximation to the real compound with m/z 219. 
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Abstract: Research on marine bioactive peptides has mainly focused on characterization of peptides in hydrolysates prepared with 
commercial industrial enzymes and the usefulness of such hydrolysates in health and functional foods. However, a relevant question 
is whether digestion of fish proteins with gastrointestinal proteases per se generates peptides that also can have health promoting 
properties and can reduce, e.g., diabetes 2, inflammation and hypertension either in relation to gastrointestinal digestion or as 
alternative to industrial proteases. The aim of the study was to investigate hydrolysates obtained from in vitro sequential digestion of 
salmon muscle and skin with gastrointestinal proteases including pepsin, pancreatic and pancreatic + mucosal proteases for their 
ability to scavenge ABTS●+ radicals and inhibit activity of angiotensin I-converting enzyme (ACE) and dipeptidyl peptidase 4 
(DPP-4). Furthermore, it was the aim to study the inhibitory mechanism and stability towards ACE and DPP-4 activity. Analysis of < 
10 kDa hydrolysates showed that gastrointestinal proteases generated peptides with clear radical scavenging activity and DPP-4 and 
ACE inhibiting activity as well. Hydrolysates from pepsin digestion exhibited the lowest EC50 values for radical scavenging activity 
and ACE inhibition, whereas EC50 increased in hydrolysates after subsequent digestion with pancreatic and mucosal proteases. 
Interestingly, EC50 values for the DPP-4 inhibition were hardly affected by sequential digestion. Inhibition modes for the muscle 
hydrolysates were both competitive and non-competitive, but prolonged incubation showed that the inhibitory properties were 
unstable and therefore they were probably digested as competitive substrates by gastrointestinal proteases.  
 
Key words: Salmon, bioactive components, ACE, DPP-4, radical scavenging, in vitro digestion, gastrointestinal proteases. 
 
1. Introduction 
Several studies have shown that fish protein 
hydrolyzed with commercial proteases could generate 
peptides with potential health promoting properties. 
Among them, there are effects on hypertension [1-3], 
diabetes 2 [4, 5], antioxidative [6-8] as well as 
anticarcinogen properties [9-11]. Much of this 
research has focused on preparation and 
characterization of hydrolysates for commercial use in 
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health and functional foods. However, a relevant 
question is whether gastrointestinal digestion of fish 
proteins per se generates peptides that could have 
similar health promoting properties and whether 
peptides generated from intestinal digest of fish 
protein can potentially influence diabetes 2, 
inflammation and hypertension. 
Intestinal dipeptidyl peptidase 4 (DPP-4) degrades 
the incretin hormones gastric inhibitory polypeptide 
(GIP) and glucagon-like peptide-1 (GLP-1), which 
stimulate the insulin response [12]. Inhibition of 
DPP-4 increases the incretin effect on insulin 
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secretion and prevents diabetes 2 [13]. Synthetic 
peptides with inhibitory properties towards DPP-4 
have been developed, where some are approved as 
therapeutic agents in diabetes 2 treatment [14]. 
Oxidative stress is characterized by an increased 
level of reactive free radicals within cells [15]. This 
can induce cell damage causing inflammation, e.g., in 
the gut. One way to suppress oxidative stress is intake 
of dietary antioxidative peptides and amino acids that 
can act as radical scavengers [16, 17]. 
Blood pressure is regulated by several factors, 
among which conversion of angiotensin I to 
angiotensin II by angiotensin I-converting enzyme 
(ACE) is particularly important and results in 
increased blood pressure. Thus, inhibition of ACE can 
prevent hypertension [18]. Ono et al. [19] showed that 
blood pressure in hypertensive rats was reduced after 
oral intake of salmon hydrolysates. Furthermore, 
research indicated that small and medium sized 
peptides could be absorbed intact through the intestine 
[20] and might therefore have systemic effects. 
Recent studies have shown that digestion of fish 
proteins with specific proteases, such as pepsin and 
chymotrypsin, produce peptides that inhibit ACE 
[21-23] and DPP-4 [4], but knowledge on which 
peptides are produced during in vitro simulated 
gastrointestinal digestion is scarce. In vitro simulated 
gastrointestinal digestion with pepsin and pancreatin 
of different milk proteins showed that DPP-4 
inhibiting peptides were generated and that inhibiting 
activity already was generated after pepsin digestion 
[4, 24]. In vitro gastrointestinal digestion of pork 
muscle generated ACE inhibiting peptides mainly 
from the muscle protein titin [25]. 
An interesting aspect is whether the generated 
peptides inhibit DPP-4 and ACE by competitive or 
non-competitive mechanisms. Peptides inhibiting 
ACE either in a competitive, non-competitive or an 
uncompetitive mode have been found in hydrolysates 
from various sources and the mode of inhibition is 
apparently dependent on both sequence and length of 
the peptide [26]. Only few studies have reported 
inhibition mode of peptides from fish muscle. Ono et 
al. [19] reported that the inhibitory mechanism of 
ACE by different dipeptides from salmon muscle 
hydrolysates is dependent on the particular amino 
acids on both C-terminal and N-terminal, where 
peptides with C-terminal Trp exhibited 
non-competitive inhibition. This agrees with Jung et al. 
[23], who isolated an ACE non-competitive inhibiting 
peptide from yellowfin sole with a hydrophobic 
C-terminal end. Several synthetic peptide competitive 
inhibitors of DPP-4 have been developed [14]. 
However, there are no reports on inhibition mode of 
DPP-4 inhibiting peptides from protein hydrolysates. 
The objective of the study was to investigate 
scavenging activity towards ABTS●+ as well as 
inhibition of ACE and DPP-4 using hydrolysates 
obtained from salmon belly flap muscle and skin 
digested in vitro with gastrointestinal proteases to 
simulate gastrointestinal digestion in vitro. 
Furthermore, the objective was to evaluate the 
inhibitory mechanisms and stability of muscle 
hydrolysate towards inhibition of ACE and DPP-4. 
2. Materials and Methods 
2.1 Materials 
2.1.1 Salmon Tissue 
Skin and belly flap muscle (subsequently referred to 
as muscle) from fresh caught farmed Atlantic salmon 
(Salmo salar) obtained from local fish monger was 
vacuum packed and stored at -40 °C until use.  
2.1.2 Preparation of Mucosal Extract 
Pig intestine from a Danish landrace/Yorkshire 
cross that had been fasted overnight before slaughter 
and then stored at -20 °C was used. 1 m jejunum was 
filled with 100 mL of 0.1 M Tris-HCl buffer, pH = 8.0 
(22 °C) and inverting briefly five times. The crude 
extract was filtered through a fine-meshed sieve and 
centrifuged at 4,000 g for 30 min at 4 °C. The 
supernatant was saved and 40 mL was dialyzed for  
24 h at 2 °C in 10 kDa dialysis tubing against 100  
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volume of 0.1 M Tris-HCl buffer, pH = 8.0. Protein 
content of the recovered dialyzed mucosal extract was 
7.2 mg/mL determined with Pierce bicinchoninic acid 
(BCA) protein assay kit from Thermo Scientific 
(Rockford, IL, USA) using bovine serum albumin 
(BSA) as standard. The recovered dialyzed mucosal 
extract was frozen in aliquots at -20 °C until use. 
This extract was used both for digestion 
experiments and as enzyme source in DPP-4 and ACE 
activity measurements. 
2.1.3 Chemicals 
2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic 
acid) (ABTS), Gly-Pro p-nitroanilide hydrochloride, 
captopril, diprotin (Ile-Pro-Ile), pancreatin, pepsin, 
sodium dodecyl sulphate (SDS), DL-dithiothreitol 
99% (DTT), O-phthaldialdehyde 97% (OPA) were all 
purchased from Sigma Aldrich (St. Louis MO). 
Abz-Gly-Phe(NO2)-Pro was purchased from Bachem 
AG (Bubendorf, Switzerland) and L-Serine (Merck 
chemicals, Darmstadt, Germany). All other reagents 
used were analytical grade chemicals. 
2.2 In Vitro Digestion 
2.2.1 Pre-treatment 
The thawed skin and muscle from salmon were cut 
into small pieces and mixed with water to a final 
protein concentration of 6.3% and 6.6% of skin and 
muscle, respectively. This is based on a protein 
content of 15.4% and 31.3% for muscle and skin, 
respectively determined by Kjeldahl analysis. The 
total amount of fish/water suspension was 42 mL. The 
fish/water suspension was heated to 95 °C in loosely 
capped blue cap bottles in a water bath. After reaching 
95 °C, the fish/water suspension was left there for 10 
min and afterwards cooled down to room temperature. 
2.2.2 In Vitro Digestion with Gastrointestinal 
Proteases 
Digestion study was carried out with seven different 
combinations of pepsin (45 mg/mL), pancreatin (30 
mg/mL) and small intestine mucosa extract (7.2 
mg/mL), respectively (Table 1). Digestion was 
performed in a water bath with shaker (Hetofrig 
CB60VS) at 37 °C. Before addition of enzymes, pH 
for treatment 2 was adjusted to 2 with 6 N HCl and 
pH for treatments 1, 5, 6 and 7 was adjusted to 8 with 
2 N NaOH. A 10 kDa cut off dialysis bag containing 
10 mL of water was added to the fish tissue 
suspension for each treatment at time zero. Treatments 
2, 3 and 4 were carried out sequentially as treatment 2 
was adjusted to pH 8 with 4 N NaOH after 2.5 h. 
After 1 h, more dialysis bags were removed and a new 
dialysis bag was added together with pancreatin 
(treatment 3) and pancreatin + mucosal extract 
(treatment 4), respectively.  
Water was added, so all seven suspensions had the 
same final volume. 
When digestion time ended, dialysis bags were 
removed and flushed with water and carefully wiped 
with paper tissue. Contents of the dialysis bags were 
transferred to Eppendorf tubes and frozen at -20 °C until 
 
Table 1  Experimental design of in vitro digestion of salmon muscle and skin with gastrointestinal proteases.  
Treatment No. Designation Enzyme Enzyme added (mL) 
Start of 
digestion Digestion pH 
Digestion time 
(h) 
Control 1 – – – None - - 8 24 
Pepsin only 2 + – – Pepsin 1 Time zero 2 2.5 
Pepsin 
+ pancreatin 3 + + – Pancreatin 1 After 3.5 h 8 21.5 
Pepsin 
+ pancreatin 
+ mucosal extract 
4 + + + Pancreatin Mucosal extract 
1 
1 After 3.5 h 8 21.5 
Mucosal extract only 5 – – + Mucosal extract 1 Time zero 8 24 
Pancreatin only 6 – + – Pancreatin 1 Time zero 8 24 
Pancreatin 
+ mucosal extract 7 – + + 
Pancreatin 
Mucosal extract 
1 
1 Time zero 8 24 
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use. Digestion controls with enzyme(s) alone were 
also carried out. 
2.3 Digest Yield  
Digest yields were measured by the OPA method 
modified after Ref. [27] using L-serine as standard 
(0.1 mg L-Serine/mL). 25 µL hydrolysate samples, 
standard solution and water, respectively, were added 
to a 96 well microplate in eight-fold determination. 
200 µL OPA reagent prepared according to Ref. [27] 
was added to each well and the plate was inserted in 
the plate reader (Biotek, Synergy 2) with automatic 
shaking. The plate was left for 2 min in the plate 
reader before the absorbance was measured at 340 nm. 
Hydrolysate samples was properly diluted so 
absorbance did not exceed 0.8. 
2.4 ABTS●+ Radical Scavenging Activity [28] 
A volume of 50 µL of hydrolysate or standard or 
dilutions thereof were combined in 96 well 
microplates with 200 µL of ABTS●+ solution (0.37 
mM in 0.1 M borate buffer, pH = 8.0), which had 
been prepared from 18.7 mM ABTS and 8.8 mM 
ammonium persulfate in water that had been 
incubated overnight at room temperature. All 
dilutions were done in borate buffer. Absorbance was 
measured at 734 nm in a microplate reader (Biotek, 
Synergy 2). ABTS●+ free radical scavenging activity 
was defined as decrease in absorbance after 30 min. 
2.5 DPP-4 Activity 
A volume of 50 µL of hydrolysate or standard or 
dilutions thereof were combined with 50 µL of 
intestinal mucosal extract (diluted 27 times in 100 
mM Tris-HCl buffer pH = 8.0) in 96 well microplates 
and were pre-warmed to 37 °C. Prewarmed DPP-4 
substrate (200 µL of 2.5 mM Gly-Pro p nitroanilide, 
0.1 M Tris-HCl buffer, pH = 8.0, 25 °C) was added 
and absorbance was measured at 405 nm (and 600 nm 
to correct for light scatter) every 2 min for 20 min in a 
microplate reader (Synergy 2, Biotek) at 37 °C. DPP-4 
activity was calculated as ∆mOD 405 nm/min as 
initial rate for the linear part of the curve and scatter 
subtracted if present. All dilutions were done in 0.1 M 
Tris-HCl buffer, pH = 8.0, 25 °C. 
2.6 ACE Activity [29] 
A volume of 50 µL of hydrolysate or standard in 
three-fold dilution was added to a well in 96 well 
microplate. Intestinal mucosal extract (50 µL of 10 
times diluted in 150 mM Tris-HCl buffer pH 8.3) was 
added to the wells. Before addition of substrate, the 
microplate was pre-warmed at 37 °C for 10 min in the 
fluorescence spectrophotometer (Gemini Max, 
Molecular Devices) with automatic mixing. The 
substrate working solution (light sensitive) (0.45 mM 
Abz-Gly-Phe(NO2)-Pro in 150 mM Tris-HCl buffer 
pH = 8.3, 25 °C with 1.125 M NaCl) was also 
incubated at 37 °C for 10 min in a water bath. 
Subsequently, 200 µL of substrate solution was added 
and fluorescence was measured as relative 
fluorescence units (RFU) after automatic shaking 
every minute for 40 min at λ (excitation) = 355 nm 
and λ (emission) = 405 nm. ACE activity is defined as 
∆RFU/min. 
2.7 Stability of +++ Muscle Hydrolysate, Diprotin 
and Captopril Inhibition of DPP-4 and ACE  
Stability of the DPP-4 and ACE inhibition by +++ 
hydrolysate, diprotin or captopril was measured when 
incubated in mucosal extract for 24 h. Hydrolysate 
(three times diluted) diprotin (0.22 mM) and captopril 
(4 µM) were mixed with mucosal extract (nine times 
diluted) or undiluted mucosal extract in ratio 1:1 in 
Eppendorf tubes and incubated in water bath at 37 °C. 
All dilutions regarding DPP-4 inhibition were done 
with 100 mM Tris-HCl buffer, pH = 8.0, and all 
dilutions regarding ACE inhibition were done with 
150 mM Tris-HCl buffer, pH = 8.3. To prevent any 
microbial growth, sodium azide was added to the 
Tris-HCl buffer to a final concentration in 
hydrolysate/mucosal extract mixture of 0.05%. 
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Sampling was done at time 0, 0.5, 1.5, 4.5 and 24 h. 
At each sampling, 100 µL of each sample was 
transferred to a 96 well microplate. Sample with 
undiluted mucosal extract was done at 24 h by 
transferring 11 µL sample + 89 µL of Tris-HCl buffer 
to a 96 well microplate. DPP-4 and ACE activity was 
immediately measured thereafter using the assay 
previous described in Section 2.5 and 2.6. 
Measurements were done as a triplicate. 
As reference to maximal activity and inhibition, the 
following controls were measured at each sampling 
point: (1) 100 µL of 50 µL fresh mucosal extract nine 
times diluted and 50 µL water; (2) 100 µL of 50 µL 
fresh mucosal extract nine times diluted and either  
50 µL fresh +++ hydrolysate, diprotin, or captopril. 
Furthermore, mucosal extract incubated alone was 
used as control to measure effect of incubation on the 
extract. 
2.8 Inhibition Kinetics Mechanism of +++ Muscle 
Hydrolysate Inhibition of DPP-4 and ACE 
A Lineweaver-Burk plot for determination of 
inhibition mode of muscle +++ hydrolysate against 
DPP-4 and ACE activity, respectively, was carried out 
as a cross titration experiments in 96 well microplates. 
Hydrolysate diluted three times in water was used as 
strongest hydrolysate concentration which 
subsequently was diluted twofold with water to 64 
times as final dilution. Concentration range of the 
DPP-4 substrate Gly-Pro p-nitroanilide and the ACE 
substrate Abz-Gly-Phe(NO2)-Pro was 2 mM to 0.016 
mM and 10 mM to 0.16 mM, respectively. The 
substrate concentration range was based on [V] versus 
[S] plot using water as sample. Substrate 
concentrations below and above an estimated Km 
value was used. 
50 µL of hydrolysates dilutions was transferred to a 
96 well microplate containing 50 µL mucosal extract 
50 times diluted with Tris-HCL 100 mM pH 8.0 for 
DPP-4 and Tris-HCl 150 mM pH 8.3 for ACE in each 
well. Eight wells contained 50 µL of water instead of 
mucosal extract. DPP-4 and ACE activity was 
measured immediately after adding 200 µL of 
substrate dilutions using the assay procedures 
previous described. 200 µL of substrate dilutions 
added to 100 µL of water were used as blank. 
2.9 Statistics 
2.9.1 Determination of EC50 Values 
Nonlinear regression—global curve fitting 
(Sigmaplot 11, Systat Software Inc.) was used to 
estimate values and Std. Error for the half maximal 
effective concentration EC50. 
Statistical analysis of EC50 values between enzyme 
treatments was performed by one-way ANOVA 
followed by Tukey’s multiple comparison        
test (Graphpad Prism Ver. 4.03, Graphpad Software 
Inc.).  
3. Results and Discussion 
3.1 Hydrolysates 
Fish proteins contain peptide sequences that may 
have DPP-4 and ACE inhibiting properties and also 
radical scavenging activity [30, 31]. Such bioactive 
peptides may be released during gastrointestinal 
digestion. The study investigated the formation of 
radical scavenging activity and inhibitory action 
towards DPP-4 and ACE during in vitro digestion of 
salmon tissue with gastrointestinal proteases. The 
gastrointestinal proteases used in sequential in vitro 
digestion represent digestion by the primary digestive 
proteases in stomach (pepsin), duodenum (pancreatin) 
and jejunum (mucosal extract). 
The in vitro digestion included both a sequential 
hydrolysis with combination of digestive proteases 
simulating a gastrointestinal digestion and hydrolysis 
with the different protease preparations alone. 
3.2 Digest Yields 
Low molecular weight (LMW) compounds below 
10 kDa were collected and total yield of the 
hydrolysates  are  shown  in Fig. 1.  The tissue  controls 
Enhanced Free Radical Scavenging and Inhibition of DPP-4 and ACE Activities by Compounds from 
Salmon Tissues Digested in Vitro with Gastrointestinal Proteases 
 
398
 
 
Fig. 1  Recovery of peptides < 10 kDa after in vitro digestion with gastrointestinal proteases, measured as serine equivalents 
using the OPA method. The diagram shows the recovery after treatment of muscle, skin and enzyme controls with or without 
proteases. Errors bars show SD of eight determinations.  
 
(no proteases added) show that a small part of the 
LMW compounds are naturally originating from 
muscle (9.3  10-3 M) and skin (2.6  10-3 M), but 
proteolytic digestion releases substantial amounts of 
OPA reactive peptides and other LMW compounds. In 
general, there is a higher degradation by 
gastrointestinal proteases of muscle proteins than of 
skin proteins, which could be expected because the 
higher content of collagen in skin makes it less 
degradable compared to muscle. Pepsin digestion of 
muscle resulted in a three-fold larger yield than pepsin 
digestion of skin. For both muscle and skin, the 
subsequent addition of pancreatin resulted in a marked 
increase of peptides below 10 kDa with 2.5 and 6 fold 
increases for skin and muscle, respectively, whereas 
addition of mucosal extract did not result in any 
further formation of peptides. This could be due to 
low endopeptidase activity in the mucosal extract 
(result not shown). 
Digestion of muscle with pancreatic alone resulted 
in yields similar to pepsin digestion whereas 
pancreatic alone degraded skin much more efficiently 
than pepsin. Digest with mucosal extract alone gave 
negligible degradation of both muscle and skin. 
However, combination of pancreatic and mucosal 
extract did result in a large increase in formation of 
peptides after digestion of muscle, whereas the same 
effect was not seen for skin. This indicates that 
combination of gastrointestinal proteases and the 
protein source is important for the degree of digestion. 
The pepsin and pancreatin preparations used did not 
result in any formation of peptides by themselves, but 
enzyme preparation with pepsin, pancreatin and 
mucosal extract added did result in a small formation 
of peptides, possibly released from the proteins in the 
mucosal extract. 
3.3 < 10 kDa Hydrolysates: Scavenging of ABTS●+ 
Radicals and Inhibition of ACE and DPP-4  
ABTS●+ radical scavenging activity, ACE and 
DPP-4 inhibiting activity of the < 10 kDa hydrolysates 
are shown in Fig. 2 as tested in vitro at various 
concentrations. The potency (EC50) of hydrolysates 
from in vitro sequential digestion of muscle and skin 
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Fig. 2  Concentration dependent effects of hydrolysates obtained from muscle (a), (b), (c) or skin (d), (e), (f) on quenching of 
ABTS●+ radicals (a), (d) or inhibition of activity of ACE (b), (e) or DPP-4 (c), (f).  
Pepsin, pancreatin and intestinal mucosal extracts were used for preparation of hydrolysates as indicated in 2a. Absorbance or 
enzymatic activity in absence of hydrolysates was normalized to 1. All activities are measured at standard assay condition described 
in Section 2.4, 2.5 and 2.6.  
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Table 2  EC50 values (Fig. 2) for quenching of ABTS●+ radicals and for inhibition of ACE and DPP-4 activity by < 10 kDa 
hydrolysates from in vitro digestion with pepsin, pancreatin and mucosal extract of salmon belly flap muscle and skin. Values 
and SD are shown in mM.  
Treatment Muscle Skin 
Pepsin Pancreatin Mucosal extract ABTS●+ ACE DPP-4 ABTS●+ ACE DPP-4 
– – – 0.37 ± 0.01a 1. 6 ± 0.1a 31 ± 10a 0.28 ± 0.02a 5 ± 2a 8 ± 3a
+ – – 0.069 ± 0.003b 0.15 ± 0.01b 1.0 ± 0.1b 0.073 ± 0.005b 0.13 ± 0.02b 0.84 ± 0.07b
+ + – 0.089 ± 0.003b 0.67 ± 0.05c 1.2 ± 0.1b 0.12 ± 0.01c 0.42 ± 0.06b 0.92 ± 0.09b
+ + + 0.13 ± 0.005c 0.39 ± 0.03d 0.9 ± 0.1b 0.13 ± 0.01c 0.30 ± 0.04b 0.73 ± 0.07b
– – + 1.30 ± 0.09d 2.7 ± 0.6e 20 ± 7c 0.47 ± 0.03d 3.4 ± 0.6c 4 ± 2c
– + – 0.069 ± 0.005b 0.17 ± 0.04b 0.69 ± 0.08b 0.56 ± 0.04e 0.50 ± 0.08b 0.37 ± 0.1db
– + + 0.32 ± 0.02e 0.9 ± 0.2f 1.4 ± 0.2b 0.70 ± 0.05f 1.4 ± 0.2d 1.8 ± 0.6eb
Statistical analysis of EC50 values between enzyme treatments were performed by one-way ANOVA followed by Tukey’s multiple 
comparison test. Values with different letters differ significantly (P < 0.05), values with same letters do not differ significantly (P > 
0.05). EC50 values in italics were determined by extrapolation.  
 
with gastrointestinal proteases and digestion with 
combinations of these are shown in Table 2. All 
hydrolysates obtained from digestion of muscle or 
skin gave complete radical scavenging activity (zero 
absorbance at 734 nm) (Figs. 2a and 2c) and nearly 
complete inhibition of ACE and DPP-4 (Figs. 2b, 2c, 
2e, and 2f). Controls, which represented that < 10 kDa 
compounds naturally present in tissue showed a clear 
radical scavenging activity for both muscle (approx. 
95% reduction in 734 nm absorbance) and skin 
(approx. 70% reduction in 734 nm absorbance). A 
certain radical scavenging activity was expected in 
controls as fish muscle contains low molecular weight 
compounds with antioxidative properties such as 
gluthatione, inosinemonophospate, anserine and free 
amino acids, e.g., histidine and tryptophan [32-36]. 
Control for muscle also showed a clear inhibition of 
ACE with approx. 50% inhibition, while control for 
skin only showed little or no inhibition of ACE 
activity (Figs. 2b and 2e). This indicated that salmon 
muscle contained LMW compounds that could inhibit 
ACE. Hou et al. [34] showed that anserine also could 
inhibit ACE. Anserine is commonly present in 
salmonide muscle [37] and might have contributed to 
the effect on ACE observed for the control. In contrast 
to radical scavenging activity and ACE inhibition, 
controls for both muscle and skin showed only little or 
no inhibition of DPP-4 (Fig. 2c and 2f).  
Thus, sequential in vitro digestion increased the 
radical scavenging activity in general indicating that 
peptides and other compounds with radical 
scavenging activity were generated. The 
dose-response curves for hydrolysates recovered from 
digestion with pepsin show the highest potency 
compared to control regarding radical scavenging 
activity and increased the EC50 value five-fold (Table 
2) for both muscle and skin which exhibited the same 
potency with EC50 = 0.069 mM for muscle and EC50 = 
0.073 mM for skin, respectively. The radical 
scavenging activity potency decreased when digestion 
proceeded with a significant increase in EC50 values 
and peptides recovered from digestion with 
pepsin/pancreatin/mucosal extract (+++ hydrolysate) 
showed the lowest potency with a two-fold increase in 
the EC50 value (0.13 mM) compared to control. 
However, the results indicated that pepsin digestion of 
fish tissues generated radical scavenging peptides that 
could contribute to decreased oxidative stress in the 
intestine. Radical scavenging activity profile is shown 
in Figs. 2a and 2c, and the estimated EC50 values are 
surprising similar for muscle and skin. The protein 
composition in the two tissues is different and a 
digestion will likely to result in a different peptide 
profile with different radical scavenging activity 
properties. It should be noted that dose-response 
curves of peptides or other compounds < 10 kDa that 
are naturally present in both muscle and skin resulted 
in radical scavenging activity with EC50 values only 
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approx. 2.5 times higher than the +++ hydrolysate. 
The development in the ACE inhibiting activity 
profile was similar to ABTS●+ radical scavenging 
activity as the dose-response curves for muscle and 
skin hydrolysates showed that pepsin digestion 
resulted in lowest EC50 values (0.15 mM and 0.13 
mM, respectively) and that the EC50 values increased 
four-fold when digestion proceeded with 
pepsin/pancreatin digestion. In contrast to radical 
scavenging activity, digestion with a combination of 
all three protease preparations decreased EC50 value 
for ACE inhibiting activity again all though not to the 
same level as the pepsin generated hydrolysate. Again, 
it is notable that peptides or other compounds 
obtained from control of muscle exhibited ACE 
inhibiting activity with an estimated EC50 value of  
1.6 mM. This could, as earlier mentioned, be due to 
the presence of anserine [34]. Even though the 
dose-response curves for skin hydrolysates in relation 
to ACE inhibition showed same pattern as muscle 
hydrolysates, the one-way ANOVA analysis could not 
show a significant difference in EC50 values between 
the three skin hydrolysates (Table 2), but showed a 
significant difference between the EC50 values for the 
hydrolysates and the estimated EC50 value for the 
control. 
In contrast to radical scavenging activity and ACE 
inhibiting activity, none of the three hydrolysates from 
the sequential digestion of muscle or skin exhibited 
different potencies in their ability to inhibit DPP-4 as 
no significant differences between EC50 values were 
observed. This could be due to that peptides generated 
by pepsin digestion were not cleaved by the 
subsequent digestion with pancreatin or 
pancreatin/mucosal extract or new inhibitory peptides 
were generated compensating for those being 
degraded. The very weak DPP-4 activity detected in 
the undiluted < 10 kDa fraction from controls of 
muscle and skin showed that fish tissue itself did not 
contain compounds with a pronounced DPP-4 
inhibitory property. In a study with sequential in vitro 
digestion of four different milk protein samples with 
pepsin and pancreatin, a high DPP-4 inhibiting 
activity was also observed in hydrolysates after pepsin 
digestion. The subsequent digestion with pancreatin 
resulted in both increase and decrease of DPP-4 
inhibitory activity [24]. It was suggested that high 
DPP-4 inhibiting activity after pepsin digestion was 
due to pepsin preference for cleaving at hydrophobic 
amino acid residues which was reported to be in 
DPP-4 inhibiting peptides [30]. As for radical 
scavenging activity and ACE inhibition, the mucosal 
extract generated hydrolysates did not show a 
pronounced DPP-4 inhibition. 
EC50 values for radical scavenging activity, ACE 
and DPP-4 inhibiting activity for muscle hydrolysate 
from digestion with pancreatin alone (Table 2) were 
notably similar to the EC50 values for hydrolysates 
from pepsin digestion alone and pepsin/pancreatin, 
except radical scavenging activity in skin hydrolysate 
generated by pancreatin digestion alone which gave an 
eight-fold higher EC50 value for ABTS●+ radical 
scavenging activity than for pepsin generated 
hydrolysates and four-fold higher EC50 value for ACE 
inhibition while the EC50 value for DPP-4 was lower. 
Noteworthy is that the combination of pancreatin and 
mucosal extract in general resulted in a much higher 
EC50 values than the other combination of proteases. 
This suggests that proteases in the mucosal extract 
depressed formation of bioactive peptides generated 
by pancreatin digestion of muscle. Digestion with 
mucosal extract alone resulted in general in low 
radical scavenging activity and inhibition of ACE and 
DPP-4 with significant higher estimated EC50 values 
than the other hydrolysates. This could be due to, as 
earlier mentioned, low endopeptidase activity in this 
extract which could result in lower content of small 
bioactive peptides. 
3.4 Inhibition Mechanism of +++ Muscle Hydrolysate 
In relation to inhibition of DPP-4 and ACE, it has 
been discussed by other researchers whether peptides 
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with standard amino acids might mainly act by 
competitive inhibition as more preferable substrates, 
or whether peptides also could act by non-competitive 
inhibition [26, 38-40]. 
The inhibitory mechanism of the +++ muscle 
hydrolysate towards ACE and DPP-4 was studied 
further by assaying the ratio between substrates and 
inhibitors for generating Lineweaver Burk plots (Figs. 
3a and 3b). All the lines intersected to the left      
of the V-1 axis for inhibition of DPP-4 (Fig. 3a) which 
 
 
Fig. 3  Lineweaver-Burk plot of (a) DPP-4 and (b) ACE activity in presence of various concentrations of < 10 kDa 
hydrolysate (+++) from in vitro digestion of salmon muscle with gastrointestinal proteases.  
Concentration of hydrolysates (mM serine equivalents): ● 28; ▼ 14; ■ 7; ◊ 3.5; ▲ 1.8; Δ 0.9; □ 0.45; ○ H2O (control). RFU: relative 
fluorescence units; OD: optical density. DPP-4 and ACE activity were measured at standard assay condition described in Section 2.5 
and 2.6. 
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indicated mixed competitive and non-competitive 
inhibition of +++ muscle hydrolysate towards DPP-4. 
This agrees with Lorey et al. [39] who showed both 
competitive a mixed inhibition of DPP-4 using 
different peptide sequences inhibition and showed that 
DPP-4 have at least two inhibitor binding sites. In the 
plot for ACE (Fig. 3b), all the lines intersected in the 
same x-intercept, but in different slopes and 
y-intercepts, and this indicated that the +++ 
hydrolysate behaved as non-competitive inhibitor 
towards ACE. In the plot for ACE (Fig. 3b), all the 
lines intersected in the same x-intercept, but with 
different slopes and y-intercept, and this indicated that 
the +++ hydrolysate behaved as non-competitive 
inhibitor towards ACE. Other studies have identified 
small ACE non-competitive inhibitory peptides from 
fish hydrolysates prepared with digestive proteases. 
Jung et al. [23] isolated a non-competitive peptide 
(Tyr-Phe-Pro) from yellowfin sole protein digested 
with chymotrypsin. Shiozaki et al. [41] identified an 
ACE non-competitive inhibiting dipeptide (Asp-Tyr) 
from in vitro digestion of oyster hydrolysates with 
pepsin and pancreatin. Ono et al. [19] isolated an ACE 
non-competitive inhibiting dipeptide (Phe-Leu) from 
hydrolysed salmon muscle but found that the reverse 
sequence (Leu-Phe) showed competitive inhibition. 
This strongly suggested that both competitive and 
non-competitive inhibiting peptides could be present 
in fish muscle hydrolysates. 
3.5 Stability of DPP-4 and ACE Inhibition of +++ 
Muscle Hydrolysate, Diprotin and Captopril 
DPP-4 and ACE inhibiting properties of +++ 
muscle hydrolysate, diprotin and ACE were measured 
during incubation in mucosal extract for 24 h at 37 °C 
(Figs. 4a and 4b) to investigate the stability of 
competitive and non- competitive inhibitory properties 
of the +++ hydrolysate in comparison with diprotin 
and captopril. Mucosal extract plus +++ hydrolysate 
exhibited approx. 75%-80% DPP-4 inhibition at time 
0 h and after 1.5 h, the inhibitory effect slowly started 
to decrease over time to approx. 40% after 24 h (Fig. 
4a). Controls showed that maximal inhibition did not 
change when incubated mucosal extract was tested 
with fresh +++ hydrolysate or diprotin (result not 
shown). This agrees with the result from the 
Lineweaver Burk plot (Fig. 3a) suggesting that 
inhibition of DPP-4 by the +++ hydrolysate was also 
influenced by peptides with non-competitive 
inhibition properties. Mucosal extract plus diprotin 
showed a different course of DPP-4 inhibition. Until 
1.5 h nearly full DPP-4 inhibition was seen, but after 
1.5 h the inhibitory effect decreased rapidly, and 
almost no inhibitory effect of diprotin was observed 
after 4.5 h suggesting that diprotin most likely was 
degraded quickly by DPP-4. This agrees with Rahfeld 
et al. [38] who studied the inhibition mechanism of 
diprotin against DPP-4 and concluded that diprotin 
should be defined more as a substrate than a 
competitive inhibitor. However, no inhibition of 
DPP-4 was observed neither by +++ hydrolysate or 
diprotin when incubated 24 h with undiluted mucosal 
extract with higher DPP-4 activity (Fig. 4a). This 
indicated that both competitive and non-competitive 
inhibiting peptides would be degraded or inactivated if 
incubation period was extended. Stability of ACE 
inhibiting properties followed a similar pattern as 
observed for the inhibition of DPP-4 even though a 
slower decrease in inhibitory effect was observed (Fig. 
4b). The slower decrease in stability of +++ 
hydrolysate inhibition could indicate a reversible 
non-competitive inhibition which could be due to 
DPP-4 degradation of the peptides. 
Mucosal extract + captopril showed full inhibition 
of ACE activity until 4.5 h compared to the controls 
and thereafter the inhibitory effect slightly decreased 
to approx. 50% inhibition after 24 h. Compared to the 
controls, diluted mucosal extract + fresh captopril and 
diluted mucosal extract + water at each sampling point 
exhibited almost full inhibition (90%) and 100% 
activity, respectively. DPP-4 control showed      
that maximal inhibition did not change when incubated  
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Fig. 4  Stability of (a) DPP-4 and (b) ACE inhibiting properties of < 10 kDa hydrolysate (+++) from in vitro digestion of 
salmon muscle with gastrointestinal proteases when incubated with mucosal extract for 24 h at 37 °C.  
(▽) Mucosal extract 9 diluted and +++ hydrolysate; (○) Mucosal extract 9 diluted and diprotin or captopril; 
(▼) Mucosal extract undiluted and +++ hydrolysate; (●) Mucosal extract undiluted and diprotin or captopril;  
(□) Fresh mucosal extract 9 diluted and water. Measurement was done in triplicate.  
RFU: Relative Fluorescence Units; OD: Optical Density. DPP-4 and ACE activity were measured at standard assay condition 
described in Section 2.5 and 2.6. 
 
mucosal extract was tested with fresh +++ hydrolysate 
(result not shown). Mucosal extract plus +++ 
hydrolysate showed a slightly different course of 
inhibition of ACE activity compared to captopril as 
inhibition slowly started to decrease already at 0.5 h 
and still exhibited approx. 60% inhibition after 24 h. 
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As for DPP-4, no inhibition was observed when 
incubated with undiluted mucosal extract for 24 h 
indicating that both competitive and non-competitive 
ACE inhibiting peptides also would be degraded or 
inactivated with a longer incubation time. 
4. Conclusions 
Sequential in vitro digestion of salmon proteins 
from muscle and skin with gastrointestinal proteases 
generated hydrolysates with distinct radical 
scavenging and DPP-4/ACE inhibitory activities. EC50 
values for all activities were lowest after digestion 
with pepsin while further digestion with pancreatic 
and mucosal proteases increased EC50 values for 
radical scavenging and ACE inhibitory activity, while 
EC50 for DPP-4 inhibitory activity was unchanged. 
These results suggested that gastrointestinal digestion 
of fish proteins might generate peptides that could 
positively influence antioxidative stress, insulin 
response and hypertension. 
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